Peritoneal dialysis in children: pathophysiological & clinical studies. by Raaijmakers, R.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/95113
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Peritoneal dialysis in children:
pathophysiological
clinical
studies&
Renske Raaijmakers
ISBN: 978-94-6191-220-6
Printed by: Ipskamp Drukkers, Nijmegen
Copyright c© 2012 by Renske Raaijmakers
All rights reserved. No part of the material protected by this copyright notice
may be reproduced or utilized in any form or by any means, electronic or me-
chanical, including photocopying, recording or by any information storage and
retrieval system, without the prior permission of the author.
Financial support for printing of this thesis was kindly provided by: Ferring BV
Typeset by Tijs Carel Nijland with the LATEX Documentation System.
Author email: renskeraaijmakers@gmail.com
Cover picture: Table Mountain, Cape Town, South Africa, as seen from the
shores of Robben Island (photograph by Godelief Raaijmakers-Dorenbosch)
Peritoneal dialysis in children:
pathophysiological
& clinical studies
Een wetenschappelijke proeve
op het gebied van de Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magniﬁcus prof.mr. S.C.J.J. Kortmann,
volgens besluit van het college van decanen
in het openbaar te verdedigen op woensdag 18 april 2012
om 15:30 uur precies
door
Renske Raaijmakers
geboren op 9 mei 1977
te Breda
Promotoren: Prof. dr. J.L Willems
Prof. dr. L.A.A. Kollee
Prof. dr. L.P.W.J. van den Heuvel
Copromotor: Dr. C.H.Schro¨der (Gelre Ziekenhuizen)
Manuscriptcommissie: Prof. dr. F.G.M. Russel
Prof. dr. R.T. Krediet (AMC, Amsterdam)
Dr. H.W. van Hamersvelt
Paranimfen: Mw. drs. G.A.L. van den Hoogen
Mw. drs. J.J.L. Rietema-Smetsers
It always seems impossible, until it’s done
-Nelson Mandela
Aan mijn ouders

Contents
List of abbreviations ii
CHAPTER 1 General introduction 1
PART I Pathophysiological studies 21
CHAPTER 2 Proteomic proﬁling and identiﬁcation in peritoneal ﬂuid of
children treated by peritoneal dialysis
23
CHAPTER 3 Investigation of longitudinal protein changes in peritoneal
dialysate of children, using proteomics technology
57
CHAPTER 4 Free water transport in children on peritoneal dialysis is
higher with more biocompatible dialysis solutions, higher
with older age and declines with time
75
PART II Clinical studies 97
CHAPTER 5 Continuous Flow Peritoneal Dialysis: ﬁrst experience in
children with acute renal failure
99
CHAPTER 6 Fungal peritonitis in children on peritoneal dialysis 117
CHAPTER 7 Peritonitis in children on peritoneal dialysis in Cape Town,
South Africa: epidemiology and risks
131
CHAPTER 8 Intestinal perforations in children on peritoneal dialysis 149
PART III Pharmacological studies 157
CHAPTER 9 Pre-treatment of dairy and breastmilk with sevelamer
hydrochloride and sevelamer carbonate to reduce
phosphate
159
CHAPTER 10 Intraperitoneal treatment with darbepoetin for children on
peritoneal dialysis
181
PART IV Closing remarks 191
CHAPTER 11 Summary, discussion & future perspectives 193
CHAPTER 12 Nederlandse samenvatting 207
Dankwoord 219
Curriculum Vitae 225
List of publications 226
i
List of abbreviations
1D-SDS-PAGE one-dimensional sodium dodecyl sulfate polyacrylamide gel
electrophoresis
3,4-DGE 3,4-dideoxyglucosone-3-ene
A˚ A˚ngstro¨m
AB antibiotics
AGE advanced glycosylation end-product
AIDS acquired immunodeﬁciency syndrome
ARF acute renal failure
ATN acute tubular necrosis
BSA body surface area
CAPD continuous ambulatory peritoneal dialysis
CCPD continuous cycling peritoneal dialysis
CFPD continuous ﬂow peritoneal dialysis
CVVH/D continuous venovenous hemoﬁltration/dialysis
darb darbepoetin
ELISA enzyme linked immunosorbent assay
emPAI exponentially modiﬁed protein abundancy index
epo epoietin
ESRD end stage renal disease
F female
FP fungal peritonitis
FWT free water transport
GDP glucose degradation product
GFR glomerular ﬁltration rate
GLAD glycerol amino-acids dextrose
HD hemodialysis
HIV human immunodeﬁciency virus
HRP horseradish peroxidase
HUS hemolytic uremic syndrome
ip intraperitoneally
ISPD international society for peritoneal dialysis
iv intravenously
ii
kDA kilodalton
KDOQI Kidney Disease Outcomes Quality Initiative
LC liquid chromatography
LIT FT-ICR linear ion trap fourier transform ion cyclotron resonance
M male
MS mass spectrometry
MTAC mass transfer area coefﬁcient
n number
NAC N-acetylcysteine
NAPRTCS north american pediatric renal trials and collaborative studies
NCBI national center for biotechnology information
NEPP nutrineal extraneal physioneal physioneal
NIPD nightly intermittent peritoneal dialysis
nLC nano liquid chromatography
PBS phosphate buffered saline
PD peritoneal dialysis
PET peritoneal equilibrium test
po per os
PPAR-y peroxisome proliferator-activated receptor gamma
PTH parathyroid hormone
RIFLE Risk Injury Failure Loss End stage kidney disease
RRT renal replacement therapy
SD standard deviation
SES socio economic status
spp. species
TAPVR total abnormal pulmonary venous return
TCUF transcapillary ultraﬁltration
UF ultraﬁltration
USRDS United States renal data system
iii
iv
CHAPTER 1
General introduction

GENERAL INTRODUCTION
1
History
The ﬁrst experience with peritoneal dialysis (PD) for uremia was described in
1923 by Ganter1. He carried out experiments in several animals and treated two
adult patients as well, but could not save the patients’ lives2. It was not until
1938 that the ﬁrst successful attempt of treating acute renal failure with PD was
made3. PD became a treatment for acute renal failure and was as such ﬁrst de-
scribed in children in the sixties4,5. Subsequently PD was attempted for patients
with chronic renal failure, at ﬁrst with repeated punctures6. Initially poor suc-
cess rates were achieved, mainly due to catheter problems and high incidence
of peritonitis7. The development of the Tenckhoff catheter in 1968 enabled the
use of the ﬁrst successful long term catheter8, and with the development of the
Continuous Ambulant PD (CAPD) technique by Popovich et al. in 19789 PD be-
came an established home treatment. The ﬁrst use in children with chronic renal
failure was described by Oropoulos10. CAPD was introduced in the Netherlands
in 1979 in adults11 and subsequently in children in 198012. The main problem in
the early years of chronic use was the high risk of peritonitis, mainly due to the
frequent disconnections with contamination. This improved dramatically with the
implementation of PD ﬂuid in plastic bags by Oreopoulos in Canada and the in-
troduction of the Y-connector set by Buoncristiani in Italy13,14. The development
of an automated portable cycler facilitated mobility for PD patients and meant an
improvement in their quality of life15,16. Furthermore, the possibility to assess
individual peritoneal transport characteristics by means of a peritoneal equilib-
rium test (PET) allowed for an individualized prescription, to further optimize PD
treatment17.
Epidemiology
End stage renal disease (ESRD) is a relatively uncommon chronic disease in
children. The most recent worldwide reported incidences vary from 9.9 to 15.5
patients per million population18,19. The incidence varies with age, as is shown
in the data of the United States Renal Data System (USRDS), reported in 2006.
These data show an annual incidence of 10.8/million in 0-4 year olds, a lower in-
cidence of 6.9/million in the age group from 5-9 years and then an increase, with
an incidence of 13.3/million in 10-14 year olds, rising to 28.2/million in 15-19 year
olds18. In these older children acquired diseases start to play a more important
role, but the most frequent underlying causes of ESRD in children are congenital
or hereditary disorders20. In a Dutch cohort study from 1987-2001 in 351 pa-
tients aged 0-16 years, congenital structural abnormalities accounted for 34.5%
of underlying diseases, hereditary renal disorders for 23.9%, glomerulonephri-
tis for 21.1%, systemic diseases for 7.4% and other diseases for 8.8%21. The
speciﬁc entities that occurred most frequently were urethral valves (14.3%), focal
3
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segmental glomerulosclerosis (10.8%), congenital hypoplasia/dysplasia (8.8%),
vesico-ureteric reﬂux (7.4%) and congenital nephrotic syndrome (6.8%). This
is in contrast to adults; over 80% of the adult ESRD patients have an acquired
disease. At the end of 2004 PD was the most frequently prescribed chronic dia-
lysis modality for children in the Netherlands, Finland, Canada, Australia, New
Zealand and in many other parts of the world. In the United States around 40%
of all children on renal replacement therapy were treated with PD18. In ﬁgure 1.1
data on dialysis modality and transplantation for Dutch children are shown from
1993-2009. Over the years a slow decrease in the number of children on dialysis
is seen, with a stabilization over the last years. Since 1993 pre-emptive kidney
transplantations have increased. In ﬁgure 1.2, the subdivision in age groups
shows a dominance of PD over hemodialysis (HD), especially in younger chil-
dren. In adults HD is used more frequently. In 2004 only 11% of all adults on
renal replacement therapy (RRT) were treated with PD22, although the percent-
ages of PD vary highly over the world. In Mexico over 70% of dialysis patients is
on PD, while in Japan PD accounts for only 4% of the total dialysis population.
The growth of PD in 2004 was nil in the regions United States of America, Japan
and Europe, while the growth rate was 11% in developing countries22, where PD
gradually becomes an option for more people.
Figure 1.1: Overview of dialysis modality and renal transplantation in Dutch pediatric
patients from 1993-2009
Source: Renal Replacement Registry The Netherlands (www.renine.nl)
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(a) 0-5 years
(b) 6-10 years
(c) 11-16 years
Figure 1.2: Dialysis modality in Dutch children from 1993-2009, subdivided by age.
Source: Renal Replacement Registry The Netherlands (www.renine.nl)
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General principles of PD
In PD excess water and waste products are removed from the circulation to the
peritoneal cavity by the use of a biological semi-permeable membrane, the peri-
toneal membrane. Dialysis ﬂuid is instilled into the peritoneal cavity and the peri-
toneal membrane functions as a transport ﬁlter between blood and dialysis ﬂuid.
Usually hypertonic glucose is used as an osmotic agent to allow for adequate re-
moval of water and solutes. The majority of pediatric patients are treated with a
night time schedule, with multiple short exchanges during nighttime, performed
by an automated cycler. This is called nightly intermittent PD (NIPD). Advan-
tages of PD over in-hospital HD are better removal of middle weight molecules,
less variance in blood levels of solutes, absence of the risk for disequilibrium syn-
drome, reduced restrictions in diet and ﬂuids and no need for an arteriovenous
ﬁstula, which can be a signiﬁcant problem especially in smaller children. Further-
more NIPD is performed at home during nighttime, allowing for a more normal
childhood life. On the other hand, PD is an intensive home treatment, which
can be a large burden for care-takers. With PD less social impairment, better
adjustment to dialysis and lower depression scores were observed in a study by
Brownbridge et al.23, although in a more recent study by Goldstein et al.24 no dif-
ferences in quality of life were found between HD and PD patients. Transplanted
patients in general show a better quality of life than dialysis patients24,25 and re-
nal transplantation remains the best treatment option for children with ESRD. Dia-
lysis often offers a bridge while patients wait for a transplant. However, although
most children are transplanted after a relative short time on dialysis, eventually
transplant failure will occur and these patients will need dialysis in their future life
again. This emphasizes the importance of preservation of peritoneal membrane
function in children.
Anatomy of the peritoneal membrane
The peritoneum consists of a large, transparent, serous membrane, lining the
peritoneal cavity. The peritoneum comprises a parietal part that lines the inner
abdominal wall and merges into the visceral peritoneum covering the majority
of the internal organs. Approximately 60% of the peritoneum consists of vis-
ceral peritoneum, 25-30% of mesenterium and omentum and 10-15% of pari-
etal peritoneum26. The peritoneal surface, after correction for body surface area
is comparable between adults and children27,28, approximately 0.6 m2/1.73m2.
The peritoneal barrier is a complex three-dimensional structure, made up of the
mesothelial cell layer, the underlying interstitial tissue and the endothelial cells
forming microvessels embedded in the interstitium29 (a schematic overview is
given in ﬁgure 1.3).
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Figure 1.3: Schematic representation of the anatomy of the peritoneal membrane
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The mesothelial cells play an important role in the secretion of lubricant solutions
by cytoplasmic lamellar bodies and in local host defense, containing and secret-
ing phospholipids and glycosaminoglycans30,31. However, the mesothelium is
not considered a signiﬁcant barrier in ﬂuid and solute transport during peritoneal
dialysis, which is supported by in vivo experiments in rats that showed no dif-
ference in transport after removal of the mesothelium32. The interstitial space
is ﬁlled with an extracellular mucopolysaccharide matrix, containing bundles of
collagen ﬁbers and parenchymal cells, interstitial cells, pericytes and endothelial
cells29. The peritoneal capillaries consist of a single layer of endothelial cells,
lying on a basement membrane. The fenestrated capillary wall is considered the
most important structure determining the peritoneal transport barrier. On the lu-
minal side of the endothelial cells the glycocalyx is located. This is a thin layer of
polysaccharides containing proteoglycans and glycosaminoglycans like hyaluro-
nan with a highly negative charge33. The glycocalyx is damaged by ischemia,
inﬂammation and hyperglycemia. The possible contribution of the glycocalyx to
the peritoneal transport is interesting, but until now not exactly known.
Transport of ﬂuid and solutes
Fluid transport in PD is dependent on the hydrostatic pressure gradient, the col-
loid osmotic pressure gradient and the crystalloid osmotic pressure gradient, to-
gether with the hydraulic permeability of the peritoneal membrane and the effec-
tive peritoneal surface area34. The hydrostatic pressure gradient is determined
by the difference in the capillary pressure and the intra-peritoneal pressure. The
colloid osmotic pressure is induced by plasma proteins. In the absence of an os-
motic dialysis solution the hydrostatic pressure (directed towards the peritoneal
cavity) is exceeded by the colloid osmotic pressure gradient (directed towards
the circulation). In PD generally a hypertonic glucose solution is used, provid-
ing the crystalloid osmotic pressure, directed towards the peritoneal cavity that
is responsible for ultraﬁltration (UF). Solute transport from the circulation to the
peritoneal cavity occurs through the mechanisms of diffusion and convection.
Diffusion is based on the difference in solute concentrations between these two
compartments. Convection, the dragging along of solutes coupled to ﬂuid trans-
port, is determined by UF rate, solute concentration and the sieving coefﬁcient
of a solute. The sieving coefﬁcient is the quotient of the solute concentration
in the dialysate and in the circulation. It can range from zero (no convective
transport occurs) to 1 (the membrane does not hinder convective transport of
a solute)34,35. Fluid and solute transport are assumed to occur through a sys-
tem of pores, according to Rippe’s three pore model’34–39 (see also ﬁgure 1.3).
Large pores with a radius of >150A˚allow for the transport of macromolecules.
Transport of small solutes together with water occurs through small pores with
a radius of 40A˚. Free water transport (FWT) occurs exclusively through the ultra
8
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small pores (also called water channels) with a radius of <5A˚, being imperme-
able to solutes. This explains the effectiveness of a small solute such as glucose
as an osmotic agent and clariﬁes the dissociation of transport of water and so-
lutes. The transendothelial water channels have been identiﬁed as aquaporin-1
channels40,41. With immunogold electron microscopy, used on mouse visceral
peritoneum, a strong signal for aquaporin-1 was shown in the plasma mem-
brane and in plasma membrane infoldings of capillary endothelial cells. Less
aquaporin-1 was observed at the basolateral site. It was proven in aquaporin-1
knock-out mice that without aquaporin-1 channels FWT cannot occur and that
aquaporin-1 mediated FWT accounts for approximately 50% of the total UF in a
hypertonic dwell42,43.
Assessment of peritoneal function
Functional assessment of the peritoneal membrane can be performed by peri-
toneal equilibrium tests (PETs), assessing ﬂuid and solute transport during a
4-hour standardized dwell with the most hypertonic dialysis solution with 3.86%
glucose, as recommended by the International Society for Peritoneal Dialysis
(ISPD)44. For small solute transport calculations mass transfer area coefﬁcients
(MTACs) are used according to Waniewski45 and for transport calculations of
larger solutes clearances are used. With the addition of a volume marker (like
dextran 70) to calculate marker clearance and measurements of sodium33,46,47,
it becomes possible to calculate FWT as well as solute coupled water trans-
port separately. FWT occurs exclusively through the ultra small pores with com-
plete sieving of sodium. By subtracting the total sodium transport (that occurs
through the small pores) from the total ﬂuid transport, FWT can be calculated,
using the magnitude in the dip of the dialysate to plasma ratio of sodium at all
timepoints48,49. PD inﬂuences and alters the peritoneal membrane50. Uremia,
long-term exposure to toxic dialysis solutions and peritonitis episodes all play
a role. This can cause alterations in composition and transport characteristics
of the peritoneal membrane. Useful markers for longitudinal follow-up are still
lacking, although cancer antigen 125 (as a marker of mesothelial cell mass) and
interleukin-6 (as a mediator of the inﬂammatory response in the peritoneal cavity)
have been shown to be of some clinical value in adult studies51.
Peritoneal dialysis solutions
Glucose based ﬂuids are the most frequently used dialysis solutions in PD. Hy-
pertonic glucose and the acidic pH with lactate buffering have detrimental effects
on the peritoneal membrane. High glucose and acidic pH give rise to glucose
9
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degradation products (GDP’s) that induce the formation of advanced glycosyla-
tion end products (AGEs). This leads to chronic inﬂammation, neoangiogenesis,
ﬁbrosis and endothelial cell dysfunction31,52–54. Important improvements in solu-
tions have been made in recent years with better biocompatibility55–58, but most
of these newer solutions still contain considerable amounts of GDP’s. In table 1
the composition of conventional and more biocompatible glucose dialysis solu-
tions is shown.
Complications of PD
The most frequent and serious complication of PD in children is peritonitis63,64.
Children have a higher risk to develop peritonitis than adults, in particular in the
ﬁrst year of dialysis65. The most recent evaluation by the North American Pedi-
atric Renal Trials and Collaborative Studies (NAPRTCS) showed an annualized
peritonitis rate of 0.71 episodes, or 1 peritonitis/16.9 patient-months65. Risk fac-
tors for peritonitis include young age, absence of prophylactic antibiotic use at
catheter implantation, and presence of a catheter exit site or tunnel infection66.
A large multi-center study performed in 14 countries evaluated the causative
organisms in children with peritonitis: gram-positive organisms occurred in 44%,
gram-negative organisms in 25%, and culture negative peritonitis occurred in
31%67. A relative increase of gram-negative organisms was seen compared
to previous results from the nineties68. This apparent increase most likely re-
ﬂects a decrease in gram-positive peritonitis associated with improved handling
and connection technologies and prophylaxis programs with mupirocin against
Staphylococcus Aureus69. Large geographical variation was seen in causative
organisms. In the United States of America more gram-negative and pseu-
domonas infections occurred, associated with prophylactic use of local mupirocin
and the frequency of exit site cleansing. Geographical variation in antibiotic sus-
ceptibility was observed as well. Gram-positive sensitivity for ﬁrst generation
cephalosporins was below average in the United States of America, but above
average in Eastern Europe. Gram-negative sensitivity for aminoglycosides was
below average in Eastern Europe69. Data on peritonitis in pediatric patients in
developing countries are very scarce. The current adult guidelines on treatment
of peritonitis, updated in 201070, advise to start empiric therapy as soon as pos-
sible, with coverage of both gram-positive and gram-negative organisms. Gram-
positive organisms can be covered with a cephalosporin, or with a glycopep-
tide like vancomycin in case of history of methicillin resistant Staphylococcus
Aureus carriership and more severe clinical illness. Gram-negative organisms
can be covered by a third-generation cephalosporin or aminoglycoside. For pe-
diatric patients the most recent guidelines date from 2000, following generally
the same advice, except vancomycine is advised as a ﬁrst choice in all chil-
dren under the age of 2 years, and aminoglycosides are not advised as an initial
10
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treatment in children. Previously aminoglycosides were completely abandoned
because of the possible development of ototoxicity and nephrotoxicity71,72, but
increasing resistance of gram-negative organisms to the currently advised ther-
apy might justify renewed future use of aminoglycosides73. Recent studies con-
clude that, given the geographical variation in causative organisms, local and
patient circumstances should be taken into consideration when prescribing ini-
tial therapy66,67. In a multi-center study by Warady et al it was found that 11%
of peritonitis episodes in children led to incomplete functional recovery or tech-
nique failure67. Peritonitis with gram-negative organisms and fungal peritonitis
are associated with a worse outcome66. The incidence of fungal peritonitis is be-
low 3%64,74,75, but morbidity and mortality are relatively high. Loss of peritoneal
function occurs frequently after fungal peritonitis, resulting in temporary or deﬁ-
nite conversion to HD. Risk factors for the development of a fungal peritonitis are
multifactorial and only partly understood.
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Aims and outline of the thesis
The main aims of this thesis were to gain more insight in peritoneal membrane
function and to provide clinical improvements in PD for children by:
I Pathophysiological studies to analyze protein composition and ﬂuid trans-
port in PD and their alterations in time (Part I). The aim is to contribute to
a better understanding of membrane function in the long term. Children are
more than any other patient group dependent on a well functioning peritoneal
membrane for their future life.
II Clinical studies to investigate possible new dialysis techniques and to study
complications of dialysis for better prevention and treatment of peritonitis
(part II) and clinical pharmacological studies in order to improve compliance
and contribute to a better quality of life (part III).
Part I describes pathophysiological studies. In chapter 2 a broad spectrum anal-
ysis of proteins in peritoneal dialysate is performed with proteomic techniques,
to give the ﬁrst overview of the proteome of peritoneal dialysate. Chapter 3
evaluates long term protein changes in dialysate, and their possible implications.
Chapter 4 gives a detailed analysis of FWT, in a cross-sectional and longitudinal
manner, reﬂecting the function of aquaporins in the peritoneal membrane. Other
transport characteristics are analyzed as well.
Part II describes clinical studies. In chapter 5 the technique of continuous ﬂow
PD (CFPD) is tested as a new application in pediatric clinical practice, to treat
acute renal failure at the pediatric intensive care unit in South Africa. Chapter
6 describes the experience with a serious complication of PD, fungal peritoni-
tis. The study is performed in a Dutch cohort, with a review of the literature
and recommendations for prevention and therapeutical options. PD is rising as
a treatment modality in developing counties, where speciﬁc challenges are en-
countered. This is described in chapter 7, showing the distinct problematic na-
ture of peritonitis in a developing country. Chapter 8 describes the experience
with intestinal perforation as a rare but high-risk complication of PD.
Part III describes clinical pharmacological studies. In chapter 9 the pre-treatment
of breastmilk and dairy products with sevelamer is studied in detail, to avoid trou-
blesome ingestion by children and to be able to safely prescribe sevelamer in
this alternative manner. Chapter 10 evaluates the possibilities of more patient
friendly intraperitoneal prescription of darbepoetin.
Part IV concludes with the summary, discussion and future perspectives (chapter
11) and a summary in Dutch (chapter 12).
13
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Abstract
Background
Proteomic technologies offer a high-throughput analysis of the expression of pro-
teins in biological samples. A ﬁrst step for proteomics in peritoneal dialysis (PD)
is protein identiﬁcation and proﬁling of normal dialysate in a well characterized
set-up, to provide a representative overview of the proteins present in PD ﬂuid.
The global analysis of the proteins in PD ﬂuid will provide a better understanding
of the biological processes of the peritoneal membrane.
Methods
The peritoneal dialysate of 9 pediatric PD patients was collected from the 2 hour
dwell of a peritoneal equilibrium test with 3.86% glucose. Samples were con-
centrated, puriﬁed and run on a 10% SDS-PAGE (Sodium Dodecyl Sulphate
Poly Acrylamide Gel Electrophorese) gel. Each lane was cut into 5 slices and
proteins were in-gel digested with trypsin. Afterwards peptides were separated
with nano scale high performance liquid chromatography on a reversed phase
column. Peptide mass and masses of their respective fragment ions were deter-
mined by subsequent mass spectrometry (MS) and MS/MS cycles. The mass
spectrometer data ﬁles were then searched against the NCBI database using
the Mascot search program. Relative protein abundances were calculated as
exponentially modiﬁed Protein Abundance Index (emPAI) for the identiﬁed pro-
teins.
Results
A total number of 189 proteins were identiﬁed in the peritoneal dialysate of 9
patients. The 9 patients had 88 proteins in common. These 88 proteins ac-
counted for 47% of the identiﬁed proteins, and for more than 90% of the total
protein content in the analyzed samples. Proteins were subdivided in 8 different
classes according to function: 1.) acute phase proteins 2.) complement factors
3.) apolipoproteins 4.) coagulation proteins 5.) extracellular matrix components
6.) hormone and vitamin binding proteins 7.) enzymes and 8.) others.
Conclusions
This study gives a representative overview of the proteins present in peritoneal
dialysate. The proteins in the dialysate reﬂect plasma proteins as well as lo-
cal peritoneal processes. Potentially interesting proteins are revealed. More
research will be needed to further elucidate the function and meaning of these
proteins for PD, and to develop biomarkers for complications of PD.
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Introduction
The proteome is the entire set of proteins expressed in a deﬁned biological sam-
ple. Proteomic techniques provide information about proteins that cannot be
derived from the information obtained by genomic sequencing, like spatial and
temporal expression in tissues and body ﬂuids and interactions of proteins1–3.
With the combined techniques of liquid chromatography and mass spectrome-
try (LC-MS/MS) high-throughput protein proﬁling and identiﬁcation can be per-
formed. In a typical LC-MS/MS experiment, peptides are ﬁrst partly separated
on an analytical column using an increasing gradient of organic solvent. The
eluting peptides are then analyzed by mass spectrometric analysis, which con-
sists of the measurement of the mass over charge ratio (m/z) of the peptide ions
and data-dependent selection of speciﬁc peptide ions for fragmentation analysis
by collision induced dissociation (CID) in a second MS event. The combination
of the masses of the intact peptides and of their respective fragment ions can be
used to identify the peptides and their sequences and thereby identify the pro-
teins from which they originated. This proteomic technique is very useful for the
study of proteins in tissues and body ﬂuids. In nephrology the proteomic mapping
of human urine has been performed4–6. A global analysis of the proteins present
in the whole human kidney has been performed7 as well as more detailed pro-
teomic proﬁling of the kidney glomerulus8 and of podocytes9 . In hemodialysis
(HD) a few proteomic studies have been performed to get an overview of the
proteins present in the hemodialysate and to get insight in the mechanism of
ultraﬁltration10–12. The differential expression of several individual proteins in
peritoneal ﬂuid has recently been studied with 2-dimensional gel electrophore-
sis. A representative overview of the proteome of peritoneal ﬂuid has not been
given so far.
Peritoneal dialysis (PD) is a frequently used renal replacement therapy, espe-
cially in young children with end stage renal disease. Protein loss from the blood
occurs by ultraﬁltration. This protein loss is size-selective and can be of consid-
erable magnitude13. The peritoneal membrane constitutes a size-but probably
not-charge selective barrier for the transport of macromolecules between blood
and dialysate during stable PD. The dialysate-to-plasma ratio can be roughly
estimated in ﬁltered proteins with a known concentration, based on molecular
weight14. In adults protein loss ranges from 5 to 13.3 gram/day, with an average
of 194 mg/kg/day15–17. In infants the protein loss is higher, with an average of
277 mg/kg/day18. Local production of proteins occurs as well. The ﬁrst step for
proteomics in PD is protein identiﬁcation and proﬁling of normal dialysate in a
well-characterized set-up, to provide a representative overview of the proteins
present in peritoneal dialysate. The global analysis of proteins in PD ﬂuid is im-
portant for a better understanding of the biological processes of the peritoneal
membrane. This article gives a representative overview of the proteins present
in peritoneal dialysate by analyzing the dialysate of 9 pediatric patients.
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Patients and methods
Patient samples
The peritoneal dialysate of 9 pediatric patients was collected from two hour
dwells during a peritoneal equilibrium test (PET) and stored at -20◦C. None of the
patients suffered from peritonitis in the 3 months prior to the collection. Patient
and ﬂuid characteristics are shown in table 2.1.
Table 2.1: Characteristics of patients and peritoneal dialysate
Patient
(Gender)
Age
(Years)
Underlying disease Time on
PD
Total
protein
(Year) content
(g/L)
1 (F) 1.7 Multicystic dysplastic kidneys 0.8 0.43
2 (M) 2.5 Dysplastic kidneys 0.8 0.58
3 (M) 3.8 Urethral valves 1.8 0.77
4 (F) 8.3 Dysplastic kidneys 0.8 0.44
5 (M) 4.3 Congenital nephrotic syndrome 1.6 568
6 (M) 3.8 Urethral valves 0.7 0.25
7 (F) 10.8 Idiopathic 1.1 0.82
8 (M) 3.8 Congenital nephrotic syndrome 0.6 0.4
9 (F) 9.4 Dysplastic kidneys 0.8 0.41
F= Female, M = Male
Experimental procedures
An overview of the used experimental proteomic procedures is given in ﬁgure
2.1.
Sample preparation The protein concentration in the dialysate was measured us-
ing a Lowry assay. From each sample, 40 μg protein was taken for analysis.
To purify and concentrate the samples, a 3 kDa Microcon centrifugal ﬁlter was
used (Millipore, Billerica, MA, USA). The samples were run on a 10% SDS-PAGE
(Sodium Dodecyl Sulfate - Poly Acrylamide Gel Electroforese) gel and stained
with ready-made colloidal coomassie staining (Severn Biotech ltd, Worcester-
shire, UK). From stacking gel to sample buffer front, each gel lane was cut into
ﬁve slices. The proteins were in-gel reduced for 20 minutes at 56C with 10 mM
dithiotreitol (Merck, Whitehouse Station, NJ, USA) and alkylated for 20 minutes
at room temperature with 50 mM iodoacetamide (Sigma-Aldrich, St. Louis, MO,
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USA). Subsequently, an overnight in-gel digestion with trypsin was performed19.
The resulting peptides were extracted from the gel by adding one volume of 2%
triﬂuoroacetic acid. The peptide mixture was desalted and concentrated to a
volume of 20 l using C18 stagetips.
Figure 2.1: Schematic ﬂow chart of the experimental proteomic procedures used in the
present study. 1PD = Peritoneal Dialysis, 21D-SDS-PAGE = one-dimensional Sodium Do-
decyl Sulfate Poly Acrylamide Gel Electrophorese, 3nLC = nano Liquid Chromatography,
4MS = Mass Spectrometry
Nano-Liquid Chromotography (nLC) andMass Spectrometer (MS) analysis For each sam-
ple, 5 μl of the desalted peptide mixture was separated on an Agilent 1100 LC
system (Agilent, Palo Alto, CA, USA). The chromatographic column was made
of a 15 cm silica tip emitter with an internal diameter of 100 μm packed by bomb
loading with 3 μm C18 beads (Reprosil-Pur C18 AQ, Dr Maisch GMBH, Ger-
many). Bound peptides were eluted from the column using an increasing ace-
tonitrile gradient. First, the concentration of acetonitrile was increased from 2.4%
to 8% in 5 minutes, followed by an increase from 8% to 24% acetonitrile in 55
minutes, and ﬁnally an increase from 24% to 40% acetonitrile in 7 minutes. Mass
spectrometric analyses were performed in a hybrid linear ion trap Fourier Trans-
form Ion Cyclotron Resonance (LIT FT-ICR) mass spectrometer. (LTQ FT-MS,
Thermo Electron Corporation, Bremen, Germany). Eluted peptides were directly
injected in the LIT FT-ICR MS, which was operated in the data-dependent mode
to automatically switch between MS and MS/MS. Survey mass spectra (350-
2000 m/z) were recorded in the ICR cell. The four most abundant ions were iso-
lated data dependently and fragmented by collision induced dissociation (CID)
in the LIT MS. All samples were measured twice to reduce experimental varia-
tion.
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Data analysis The mass spectrometry data ﬁles for each sample were merged
and searched against the NCBI database (version 20070212∗) using the Mascot
search program (Matrix Science Inc., Boston, MA USA, version 2.1). The search
algorithm was set to perform a tryptic search allowing 2 miscleavages and requir-
ing carbamidomethyl modiﬁcations of cysteine residues as a ﬁxed modiﬁcation.
Variable modiﬁcations were allowed for oxidation of methionine and deamidation
of asparagines and glutamine, since they are often experimentally induced. Mass
tolerance was set to 20 ppm for precursor ions (measured in the ICR cell) and
and 0.8 Da for fragment ions (measured in the LIT). Searches were repeated
against a reversed database with the same settings, to allow for false discov-
ery rate validation. Protein identiﬁcations were validated using the PROVALT20
algorithm to achieve a false-discovery rate (FDR) of <1%. Brieﬂy, the algorithm
counts peptide hits from the normal database and false-positive peptide hits from
the reversed database. Peptide score thresholds are adjusted to achieve a FDR
of <1%. With this extra validation step the statistical chance of a hit by coin-
cidence is minimalized. Gene ontology classiﬁcations were made by means of
ProteinCenter†. To provide an estimation of protein concentration, exponentially
modiﬁed Protein Abundance Index (emPAI) values were calculated for the iden-
tiﬁed proteins using the method as described by Ishihama et al21. To calculate
emPAI values, the theoretical number of peptides present per protein was calcu-
lated by in silico digestion with trypsin. The ratio between the detected number of
peptides and the number of possibly detectable peptides gives a measure for the
abundancy of a protein in relation to the other proteins in the sample. The emPAI
method has been validated by Yang et al, by mixing a known ratio of two proteins
and comparing this with the emPAI ratio’s, with good correlation22.
Results
A total number of 189 proteins were identiﬁed in the peritoneal dialysate of 9
pediatric patients after measurement of all samples in duplicate. Keratins were
excluded since they are known contaminants. All proteins with isoforms and
hypothetical alternatives of the observed proteins are listed in the supplemen-
tary table. Listed in bold are the identiﬁed proteins. Listed below the identiﬁed
proteins are the possible present, but less abundant isoforms, and theoretical
alternatives that cannot be excluded based on the detected peptides. With the
present proteomic techniques used, the lower limit of molecular weight was ap-
proximately 10 kDa, so low molecular weight proteins are not included in the
classiﬁcation. The 88 proteins that all patients shared accounted for >90% of
the total protein content, as was calculated by emPAI (ﬁgure 2.2). The other 101
proteins were the less-abundant proteins, divided among all patients. So, in ev-
∗www.ncbi.nlm.nih.gov
†www.proxeon.com
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ery patient a small number of unique proteins or proteins only shared with one or
a few other patient were present, whilst 88 proteins were shared between all pa-
tients. We did not ﬁnd speciﬁc proteins expressed, based on patient characteris-
tics like sex or occurrence of peritonitis in the past. To evaluate the comparability
of the protein constitution in the samples we looked at the origin of the found pro-
teins according to their gene ontology (GO) cellular component annotation23 and
divided all proteins according to their physiological cellular localization. Figure
2.3 shows the high comparability based on the origin of the proteins between the
9 patients. The division of the 88 shared proteins based on physiological cellular
localization according to the GO annotation is shown in ﬁgure 2.4. In ﬁgure 2.5
the proteome of the peritoneal dialysate was compared to the plasma proteome,
showing that in dialysate extra cellular matrix proteins form a much larger part
of the total proteome. To give more insight in the etiology and function of the
shared proteins we classiﬁed the shared proteins according to their occurrence
as acute phase protein and their function (table 2.2). We subdivided the proteins
in 8 different classes. With emPAI it was possible to estimate protein expression
levels in each patient. Patients were compared according to their abundance
index and a median emPAI value and range was given for each protein, indicat-
ing the relative amount of all classiﬁed proteins present in peritoneal ﬂuid. The
most abundant proteins found were albumin, alpha-1-antitrypsin, apolipoprotein
A, and serotransferrin.
Figure 2.2: Distribution of emPAI (exponentially modiﬁed Protein Abundancy Index) val-
ues (%) between the shared proteins and the other proteins present in the 9 patients
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Figure 2.3: Comparison of all identiﬁed proteins in the PD ﬂuid from the 9 patients ac-
cording to their physiological cellular localization, based on the gene ontology cellular
component annotation. Proteins can be present in more than one
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Figure 2.4: Origin of the shared proteins present in all 9 patients, based on the gene
ontology cellular components annotation. Proteins can be present in more than one com-
ponent
Figure 2.5: Comparison of proteins present in plasma with proteins present in PD ﬂuid
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Table 2.2: Protein classiﬁcation list: classiﬁcation according to function of the proteins
present in all 9 pediatric peritoneal dialysis patients; relative abundance is given with
emPAI1 value
Classiﬁcation Accession
number2
Protein name Mean
peptides
Mean
emPAI1
(SD) (SD)
1. Acute phase proteins
a. antiproteases
66932947 alpha-2-macroglobulin precursor 77 (7) 8 (3.5)
4503107 cystatin C precursor 4.3 (0.5) 1.7 (0.6)
4504781 inter-alpha (globulin) inhibitor H1 13.7 (3.9) 0.6 (0.3)
54400755 inter-alpha (globulin) inhibitor H3 5.2 (3.3) 0.2 (0.1)
31542984 inter-alpha (globulin) inhibitor H4 24.2 (4.7) 1.2 (0.5)
70778918 inter-alpha globulin inhibitor H2
polypeptide
21 (5.1) 1 (0.4)
4506355 pregnancy-zone protein 10.9 (2.2) 0.4 (0.1)
21361195 serine proteinase inhibitor, clade A
(antitrypsin), member 5
7.7 (4) 0.6 (0.4)
4507377 serine proteinase inhibitor, clade A,
member 7
8.4 (1.1) 0.6 (0.1)
50363219 serine proteinase inhibitor, clade A
(antitrypsin), member 1
34.6 (1.7) 61.3
(14.9)
21361302 serine proteinase inhibitor, clade A
(antitrypsin), member 4
8.3 (2.4) 0.7 (0.4)
4502261 serine proteinase inhibitor, clade C
(antithrombin), member 1
26.6 (2.3) 3.6 (0.9)
39725934 serine proteinase inhibitor, clade F
(alpha-2 antiplasmin), member 1
20.6 (2.2) 4.4 (1.1)
b. transport proteins
4826762 haptoglobin 27.8 (2.6) 10.1 (3.3)
45580723 haptoglobin-related protein 18 (2.6) 3.8 (1.1)
11321561 hemopexin 21.1 (2.3) 4.5 (1.4)
c. other acute phase proteins
4502027 albumin precursor 88.6 (6.7) 1269.8
(657.6)
21071030 alpha 1B-glycoprotein 13.9 (3) 2.2 (0.7)
4502005 alpha-2-HS-glycoprotein 7.4 (1.9) 2.1 (0.7)
47132555 ﬁbronectin 1 isoform 4 prepropro-
tein
35.1
(12.4)
0.5 (0.2)
9257232 orosomucoid 1 precursor 9.4 (0.9) 5.2 (2.1)
4505529 orosomucoid 2 9.2 (1.4) 2.3 (0.7)
4557871 transferrin 59 (6.4) 43.2
(27.5)
4507725 transthyretin 8.7 (1.7) 7.2 (4.3)
continued on next page
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Table 2.2 continued
Classiﬁcation Accession
number2
Protein name Mean
peptides
Mean
emPAI1
(SD) (SD)
2. Complement factors
73858568 complement component 1 inhibitor
precursor
18.7 (0.7) 5.2 (1.1)
14550407 complement component 2 pre-
cursor
14.7 (4.8) 0.5 (0.2)
115298678 complement component 3 pre-
cursor
110.1 (8) 7.3 (1.9)
67190748 complement component 4A prepro-
protein
65.4
(10.5)
2.4 (0.8)
50345296 complement component 4B prepro-
protein
65.7
(11.2)
2.4 (0.9)
38016947 complement component 5 23.3
(12.1)
0.4 (0.2)
4559406 Complement component 6 pre-
cursor
14.6 (2.7) 0.4 (0.1)
45580688 complement component 7 pre-
cursor
19.4 (3.9) 0.7 (0.2)
4557389 complement component 8, alpha
polypeptide precursor
3 (0.7) 0.1 (0)
4557393 complement component 8, gamma
polypeptide
5.3 (1.7) 0.8 (0.4)
4502511 complement component 9 10.8 (2.4) 0.6 (0.2)
67782358 complement factor B preproprotein 27.6 (2.7) 1.8 (0.4)
42544239 complement factor D preproprotein 12.9 (2.4) 5.2 (1.9)
62739186 complement factor H isoform a pre-
cursor
38.9
(10.3)
2.1 (1)
118442839 complement factor H-related 1 5.8 (1.9) 0.8 (0.3)
54792787 complement factor H-related 3 1.2 (0.7) 0.2 (0.1)
119392081 complement factor I 4.9 (1.1) 0.2 (0)
5031695 H factor (complement)-like 3 5.1 (2) 0.8 (0.4)
3. Apolipoproteins
4557321 apolipoprotein A-I preproprotein 27.7 (3.1) 20.9
(12.8)
4502149 apolipoprotein A-II preproprotein 5 (0.9) 6.4 (3.4)
71773110 apolipoprotein A-IV precursor 30.9 (2.8) 19.9
(12.6)
105990532 apolipoprotein B precursor 98 (54.8) 0.7 (0.5)
4502163 apolipoprotein D precursor 3.6 (1.4) 0.7 (0.4)
4557327 apolipoprotein H precursor 11 (3.2) 1.4 (0.5)
22091452 apolipoprotein M 4.9 (1.2) 1 (0.5)
continued on next page
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Table 2.2 continued
Classiﬁcation Accession
number2
Protein name Mean
peptides
Mean
emPAI1
(SD) (SD)
4. Coagulation proteins
4503635 coagulation factor II precursor 19.7 (7.5) 1.2 (0.6)
4503629 coagulation factor XII precursor 10.1 (3) 0.5 (0.2)
4503689 ﬁbrinogen, alpha polypeptide iso-
form alpha-E preproprotein
18.1 (6.3) 0.9 (0.5)
73858566 heparin cofactor II precursor 14.1 (1.8) 1 (0.2)
4504893 kininogen 1 14.8 (1.7) 1.3 (0.2)
78191798 plasma kallikrein B1 precursor 5.8 (2.3) 0.2 (0.1)
4505881 plasminogen 22.2 (6.6) 1 (0.4)
88853069 vitronectin precursor 6.1 (2) 0.4 (0.2)
5. Extracellular matrix proteins
110349772 alpha 1 type I collagen prepropro-
tein
3.3 (1.7) 0.1 (0)
110611235 alpha 1 type XVIII collagen isoform
1 precursor
3.3 (1.1) 0.1 (0)
115583663 alpha-2-plasmin inhibitor 12.6 (2.1) 1.2 (0.3)
4501885 beta actin 11.4 (3) 1.5 (0.8)
4885049 cardiac muscle alpha actin 1 pro-
protein
8.6 (2.4) 0.9 (0.4)
4507557 C-type lectin domain family 3, mem-
ber B
6.1 (2.5) 1.5 (0.8)
62859979 heparan sulfate proteoglycan 2 9.4 (1.5) 0.1 (0)
4505047 lumican precursor 10.3 (2.3) 1.4 (0.5)
6. Hormone and vitamin binding proteins
4501987 afamin precursor 22 (4.4) 1.3 (0.3)
4557287 angiotensinogen preproprotein 10.1 (0.8) 0.9 (0.3)
73858564 corticosteroid binding globulin pre-
cursor
7.6 (2.3) 0.7 (0.3)
55743122 retinol-binding protein 4, plasma
precursor
11.4 (1.5) 12.8 (8.1)
32483410 vitamin D-binding protein precursor 24.7 (4.6) 4.1 (1.5)
7. Enzymes
4557894 lysozyme precursor 7.8 (1.4) 3.1 (1.3)
19923106 paraoxonase 1 10.2 (1.9) 1.2 (0.4)
32171249 prostaglandin H2 D-isomerase 5.2 (1.4) 1.8 (0.4)
4506145 protease, serine, 1 preproprotein 2.6 (0.5) 0.9 (0.4)
continued on next page
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Table 2.2 continued
Classiﬁcation Accession
number2
Protein name Mean
peptides
Mean
emPAI1
(SD) (SD)
8. Others
4502067 alpha-1-microglobulin/bikunin pre-
cursor
14.4 (1.5) 2.6 (0.6)
4502337 alpha-2-glycoprotein 1, zinc 17.2 (2.6) 6.7 (2.2)
21450863 attractin isoform 2 7.9 (4.2) 0.2 (0.1)
4757826 beta-2-microglobulin precursor 5 (1.2) 4 (1.8)
109255234 centrosomal protein 290kDa 2.4 (0.5) 0 (0)
4557485 ceruloplasmin precursor 46.7 (5.2) 4.2 (1)
4504165 gelsolin isoform a precursor 23.7 (4) 1.8 (0.9)
4504489 histidine-rich glycoprotein precursor 15.7 (2.3) 2.3 (0.8)
57864582 hornerin 10 (3.4) 0.2 (0.1)
31542986 intelectin 6.9 (2.3) 0.8 (0.3)
16418467 leucine-rich alpha-2-glycoprotein 1 11.3 (0.9) 1.6 (0.3)
21361845 peptidoglycan recognition protein L
precursor
3 (1.3) 0.1 (0.1)
50659080 serpin peptidase inhibitor, clade A,
member 3 precursor
20.9 (1.8) 3.2 (1.1)
110349719 titin isoform N2-A 3.3 (1.1) 0 (0)
1 emPAI = Exponentially Modiﬁed Protein Abundancy Index
2 according to the NCBI database
Discussion
The proteomic composition of the peritoneal dialysate originating from 9 patients
is elucidated, giving a representative overview of the total proteome in dialysate.
A next step will be to compare the normal proteome with differential expression
proﬁles in complications of PD. This information can then be used to generate
a set of candidates for focused functional studies with quantitative techniques,
based on antibody detection techniques with high speciﬁcity, like ELISA and
Western blotting. In the presented PD proteome 189 proteins are identiﬁed and
the common occurrence of 47% of the proteins is revealed. Variation in the identi-
ﬁed proteins is due to variable overlap of peptide elution peaks, which is inherent
to the chosen approach of peptide-based proteomics. The experimental varia-
tion is minimized by running each sample twice and using nine patients. This is
conﬁrmed with ﬁgure 2.2, showing that >90% of the protein content is present in
the shared protein list, proving that it gives a representative overview of the most
abundant proteins of the PD-proteome. The number of proteins that is shared by
all patients is by far the highest, compared to the other proteins, so the patients
are comparable according to their proteome. The origin of the proteins based
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on cellular localization shows that the majority of the identiﬁed proteins are ex-
tra cellular matrix proteins, the percentage being considerably higher than in the
plasma proteome. This reﬂects the clear relation of the dialysate with the ex-
tracellular space. Membrane proteins have a considerable contribution as well,
presumably originating mainly from cell membranes of mesothelial cells and in-
terstitial cells, as well as from endothelial cells and blood cells.
More detailed information on the PD proteome is provided in our analysis of
the 88 shared proteins. These proteins are selected on the basis of common
presence in all 9 patients, proving that it is not an accidental occurrence. The
proteome of PD, as reported in table 2.2, conﬁrms the occurrence of a number
of frequently occurring proteins in the dialysate. Sustained low-grade inﬂamma-
tion is reﬂected by the presence of acute phase proteins24. Most attention in
former studies has been paid to albumin, being the quantitatively most important
protein in the dialysate, as is shown in our protein list as well. Because of the
feared complication of peritonitis, immunoglobulins and complement factors were
also extensively studied. In addition there are clear indications that complement
activation occurs in the peritoneal cavity, both in the resting and the inﬂamed
state25,26. Losses of coagulation factors, hormones and hormone-binding pro-
teins and apolipoproteins have been reported as well27–33.
In recent years MS based proteomics have been widely used for protein identiﬁ-
cation. Different mass spectrometers can be used, and a number of separation
and fractionation steps on either protein- or peptide level can be performed to re-
duce sample complexity. Depending on the sample characteristics the most ideal
techniques have to be applied. In this study, a pre-fractionation of proteins on
one-dimensional SDS-PAGE was used in combination with a nLC-MS/MS anal-
ysis to assess the protein content of the peritoneal dialysate. A reversed phase
column was used to separate peptides based on their hydrophobicity. We ampli-
ﬁed the level of separation by pre-fractionating the proteins on one dimensional
SDS-PAGE. This approach was preferred over a two-dimensional SDS-PAGE
based method, in order to be able to cover the broad range of proteins, and
encounter less interference of high abundant proteins present in PD ﬂuid. With
two-dimensional SDS-PAGE, proteins might be unable to resolve by their iso-
electrical point or to enter the gel effectively34. However, it has to be taken into
account that two-dimensional gels provide information on the actual mass of pro-
teins and thus can be useful in identifying speciﬁc pathophysiological processes
like proteolysis. The chosen approach of one-dimenstional SDS-PAGE and nLC-
LIT FT-ICR-MS offers a reliable identiﬁcation of proteins, which is not possi-
ble with proﬁling techniques like surface enhanced laser desorption/ionization
(SELDI). The LIT FT-ICR MS offers both a high cycle time, high mass resolution
and a higher mass accuracy than any other type of MS35. The choice of ana-
lytical methods used to investigate the proteome does inﬂuence the subset of
proteins that will be identiﬁed. The described combination of techniques is the
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most suitable for our research goal, to achieve a sensitive identiﬁcation of this
complex set of proteins.
With the list of shared proteins we provided a representative proﬁle of proteins
in stable PD patients. This will allow us to study the inﬂuence of complications
such as peritonitis, the effect of diverse PD ﬂuids and the effect of prolonged
PD treatment on this proﬁle. With peritonitis protein losses are higher13, and
local inﬂammatory proteins are produced. Little is known about the losses of
individual proteins with peritonitis. Various PD ﬂuids have distinct effects on the
peritoneal membrane. Conventional glucose based PD ﬂuids versus icodextrin
and amino acid based PD ﬂuids have different inﬂammatory effects36. The pat-
terns of individual proteins involved in peritoneal defence and angiogenesis will
be compared. Long-term peritoneal dialysis will lead to peritoneal membrane
failure. Morphologic abnormalities, consisting of increasing thickness in the sub-
mesothelial compact collageneous zone, can develop, sometimes accompanied
by loss of surface mesothelia. Interstitial ﬁbrosis can be found together with ex-
tensive vascular abnormalities and increase of the number of blood vessels37. It
will be interesting to follow the proteomic proﬁle in the peritoneal dialysate dur-
ing a prolonged period of treatment and relate these data to solute transport
and ultraﬁltation capacity38. The inﬂuence of transport status on differential ex-
pression of individual proteins present in the peritoneal dialysate was studied by
Sritippayawan et al39, showing lower values of complement factor 4A and im-
munoglobulin κ in patients with low transport status. The inﬂuence of transport
status was not analyzed in our study population, since practically all children
have high or high average transport status. This study on differential expression
of proteins however supports the fact that the comparison of proteins in different
PD states can be performed with proteomic techniques, and the presented tech-
niques and overview given in our study will be useful for future studies.
The proteome of the peritoneal dialysate reveals some interesting new proteins,
asking for the elucidation of their possible role. Interesting proteins in the shared-
proteins list are for example gelsolin, intelectin and paraoxonase. Gelsolin exists
as an intracellular actin-severing protein but also exists as a plasma form. It has
been proposed to protect the organism from deleterious effects of cytoskeletal
actin-containing ﬁlaments released with tissue injury and cell death40. Gelsolin
can bind cytokines and gram-negative endotoxines as well. In animal sepsis-
models gelsolin depletion leads to adverse outcomes and repletion of gelsolin
may be a potential therapy. Gelsolin is proposed as a possible biomarker for the
severity of sepsis41. In mice lacking gelsolin, delayed migration of neutrophils
in peritoneal exudates was seen42. In PD gelsolin could play a protective role
in mesothelial cell damage and against infections. Intelectin is a mammalian
lectin known to be exposed in the goblet and paneth cells in the small intes-
tine, possibly as a component of the protective immune response to parasites43.
Another location of intelectin is the enterocyte brush border, where it was sug-
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gested to serve as an organizer and stabilizer of the brush border membrane
preventing loss of digestive enzymes and protecting the glycolipid microdomains
from pathogens44. Intelectin was also identiﬁed as a new adipocytokine, also
named omentin, as it was expressed in omental tissue, with a possible role in the
defense against intestinal bacterial permeation45. In the peritoneal dialysate it
could be encountered originating from the omentum. Paraoxonase is known as a
serum enzyme, associated with high density lipoproteins, protecting lipoproteins
from toxic oxidative modiﬁcations, exhibiting anti-atherogenic capacities46,47. Ac-
cording to a study by Liberopoulos et al. serum paraoxonase activity is increased
in PD patients compared to healthy controls48. It was suggested this is due to
increased resistance to oxidation of HDL in PD patients. Other studies however,
found that paraoxonase activity was reduced in PD patients, HD patients and
non-end-stage renal failure patients, compared with healthy controls49,50. This
was also found in children on PD51. The decrease in paraoxonase activity could
give a reduction in its anti-atherogenic properties and could play a role in vascu-
lar aging. The possible correlation with early atherosclerotic changes has to be
further investigated.
The proteome of the peritoneal ﬂuid of PD patients has very interesting potential,
asking for more functional proteomic research in the near future.
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Table 2.3: (Supplementary table) All proteins identiﬁed in the PD ﬂuid of 9 paediatric
patients with isoforms and hypothetical alternatives. Listed in bold text are the identiﬁed
proteins, all non-bold listed are the isoforms and hypothetical alternatives that cannot be
excluded based on the detected peptides
Protein
number
Accession
number
Protein name
1 105990532 apolipoprotein B precursor
55770852 glutamate receptor, ionotropic, delta 1
93277113 GTP binding protein
2 115298678 complement component 3 precursor
89057120 PREDICTED: similar to Complement C3 precursor
15553097 hypothetical protein MGC9084
3 4502027 albumin precursor
32528310 hypothetical protein LOC145447 isoform c
32451492 hypothetical protein LOC145447 isoform b
4 66932947 alpha-2-macroglobulin precursor
119943096 dopamine receptor interacting protein
40254471 UDP glycosyltransferase 8 (UDP-galactose ceramide
galactosyltransferase)
5 50345296 complement component 4B preproprotein
6 67190748 complement component 4A preproprotein
7 4557871 transferrin
8 4557485 ceruloplasmin precursor
9 47132555 ﬁbronectin 1 isoform 4 preproprotein
16933542 ﬁbronectin 1 isoform 3 preproprotein
47132549 ﬁbronectin 1 isoform 6 preproprotein
47132553 ﬁbronectin 1 isoform 5 preproprotein
47132557 ﬁbronectin 1 isoform 1 preproprotein
47132551 ﬁbronectin 1 isoform 2 preproprotein
47132547 ﬁbronectin 1 isoform 7 preproprotein
10 62739186 complement factor H isoform a precursor
62739188 complement factor H isoform b precursor
11 50363219 serine (or cysteine) proteinase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 1
50363221 serine (or cysteine) proteinase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 1
50363217 serine (or cysteine) proteinase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 1
89037848 PREDICTED: similar to Alpha-1-antitrypsin-related protein
precursor
118582255 ATP-binding cassette, sub-family C, member 8
12 38016947 complement component 5
9055284 myosin VC
13 71773110 apolipoprotein A-IV precursor
14 4826762 haptoglobin
15 31542984 inter-alpha (globulin) inhibitor H4
continued on next page
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Table 2.3 continued
Protein
number
Accession
number
Protein name
16 32483410 vitamin D-binding protein precursor
17 4557321 apolipoprotein A-I preproprotein
7656952 calcyclin binding protein isoform 1
18 4502261 serine (or cysteine) proteinase inhibitor, clade C
(antithrombin), member 1
19 4504165 gelsolin isoform a precursor
38044288 gelsolin isoform b
20 67782358 complement factor B preproprotein
21 4505881 plasminogen
113413126 PREDICTED: similar to anaphase promoting complex
subunit 1 isoform 6
74048573 plasminogen-like B1
4505883 plasminogen-related protein B2
22 4503635 coagulation factor II precursor
23 45580688 complement component 7 precursor
16933540 ﬁbroblast activation protein, alpha subunit
24 70778918 inter-alpha globulin inhibitor H2 polypeptide
25 50659080 serpin peptidase inhibitor, clade A, member 3 precursor
26 11321561 hemopexin
27 70906435 ﬁbrinogen, beta chain preproprotein
28 39725934 serine (or cysteine) proteinase inhibitor, clade F
(alpha-2 antiplasmin, pigment epithelium derived
factor), member 1
29 4501987 afamin precursor
30 4504781 inter-alpha (globulin) inhibitor H1
31 4503689 ﬁbrinogen, alpha polypeptide isoform alpha-E
preproprotein
11761629 ﬁbrinogen, alpha polypeptide isoform alpha preproprotein
32 4559406 Complement component 6 precursor
33 45580723 haptoglobin-related protein
34 73858568 complement component 1 inhibitor precursor
73858570 complement component 1 inhibitor precursor
35 4502067 alpha-1-microglobulin/bikunin precursor
36 14550407 complement component 2 precursor
5174545 MADS box transcription enhancer factor 2, polypeptide D
(myocyte enhancer factor 2D)
37 4502337 alpha-2-glycoprotein 1, zinc
38 70906437 ﬁbrinogen, gamma chain isoform gamma-A precursor
70906439 ﬁbrinogen, gamma chain isoform gamma-B precursor
39 4504489 histidine-rich glycoprotein precursor
40 21071030 alpha 1B-glycoprotein
continued on next page
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Table 2.3 continued
Protein
number
Accession
number
Protein name
41 4504893 kininogen 1
42 57864582 hornerin
113412358 PREDICTED: similar to Hornerin
43 42544239 complement factor D preproprotein
44 4506355 pregnancy-zone protein
45 55743122 retinol-binding protein 4, plasma precursor
46 4557325 apolipoprotein E precursor
47 4501885 beta actin
4501887 actin, gamma 1 propeptide
113413194 PREDICTED: similar to Prostate, ovary, testis expressed
protein on chromosome 2
63055057 hypothetical protein LOC345651
88953571 PREDICTED: similar to Prostate, ovary, testis expressed
protein on chromosome 2 isoform 2
113424511 PREDICTED: similar to actin-like protein
89037243 PREDICTED: similar to actin-like protein
113413200 PREDICTED: similar to Prostate, ovary, testis expressed
protein on chromosome 2
62990121 actin-like protein
89040395 PREDICTED: similar to actin, alpha 2, smooth muscle, aorta
89040918 PREDICTED: similar to actin, alpha 2, smooth muscle, aorta
88942515 PREDICTED: similar to cytoplasmic beta-actin
88947619 PREDICTED: similar to cytoplasmic beta-actin
48 4557327 apolipoprotein H precursor
49 21450863 attractin isoform 2
21450861 attractin isoform 1
50 16418467 leucine-rich alpha-2-glycoprotein 1
51 4557287 angiotensinogen preproprotein
52 4507725 transthyretin
53 73858566 heparin cofactor II precursor
54 4502511 complement component 9
55 62859979 heparan sulfate proteoglycan 2
56 9257232 orosomucoid 1 precursor
57 73858564 corticosteroid binding globulin precursor
58 58530840 desmoplakin isoform I
58530842 desmoplakin isoform II
59 4505047 lumican precursor
50345870 DENN/MADD domain containing 3
60 4507377 serine (or cysteine) proteinase inhibitor, clade A,
member 7
continued on next page
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Table 2.3 continued
Protein
number
Accession
number
Protein name
61 21361195 serine (or cysteine) proteinase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 5
62 115583663 alpha-2-plasmin inhibitor
63 4505529 orosomucoid 2
64 19923106 paraoxonase 1
65 4826772 insulin-like growth factor binding protein, acid labile
subunit
66 4502495 complement component 1, s subcomponent
41393602 complement component 1, s subcomponent
21264357 mannan-binding lectin serine protease 1 isoform 1 precursor
73623026 mannan-binding lectin serine protease 1 isoform 3
21264359 mannan-binding lectin serine protease 1 isoform 2 precursor
55770872 l(3)mbt-like 3 isoform b
55770870 l(3)mbt-like 3 isoform a
67 50845388 annexin A2 isoform 1
50845386 annexin A2 isoform 2
4757756 annexin A2 isoform 2
68 78191798 plasma kallikrein B1 precursor
15529990 granzyme H
69 4503629 coagulation factor XII precursor
70 4507557 C-type lectin domain family 3, member B
71 54400755 inter-alpha (globulin) inhibitor H3
72 4502005 alpha-2-HS-glycoprotein
73 4885049 cardiac muscle alpha actin 1 proprotein
4501881 alpha 1 actin precursor
4501883 alpha 2 actin
4501889 actin, gamma 2 propeptide
74 31542986 intelectin
18254480 intelectin 2
75 34734066 ﬁbulin 1 isoform D
34734064 ﬁbulin 1 isoform B precursor
34734068 ﬁbulin 1 isoform A precursor
76 4502503 complement component 4 binding protein, alpha chain
precursor
77 34734062 ﬁbulin 1 isoform C precursor
78 119392081 complement factor I
79 4502133 serum amyloid P component precursor
80 4557894 lysozyme precursor
81 4557393 complement component 8, gamma polypeptide
82 21361302 serine (or cysteine) proteinase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 4
continued on next page
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Table 2.3 continued
Protein
number
Accession
number
Protein name
83 118442839 complement factor H-related 1
13540563 complement factor H-related 5
84 88853069 vitronectin precursor
4505213 matrix metalloproteinase 19 isoform rasi-1 preproprotein
113431303 PREDICTED: similar to Matrix metalloproteinase-19
precursor (MMP-19) (Matrix metalloproteinase RASI)
(MMP-18)
85 110349772 alpha 1 type I collagen preproprotein
86 21735614 apolipoprotein L1 isoform a precursor
21735616 apolipoprotein L1 isoform b precursor
22035642 apolipoprotein L3 isoform 2
22035646 apolipoprotein L3 isoform 1
22035644 apolipoprotein L3 isoform 2
22035648 apolipoprotein L3 isoform 3
22035650 apolipoprotein L3 isoform 3
7656973 apolipoprotein L3 isoform 2
87 5174411 CD5 antigen-like (scavenger receptor cysteine rich
family)
88 88971372 PREDICTED: similar to Carboxypeptidase N subunit 2
precursor (Carboxypeptidase N polypeptide 2)
(Carboxypeptidase N 83 kDa chain) (Carboxypeptidase
N regulatory subunit) (Carboxypeptidase N large
subunit)
88967170 PREDICTED: similar to Carboxypeptidase N subunit 2
precursor (Carboxypeptidase N polypeptide 2)
(Carboxypeptidase N 83 kDa chain) (Carboxypeptidase N
regulatory subunit) (Carboxypeptidase N large subunit)
89 32171249 prostaglandin H2 D-isomerase
90 5031695 H factor (complement)-like 3
91 12056468 junction plakoglobin
4504811 junction plakoglobin
92 4757826 beta-2-microglobulin precursor
93 66347875 complement component 1, r subcomponent
30425518 hypothetical protein LOC339779
7706083 complement component 1, r subcomponent-like precursor
94 42716297 clusterin isoform 1
42740907 clusterin isoform 2
95 4507645 triosephosphate isomerase 1
113412118 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 2
113412120 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 3
continued on next page
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Table 2.3 continued
Protein
number
Accession
number
Protein name
113412122 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 4
113412124 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 5
113412126 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 6
113408757 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 2
113408759 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 3
113408761 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 4
113408763 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 5
113412128 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 1
113408766 PREDICTED: similar to Triosephosphate isomerase (TIM)
(Triose-phosphate isomerase) isoform 1
96 21361845 peptidoglycan recognition protein L precursor
97 55743098 alpha 3 type VI collagen isoform 1 precursor
55743100 alpha 3 type VI collagen isoform 2 precursor
55743102 alpha 3 type VI collagen isoform 3 precursor
55743104 alpha 3 type VI collagen isoform 4 precursor
55743106 alpha 3 type VI collagen isoform 5 precursor
98 4502101 annexin I
99 38455402 lipocalin 2
100 4758236 extracellular matrix protein 1 isoform 1 precursor
12707572 extracellular matrix protein 1 isoform 2 precursor
101 22091452 apolipoprotein M
102 4503107 cystatin C precursor
103 4504349 beta globin
4504351 delta globin
28302131 A-gamma globin
6715607 G-gamma globin
4885393 epsilon globin
104 4506117 protein S (alpha)
105 87298828 complement component 1, q subcomponent, B chain
precursor
106 4505643 procollagen C-endopeptidase enhancer
107 110611235 alpha 1 type XVIII collagen isoform 1 precursor
110611233 alpha 1 type XVIII collagen isoform 2 precursor
108 4502149 apolipoprotein A-II preproprotein
109 116812622 phosphatidylethanolamine-binding protein 4
continued on next page
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number
Accession
number
Protein name
110 4557391 complement component 8, beta polypeptide
preproprotein
111 4826898 proﬁlin 1
112 7382460 sex hormone-binding globulin
113 21735625 tyrosine 3/tryptophan 5 -monooxygenase activation
protein, zeta polypeptide
4507953 tyrosine 3/tryptophan 5 -monooxygenase activation protein,
zeta polypeptide
5454052 stratiﬁn
4507949 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, beta polypeptide
5803225 tyrosine 3/tryptophan 5 -monooxygenase activation protein,
epsilon polypeptide
5803227 tyrosine 3/tryptophan 5 -monooxygenase activation protein,
theta polypeptide
4507951 tyrosine 3/tryptophan 5 -monooxygenase activation protein,
eta polypeptide
21328448 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein, beta polypeptide
114 4502163 apolipoprotein D precursor
115 10835095 serum amyloid A4, constitutive
116 4504383 HGF activator preproprotein
117 31543212 macrophage stimulating 1 (hepatocyte growth
factor-like)
118 67782336 tenascin XB isoform 1
20665034 tenascin XB isoform 2
119 4506773 S100 calcium-binding protein A9
120 5031863 galectin 3 binding protein
121 56786155 complement component 1, q subcomponent, gamma
polypeptide
122 4504549 tenascin C (hexabrachion)
123 110349719 titin isoform N2-A
110349715 titin isoform N2-B
110349713 titin isoform novex-1
110349717 titin isoform novex-2
4502477 beta-transducin repeat containing protein isoform 2
16117783 beta-transducin repeat containing protein isoform 1
124 34577112 aldolase A
34577110 aldolase A
4557305 aldolase A
4885063 fructose-bisphosphate aldolase C
40354205 aldolase B
125 119703744 desmoglein 1 preproprotein
continued on next page
50
PROTEOMIC PROFILING
2
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Protein
number
Accession
number
Protein name
126 4557389 complement component 8, alpha polypeptide precursor
127 4502951 collagen, type III, alpha 1 preproprotein
128 4503011 carboxypeptidase N, polypeptide 1, 50kD precursor
129 4503005 plasma carboxypeptidase B2 isoform a preproprotein
16915928 plasma carboxypeptidase B2 isoform b
130 4507171 secreted protein, acidic, cysteine-rich (osteonectin)
131 4506557 ribonuclease, RNase A family, 4 precursor
37577172 ribonuclease, RNase A family, 4 precursor
37577170 ribonuclease, RNase A family, 4 precursor
132 48762934 alpha 2 type I collagen
133 4503571 enolase 1
134 32307172 dermatopontin precursor
135 4557779 myocilin
136 21264363 mannan-binding lectin serine protease 2 isoform 1
precursor
21264361 mannan-binding lectin serine protease 2 isoform 2 precursor
137 116008152 alpha 1 type XV collagen precursor
138 4506145 protease, serine, 1 preproprotein
116256363 transmembrane protease, serine 13
4506147 protease, serine, 2 preproprotein
139 4503113 cystatin M precursor
113422961 PREDICTED: similar to Cystatin M precursor (Cystatin E)
41872646 cullin 7
140 113429091 PREDICTED: similar to peptidylprolyl isomerase A
isoform 1
10863927 peptidylprolyl isomerase A
113429184 PREDICTED: similar to peptidylprolyl isomerase A isoform 1
113422150 PREDICTED: similar to peptidylprolyl isomerase A isoform 1
113421727 PREDICTED: similar to peptidylprolyl isomerase A isoform 1
141 54873613 agrin
142 19743846 decorin isoform a preproprotein
4503271 decorin isoform a preproprotein
19743848 decorin isoform b precursor
19743850 decorin isoform c precursor
143 77539758 histone cluster 2, H4b
continued on next page
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Table 2.3 continued
Protein
number
Accession
number
Protein name
4504321 H4 histone family, member M
4504303 H4 histone family, member B
4504301 H4 histone family, member A
4504305 H4 histone family, member C
4504313 H4 histone family, member I
4504309 H4 histone family, member G
4504311 H4 histone family, member H
4504315 H4 histone family, member J
4504307 H4 histone family, member D
11415030 H4 histone family, member E
4504317 H4 histone family, member K
4504323 histone 2, H4
28173560 histone H4
144 109255234 centrosomal protein 290kDa
145 54792787 complement factor H-related 3
117320518 complement factor H-related 4
146 21536452 mesotrypsin preproprotein
147 70780384 protease inhibitor 16 precursor
148 4557313 angiogenin, ribonuclease, RNase A family, 5 precursor
149 21614544 S100 calcium-binding protein A8
150 68563515 keratinocyte expressed, proline-rich protein
151 5729877 heat shock 70kDa protein 8 isoform 1
24234686 heat shock 70kDa protein 8 isoform 2
5123454 heat shock 70kDa protein 1A
27436929 heat shock 70kDa protein 1-like
4885431 heat shock 70kDa protein 1B
13676857 heat shock 70kDa protein 2
16507237 heat shock 70kDa protein 5
34419635 heat shock 70kDa protein 6 (HSP70B’)
152 21464101 tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein, gamma
polypeptide
153 13259372 osteoglycin preproprotein
7661704 osteoglycin preproprotein
14916498 osteoglycin preproprotein
154 4503117 cystatin B
155 4758146 defensin, alpha 1 preproprotein
113419903 PREDICTED: similar to Neutrophil defensin 1 precursor
(HNP-1) (HP-1) (HP1) (Defensin, alpha 1)
4885179 defensin, alpha 3 preproprotein
156 4758328 fatty acid binding protein 3
157 16751921 dermcidin preproprotein
continued on next page
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Table 2.3 continued
Protein
number
Accession
number
Protein name
158 62122917 ﬁlaggrin 2
113412360 PREDICTED: similar to ﬁlaggrin 2
159 4557373 biotinidase precursor
160 4504345 alpha 2 globin
4504347 alpha 1 globin
161 10835248 regenerating islet-derived 1 beta precursor
29725633 regenerating islet-derived 1 alpha precursor
162 4557581 fatty acid binding protein 5 (psoriasis-associated)
113422908 PREDICTED: similar to Fatty acid-binding protein,
epidermal (E-FABP) (Psoriasis-associated fatty acid-binding
protein homolog) (PA-FABP)
89038645 PREDICTED: similar to Fatty acid-binding protein,
epidermal (E-FABP) (Psoriasis-associated fatty acid-binding
protein homolog) (PA-FABP)
89037119 PREDICTED: similar to Fatty acid-binding protein,
epidermal (E-FABP) (Psoriasis-associated fatty acid-binding
protein homolog) (PA-FABP)
89039254 PREDICTED: similar to Fatty acid-binding protein,
epidermal (E-FABP) (Psoriasis-associated fatty acid-binding
protein homolog) (PA-FABP)
89036788 PREDICTED: similar to Fatty acid-binding protein,
epidermal (E-FABP) (Psoriasis-associated fatty acid-binding
protein homolog) (PA-FABP)
113422396 PREDICTED: similar to Fatty acid-binding protein,
epidermal (E-FABP) (Psoriasis-associated fatty acid-binding
protein homolog) (PA-FABP)
163 11321593 insulin-like growth factor binding protein 6
164 13435366 desmocollin 2 isoform Dsc2b preproprotein
13435364 desmocollin 2 isoform Dsc2a preproprotein
165 4502157 apolipoprotein C-I precursor
166 22538442 cathepsin Z preproprotein
167 29171717 glycosylphosphatidylinositol speciﬁc phospholipase D1
isoform 1 precursor
168 21489959 immunoglobulin J chain
169 4757960 cadherin 1, type 1 preproprotein
170 13435369 desmocollin 3 isoform Dsc3b preproprotein
4503399 desmocollin 3 isoform Dsc3a preproprotein
171 4505909 peripheral myelin protein 2
4557579 fatty acid binding protein 4, adipocyte
172 4757760 adiponectin precursor
173 4826702 desmocollin 1 isoform Dsc1b preproprotein
13435361 desmocollin 1 isoform Dsc1a preproprotein
continued on next page
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Table 2.3 continued
Protein
number
Accession
number
Protein name
174 4503475 eukaryotic translation elongation factor 1 alpha 2
4503471 eukaryotic translation elongation factor 1 alpha 1
175 89062025 PREDICTED: similar to immunoglobulin iota chain
preproprotein
176 12025678 actinin, alpha 4
4501893 actinin, alpha 2
4501891 actinin, alpha 1
4557241 skeletal muscle speciﬁc actinin, alpha 3
177 118582275 superoxide dismutase 3, extracellular precursor
178 116517328 G-protein coupled receptor 115
179 7669492 glyceraldehyde-3-phosphate dehydrogenase
180 89035644 PREDICTED: similar to Phosphoglycerate mutase 1
(Phosphoglycerate mutase isozyme B) (PGAM-B)
(BPG-dependent PGAM 1) isoform 1
89035650 PREDICTED: similar to Phosphoglycerate mutase 1
(Phosphoglycerate mutase isozyme B) (PGAM-B)
(BPG-dependent PGAM 1) isoform 4
113414929 PREDICTED: similar to Phosphoglycerate mutase 1
(Phosphoglycerate mutase isozyme B) (PGAM-B)
(BPG-dependent PGAM 1)
89035672 PREDICTED: similar to Phosphoglycerate mutase 1
(Phosphoglycerate mutase isozyme B) (PGAM-B)
(BPG-dependent PGAM 1) isoform 1
89036292 PREDICTED: similar to Phosphoglycerate mutase 1
(Phosphoglycerate mutase isozyme B) (PGAM-B)
(BPG-dependent PGAM 1) isoform 1
113414382 PREDICTED: similar to Phosphoglycerate mutase 1
(Phosphoglycerate mutase isozyme B) (PGAM-B)
(BPG-dependent PGAM 1)
4505753 phosphoglycerate mutase 1 (brain)
50593010 phosphoglycerate mutase 2 (muscle)
181 31543397 phosphoglycerate kinase 2
4505763 phosphoglycerate kinase 1
182 113427619 PREDICTED: similar to Metalloproteinase inhibitor 2
precursor (TIMP-2) (Tissue inhibitor of
metalloproteinases 2) (CSC-21K)
4507511 tissue inhibitor of metalloproteinase 2 precursor
183 56682959 ferritin, heavy polypeptide 1
184 4758950 peptidylprolyl isomerase B precursor
185 7657532 S100 calcium-binding protein A6
186 27754776 ﬁcolin 3 isoform 1 precursor
27754778 ﬁcolin 3 isoform 2 precursor
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Table 2.3 continued
Protein
number
Accession
number
Protein name
187 33457348 chromosome 19 open reading frame 10
188 4506713 ubiquitin and ribosomal protein S27a precursor
11024714 ubiquitin B precursor
113423966 PREDICTED: similar to Ubiquitin-63E CG11624-PA, isoform
A
67191208 ubiquitin C
77539055 ubiquitin and ribosomal protein L40 precursor
4507761 ubiquitin and ribosomal protein L40 precursor
189 4504279 H3 histone, family 3A
31742503 H3 histone family, member M
4504299 H3 histone family, member T
70608086 histone H2, H3-like
4504285 H3 histone family, member C
4504281 H3 histone family, member A
4504289 H3 histone family, member F
10440560 H3 histone family, member I
4504293 H3 histone family, member J
4504291 H3 histone family, member H
4504297 H3 histone family, member L
89060765 PREDICTED: similar to H3 histone, family 3B
61966849 hypothetical protein LOC440093
88943485 PREDICTED: similar to H3 histone, family 2 isoform 2
53793688 histone 2, H3a
89059701 PREDICTED: similar to H3 histone, family 3B
4885385 H3 histone, family 3B
21071021 H3 histone family, member B
4504287 H3 histone family, member D
4504295 H3 histone family, member K
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Abstract
Background
Proteomic technologies offer a high-throughput analysis of the expression of pro-
teins in biological samples. In this study a longitudinal follow-up was performed
to investigate long-term protein changes in peritoneal dialysis (PD), as a possible
reﬂection of the function of the peritoneal membrane.
Methods
The dialysate of 7 pediatric PD patients (age 0.5 to 10 years), was collected in
the ﬁrst year of dialysis (t0) from the 2 hour dwell of a peritoneal equilibrium test
and again 2 years later (t1). Samples were concentrated, puriﬁed and run on a
10% 1D-SDS-PAGE and in-gel digested with trypsin. Peptides were separated
using nano scale high performance liquid chromatography (nLC). Peptide mass
and masses of their respective fragment ions were determined by subsequent
mass spectrometry (MS) and MS/MS cycles and searched against the NCBI
database. Relative quantiﬁcation was performed with spectral counts (unique
ions per protein). Western blotting was performed as well as orosomucoid stain-
ing on peritoneal biopsies, for extra validation.
Results
A total number of 186 individual proteins were identiﬁed in 14 samples from 7
patients. Only the protein orosomucoid was found to be present in a higher
concentration in all samples at t1, compared to t0 (p=0.006). Orosomucoid is
an acute phase protein, that is upregulated in states of inﬂammation and tissue
damage. With peritoneal biopsies the deposition of orosomucoid in time was
conﬁrmed. With Western blotting measurements results were only partially in
concordance.
Conclusions
Using 1-SDS-PAGE combined with nLC-MS/MS an increased concentration of
orosomucoid was found in all patients after 2 years of dialysis, probably due to
increased endothelial synthesis combined with augmented vascular permeability
in the presence of increased inﬂammation. The results were not in complete
concordance with the Western Blotting results, which could partly be due to the
multiple isoforms of orosomucoid.
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Introduction
Peritoneal dialysis (PD) is a widely used modality for the treatment of end stage
renal failure and is especially preferred in younger children. The proteome is
the entire set of proteins expressed in a deﬁned biological sample. Proteomic
techniques offer a high-throughput analysis of the expression of proteins. In peri-
toneal dialysis proteomics can potentially provide clinically relevant information
about functional changes of proteins in the peritoneal membrane1. An analysis of
the total proteome of the dialysate from 9 stable pediatric PD patients has been
performed with liquid chromatography combined with mass spectrometry (LC-
MS/MS) with pre-fractionation with 1-dimensional gel electrophoresis (1D-SDS-
PAGE)2. The ﬁrst comparisons of protein proﬁles of PD ﬂuid in different settings
have been made in recent years as well. In one study different transport types of
peritoneal membranes were detected3. With a 2-dimensional gel electrophore-
sis technique, combined with MALDI-TOF MS and tandem MS/MS, 5 proteins
were found to be less expressed in the lowest transport groups (albumin, alpha-
1-antitrypsin, complement factor C4A, immunoglobulin kappa light chain and
apolipoprotein A-I). Lin et al.4 compared 16 peritonitis patients with peritonitis-
free patients, using the combined techniques of 2D-gel-electrophoresis with SEL-
DI-TOF-MS. They found beta-2-microglobulin to be upregulated in peritonitis
patients, which conﬁrmed previously reported ﬁndings of beta-2-microglobulin
as a biomarker for peritonitis. Recently, the effect of glucose concentration
in PD ﬂuids was studied in 15 patients by Cuccurullo et al.5, with 1D-SDS-
PAGE combined with LC - MS/MS. It was shown that 4 inﬂammation related
proteins (apolipoprotein A-IV, ﬁbrinogen, transthyrethin and alpha-1-antitrypsin)
were under-expressed in the highest glucose concentration of 4.25%. In another
study by Wang et al.6, 5 diabetic PD patients were compared to 2 healthy con-
trols. Protein proﬁles were analyzed by means of 2D-gel electrophoresis followed
by LC-MS/MS. In the diabetic PD patients a higher level of vitamin D-binding pro-
tein, haptoglobin, and alpha-2-microglobulin were observed. The only compar-
ative pediatric study was performed by Brusschi et al. in 20117, who compared
the proﬁle of icodextrin versus glucose based PD ﬂuids in 16 children on PD.
They used a combination of 2D gel electrophoresis followed by LC-MS/MS. They
concluded that icodextrin provides a better removal of small proteins, based on
higher transport kinetics for beta-2-microglobulin and cystatin C. In this present
study we performed the ﬁrst longitudinal follow up in PD patients with proteomics.
Protein changes in long-term dialysis may give information about changes in the
function of the peritoneal membrane and offers the possibility to identify new
biomarkers. The peritoneal dialysates of 7 pediatric patients on PD were ana-
lyzed over the course of 2 years, to evaluate possible longitudinal changes in
the protein proﬁle in an unbiased high-throughput manner with the combined
proteomic techniques of 1D-SDS-PAGE with LC-MS/MS.
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Patients and methods
Patients
The dialysate of 7 pediatric patients was collected at 2 time-points from two hour
dwells during a peritoneal equilibrium test (PET) and stored at -20◦C. PD ﬂuid
was collected in the ﬁrst year of dialysis (t0) and 2 years later (t1). None of the
patients suffered from peritonitis in the 3 months prior to the collection. Patient
and ﬂuid characteristics are shown in table 3.1.
Proteomic techniques
The protein concentration in the dialysate was measured with the 2D- Quant
Kit (General Electric Healthcare Bio-sciences R©, USA). From each sample, 40
μg of protein was taken for analysis. Analysis of the samples was performed
as described before2. In summary samples were run on a 10% 1D-SDS-PAGE
and stained with ready-made colloidal coomassie staining (Severn Biotech ltd,
Worcestershire, UK). From stacking gel to sample buffer front, each gel lane was
cut into ﬁve slices. The proteins were reduced, alkylated and in-gel digested
with trypsin overnight. The resulting peptides were extracted from the gel by
adding one volume of 2% triﬂuoroacetic acid. For each sample, 5 μl of the pep-
tide mixture was separated on an Agilent 1100 LC system (Agilent, Palo Alto,
CA, USA). Bound peptides were eluted from the column using an increasing
acetonitrile gradient. Mass spectrometric analyses were performed in a hybrid
linear ion trap Fourier Transform Ion Cyclotron Resonance (LIT FT-ICR) mass
spectrometer. (LTQ FT-MS, Thermo Electron Corporation, Bremen, Germany).
Eluted peptides were directly injected in the LIT FT-ICR MS, which was operated
in the data-dependent mode to automatically switch between MS and MS/MS.
Survey mass spectra (350-2000 m/z) were recorded in the ICR cell. The four
most abundant ions were isolated data dependently and fragmented by collision
induced dissociation (CID) in the LIT MS. All samples were measured twice to re-
duce experimental variation. The mass spectrometry data ﬁles for each sample
were merged and searched against the NCBI database using the Mascot search
program (Matrix Science Inc., Boston, MA USA, version 2.1). Searches were
repeated against a reversed database with the same settings, to allow for false
discovery rate validation. Relative protein quantiﬁcation was performed with the
technique of spectral counting. Hereby the number of identiﬁed MS/MS spectra
from the same protein are compared in each of the multiple LC-MS/MS datasets,
which correlates directly with relative protein abundance8. Spectral counts have
been proven to give a reliable index for relative protein quantiﬁcation9.
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Western blotting experiments
(Semi)-quantitative analyses of orosomucoid levels were performed by in duplo
Western blotting experiments, with 15% SDS-PAGE gel. A polyclonal orosomu-
coid rabbit anti human antibody (Dako Q 0326) was used. Orosomucoid quantity
was measured by densitometry (Molecular Imager , Biorad Chemidoc XRST R©,
Hercules, USA; software by Image Lab R©, Copenhagen, Denmark ). Measure-
ments with ELISA techniques were performed to compare with Western blotting
results, but the available ELISA kit (Quantikine R©, R&D systems Inc., Minneapo-
lis, USA), using a monoclonal antibody led to non-reproducible results that were
not consistent with the values obtained byWestern blotting, so these experiments
could not be used for analysis.
Immunohistochemical staining of peritoneal tissue of PD patients
Biopsies of the parietal peritoneum of three PD patients were obtained during
kidney transplantation procedure. Patient 1 and 2 were treated with PD for
respectively 7 months and 11 months and patient 3 had a PD duration of 26
months. Peritoneal tissue was ﬁxed in 4% formalin for 24 hours and embedded
in parafﬁn. Four μm thick tissue sections were deparafﬁnized and rehydrated.
Endogenous peroxidase activity was inactivated using 1.5% hydrogen peroxide
in methanol. Antigen retrieval was done by boiling in 0.1 M sodiumcitrate buffer
(pH 6) for 20 minutes. Sections were incubated for 1 hour with monoclonal anti-
orosomucoid1-antibody (Abnova Corporation, Taipei, Taiwan), diluted 1:2000 in
PBS with 1% BSA. After washing, sections were incubated with poly-HRP-goat
anti-mouse IgG (BrightVision, Klinipath, Duiven, the Netherlands) for 30 minutes,
followed by washing in PBS. HRP activity was detected using diaminobenzidine,
and nuclear counterstaining was performed with hematoxylin.
Table 3.1: Characteristics of patients and peritoneal dialysate
Patient
(Gender)
Age at
start PD
(Years)
Underlying disease Time on
PD at t0
(Years)
Time on
PD at t1
(Years)
1 (F) 0.4 Mesangial sclerosis 0.2 2.2
2 (F) 7.5 Dysplastic kidneys 0.2 2.3
3 (M) 2.2 Urethral valves 1.0 3.0
4 (M) 2.7 Congenital nephrotic sndrome 0.6 2.3
5 (M) 10.6 Hereditary nephrotic syndrome 0.3 2.1
6 (M) 2.4 Urethral valves 0.7 2.8
7 (F) 8.7 Idiopathic 0.3 2.4
F= Female, M = Male
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Results
A total number of 186 individual proteins were identiﬁed with 3 or more peptide
counts per protein, after measurement of all samples in duplicate. Keratins and
hypothetical proteins were excluded. A number of 106 proteins were present in
all patients on t0, 101 proteins were present in all patients on t1. An overview of
the proteins present in all patients at timepoint t0 and/or t1 with a classiﬁcation
according to function is given in table 3.2.
Table 3.2: Overview of proteins present in all patients at t0 and/or at t1, with classiﬁcation
according to function
Classiﬁcation Accession
number
Protein name Mean
peptide
count t0
Mean
peptide
count t1
(SD) (SD)
1. Acute phase proteins
a. antiproteases
66932947 alpha-2-macroglobulin precursor 110.7
(9.3)
102.8
(14.1)
4503107 cystatin C precursor 1.8 (0.4) 1.8 (0.8)
156119625 inter-alpha (globulin) inhibitor H1 16.4 (3.1) 16.1 (3.2)
70778918 inter-alpha (globulin) inhibitor H2
polypeptide
20.4 (6.1) 20.0 (7.7)
133925809 inter-alpha (globulin) inhibitor H3
preproprotein
6.3 (3.3) 4.3 (2.9)
31542984 inter-alpha (globulin) inhibitor H4 25.8 (5.7) 24.5 (8.9)
162809334 pregnancy-zone protein 16.1 (1.6) 14.6 (2.3)
194018472 serine proteinase inhibitor, clade A
( antitrypsin), member 5*
2.7 (1.1) 2.8 (1.7)
21361302 serine proteinase inhibitor, clade A
(antitrypsin), member 4
8.0 (2.0) 7.4 (2.3)
189163534 serine proteinase inhibitor, clade A,
member 1
47.2 (7.0) 48.9 (3.5)
4507377 serine proteinase inhibitor, clade A,
member 7
6.3 (1.8) 6.6 (1.7)
17998551 serine proteinase inhibitor, clade B
(ovalbumin), member 12
2.9 (0.8) 3.5 (1.1)
5902072 serine proteinase inhibitor, clade B
(ovalbumin), member 3**
2.1 (1.3) 2.1 (1.3)
4502261 serine proteinase inhibitor, clade C
(antithrombin), member 1
25.5 (2.4) 26.1 (3.2)
39725934 serine proteinase inhibitor, clade F
(alph-2 antiplasmin), member 1
15.4 (2.7) 16.0 (2.5)
continued on next page
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Table 3.2 continued
Classiﬁcation Accession
number
Protein name Mean
peptide
count t0
Mean
peptide
count t1
(SD) (SD)
b. transport proteins
4826762 haptoglobin isoform 1 preproprotein 24.9 (4.6) 22.6 (5.5)
45580723 haptoglobin-related protein 10.5 (2.1) 9.4 (3.0)
11321561 hemopexin 22.9 (3.4) 24.2 (3.2)
c. other acute phase proteins
4502027 albumin preproprotein 126.6
(17.9)
139.6
(26.0)
21071030 alpha 1B-glycoprotein precursor 10.6 (2.2) 11.7 (1.4)
156523970 alpha-2-HS-glycoprotein 9.0 (1.4) 8.4 (2.4)
47132557 ﬁbronectin 1 isoform 1 prepropro-
tein
31.8 (9.2) 23.2
(12.3)
16933542 ﬁbronectin 1 isoform 3 prepropro-
tein
32.0 (9.3) 23.4
(12.3)
47132553 ﬁbronectin 1 isoform 5 prepropro-
tein
31.6 (9.2) 23.3
(12.2)
54607120 lactotransferrin precursor 2.6 (1.3) 2.0 (0.6)
167857790 orosomucoid 1 precursor 10.7 (1.8) 13.5 (1.3)
4505529 orosomucoid 2 4.7 (1.2) 5.2 (1.1)
4557871 transferrin 92.4
(12.4)
100.1
(19.6)
4507725 transthyretin 4.8 (1.1) 5.3 (0.9)
2. Complement factors
73858568 complement component 1 inhibitor
precursor
21.0 (2.6) 20.6 (3.5)
4502495 complement component 1, s sub-
component*
2.2 (0.9) 1.2 (1.4)
14550407 complement component 2 pre-
cursor
10.8 (2.2) 10.7 (2.5)
115298678 complement component 3 pre-
cursor
129.4
(10.7)
123.1
(8.9)
67190748 complement component 4A prepro-
protein
62.8 (5.5) 56.5 (9.8)
178557739 complement component 4B prepro-
protein
64.6 (5.6) 57.9 (9.3)
continued on next page
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Table 3.2 continued
Classiﬁcation Accession
number
Protein name Mean
peptide
count t0
Mean
peptide
count t1
(SD) (SD)
38016947 complement component 5 prepro-
protein
17.1 (6.3) 17.4 (9.0)
189242612 complement component 6 pre-
cursor
7.9 (1.1) 7.3 (1.4)
45580688 complement component 7 pre-
cursor
12.7 (3.7) 11.4 (3.3)
4557389 complement component 8, alpha
polypeptide precursor*
1.9 (0.9) 1.4 (1.5)
4502511 complement component 9 6.5 (1.9) 8.4 (2.0)
67782358 complement factor B preproprotein 23.2 (1.7) 20.9 (2.7)
42544239 complement factor D preproprotein 4.9 (2.3) 6.2 (1.9)
62739186 complement factor H isoform a pre-
cursor
26.7 (5.3) 24.6 (6.4)
118442839 complement factor H-related 1 3.5 (1.4) 3.7 (1.4)
119392081 complement factor I preproprotein 2.9 (0.7) 2.9 (0.4)
3. Apolipoproteins
4557321 apolipoprotein A-I preproprotein 24.8 (3.5) 23.2 (2.7)
4502149 apolipoprotein A-II preproprotein* 2.3 (0.8) 1.7 (1.1)
71773110 apolipoprotein A-IV precursor 24.5 (2.4) 22.2 (6.3)
105990532 apolipoprotein B precursor 79.5
(69.1)
56.7
(45.9)
153266841 apolipoprotein H precursor 4.4 (2.2) 4.1 (1.7)
4. Coagulation proteins
145275213 coagulation factor XII precursor 4.6 (1.7) 3.7 (1.9)
70906435 ﬁbrinogen, beta chain preproprotein 15.8 (7.9) 10.8 (4.9)
70906437 ﬁbrinogen, gamma chain isoform
gamma-A precursor
24.2 (7.1) 16.6 (7.4)
73858566 heparin cofactor II precursor 7.8 (1.3) 8.0 (1.9)
4504893 kininogen 1 isoform 2 12.1(1.9) 12.5 (3.1)
78191798 plasma kallikrein B1 precursor* 5.1 (1.0) 3.1 (2.3)
4505881 plasminogen 16.0 (2.3) 13.6 (5.9)
5. Extracellular matrix proteins
63055057 actin, beta-like 2 3.2 (0.9) 3.2 (1.4)
4501889 actin, gamma 2 propeptide 5.8 (1.7) 5.0 (1.8)
110349772 alpha 1 type I collagen prepropro-
tein**
1.5 (0.9) 1.6 (1.1)
115583663 alpha-2-plasmin inhibitor 6.9 (1.2) 6.1 (2.7)
55743104 alpha-3 type VI collagen isoform 4
precursor*
2.1 (1.5) 1.8 (1.9)
continued on next page
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Table 3.2 continued
Classiﬁcation Accession
number
Protein name Mean
peptide
count t0
Mean
peptide
count t1
(SD) (SD)
4501885 beta actin 8.4 (2.6) 7.2 (2.8)
156627579 C-type lectin domain family 3, mem-
ber B
2.0 (1.1) 1.6 (0.9)
34734066 ﬁbulin 1 isoform D* 2.0 (1.3) 1.9 (2.3)
126012571 heparan sulfate proteoglycan 2 5.3 (1.5) 5.1 (2.1)
4505047 lumican precursor 5.7 (0.9) 4.9 (1.8)
6. Hormone and vitamine binding proteins
4501987 afamin precursor 8.6 (1.7) 8.6 (2.0)
4557287 angiotensinogen preproprotein 7.1 (1.4) 7.9 (1.6)
73858564 corticosteroid binding globulin pre-
cursor
3.2 (0.7) 3.3 (0.9)
4826772 insulin-like growth factor binding
protein, acid labile subunit**
4.6 (2.9) 5.4 (3.2)
55743122 retinol-binding protein 4, plasma
precursor
14.7 (2.3) 15.5 (2.3)
32483410 vitamin D-binding protein precursor 22.1 (2.8) 24.1 (2.5)
7. Enzymes
10947139 arginase, type I 3.7 (1.2) 2.7 (0.8)
4557367 bleomycin hydrolase 0.9 (0.4) 1.3 (0.6)
122937470 carboxypeptidase N, polypeptide 2* 2.5 (1.3) 2.1 (1.3)
7669492 glyceraldehyde-3-phosphate dehy-
drogenase
4.9 (1.8) 4.9 (2.3)
4504333 histidine ammonia-lyase 1.8 (0.4) 2.2 (0.9)
4557894 lysozyme precursor 3.1 (1.3) 3.9 (0.8)
170296790 mesotrypsin isoform 1 prepropro-
tein
0.9 (0.4) 1.6 (0.9)
19923106 paraoxonase 8.8 (1.5) 9.1 (0.7)
4505591 peroxiredoxin 1 1.8 (0.5) 2.3 (0.6)
126273569 plasma carboxypeptidase B2 iso-
form a preproprotein
1.8 (0.8) 2.2 (0.6)
32171249 prostaglandin H2 D-isomerase 2.6 (0.8) 2.4 (1.0)
4506145 protease, serine, 1 preproprotein 3.1 (0.9) 3.3 (0.9)
continued on next page
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Table 3.2 continued
Classiﬁcation Accession
number
Protein name Mean
peptide
count t0
Mean
peptide
count t1
(SD) (SD)
8. Others
4502067 alpha-1-microglobulin/bikunin pre-
proprotein
16.6 (5.1) 18.1 (5.8)
4502337 alpha-2-glycoprotein 1, zinc 6.9 (1.5) 6.6 (2.4)
4757756 annexin A2 isoform 2 3.5 (0.8) 4.7 (1.8)
21450861 attractin isoform 1 1.8 (0.8) 1.5 (0.6)
4757826 beta-2-microglobulin precursor 5.2 (1.4) 6.0 (1.5)
21614544 calcium-binding protein A8 3.5 (0.8) 4.3 (0.8)
4506773 calcium-binding protein A9 4.2 (0.8) 5.4 (1.4)
4557485 ceruloplasmin precursor 52.2 (5.4) 52.6 (7.4)
16751921 dermcidin preproprotein 4.3 (0.6) 4.6 (1.0)
4826702 desmocollin 1 isoform Dsc1b pre-
proprotein
3.0 (1.7) 2.1 (1.3)
119703744 desmoglein 1 preproprotein 9.2 (2.4) 9.0 (2.7)
58530840 desmoplakin isoform I 31.6 (9.7) 31.5
(12.0)
4503471 eukaryotic translation elongation
factor 1 alpha 1
2.8 (1.2) 2.8 (1.7)
4504165 gelsolin isoform a precursor 23.3 (3.3) 23.6 (6.4)
4504489 histidine-rich glycoprotein precursor 11.2 (2.8) 12.2 (4.4)
57864582 hornerin 4.8 (2.9) 3.0 (2.3)
31542986 intelectin 4.7 (2.0) 6.5 (2.9)
4504811 junction plakoglobin 15.4 (3.5) 17.3 (3.5)
16418467 leucine-rich alpha-2-glycoprotein 1 5.7 (1.8) 5.5 (1.3)
50659080 serpin peptidase inhibitor, clade A,
member 3 precursor
25.2 (3.4) 27.4 (2.6)
4502133 serum amyloid P component pre-
cursor
4.2 (1.3) 3.7 (1.6)
50592994 thioredoxin 0.9 (0.3) 1.3 (0.4)
110349719 titin isoform N2-A 3.2 (0.9) 3.7 (0.8)
4506713 ubiquitin and ribosomal protein
S27a precursor
1.6 (0.5) 1.8 (0.4)
*not present in all patients at t1
**not present in all patients at t0
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With the present proteomic techniques used, the lower limit of molecular weight
was approximately 10 kDa, so very low molecular weight proteins could not be in-
cluded. The most abundant proteins found were albumin, alpha-2-macroglobulin,
complement component 3 and transferrin. The proteins orosomucoid en galectin-
7 were found to be signiﬁcantly upregulated in all patients at t1 compared to t0,
but the counts of galectin-7 were all <3, so these results were not considered re-
liable enough for further evaluation. Orosomucoid was further evaluated. First it
was investigated with immunohistochemistry in peritoneal biopsies if an increase
in orosomucoid deposition could be demonstrated in time, to prove that oroso-
mucoid increases due to local peritoneal processes. This could indeed be shown
in the endothelial cell layer as well as in mesothelial cells, as is indicated in ﬁg-
ure 3.1 and 3.2. Further orosomucoid was measured with the (semi-)quantitative
technique of Western blotting. One clear band was blotted, with an increase in
density at t1 in all patients but one. The results were globally, but not completely
in concordance with the proteomics results. This is shown in table 3.3. The
commercially available ELISA kit for orosomucoid could not give reproducible re-
sults for dialysate samples, so unfortunately these could not be used for extra
validation.
Table 3.3: Orosomucoid results per patient at t0 and t1: proteomics versus Western blot
Patient Proteomics (normalized Western Blot Total protein
peptide counts) (densitometry/ 1μg protein) content (mg/mL)
t0 t1 t0 t1 t0 t1
1 12.0 14.1 26.7 33.4 0.146 0.100
2 11.2 15.2 17.9 35.9 0.258 0.154
3 9.7 13.0 -* -* 0.072 0.054
4 8.9 12.2 17.7 32.9 0.186 0.388
5 8.1 11.5 23.9 29.4 0.236 0.332
6 12.3 14.4 40.9 29.8 0.122 0.166
7 12.6 13.8 26.8 32.4 0.082 0.084
*Not enough material available
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Figure 3.1: Small vessel in a parietal peritoneum section of two PD patients (magniﬁ-
cation 20x) A: After 11 months of PD the endothelial cell layer is orosomucoid negative
(white arrows). B: After 26 months of PD the endothelial cell layer is orosomucoid positive
(black arrows).
Figure 3.2: Parietal peritoneum section of two PD patients (magniﬁcation 20x) A: After 7
months of PD the mesothelial cell layer is orosomucoid negative (white arrows). The sub-
mesothelial compact zone (white asterisks) consists of loosely arranged collagen ﬁbers.
B: After 26 months of PD several mesothelial cells are orosomucoid positive (black ar-
rows). The compact zone is typically thickened and ﬁbrotic (black asterisks).
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Discussion
The proteome of the dialysate from 7 pediatric patients was investigated with the
combined techniques of 1-SDS-PAGE followed by nLC-MS/MS to detect possi-
ble long-term changes in protein composition. In all patients a signiﬁcant up-
regulation of orosomucoid was detected. Orosomucoid is also known as alpha-
1-acid-glycoprotein and is classiﬁed as an acute phase protein, showing an in-
crease during infection, inﬂammation or tissue damage. Orosomucoid is a nec-
essary protein for the maintainance of capillary permeability. The endothelial
cell produces orosomucoid and other components of its glycocalyx. It seems
to be a part of the charge barrier, and will increase the polyanionic charge se-
lectivity. Orosomucoid thus contributes to the functional properties of the gly-
cocalyx and impaired orosomucoid production could cause endothelial dysfunc-
tion10,11. Orosomucoid was also found to be speciﬁcally inducible in alveolar
macrophages12,13. However the exact function of orosomucoid is not fully elu-
cidated yet. It was suggested that orosomucoid can inhibit neutrophil migration
by an NO-dependent process, playing a role in sepsis14. In nephrologic patients
urinary orosomucoid excretion was correlated with the development and pro-
gression of diabetic nephropathy15. In dialysate levels were found to be very low,
about 2-5% from plasma levels16, but dialysate levels were upregulated indepen-
dently from serum levels with peritonitis17. A locally increased concentration of
orosomucoid, produced by the endothelial cells at the glycocalyx, might induce
an increase of orosomucoid in the dialysate18. By enhancing the functional neg-
ativity of the capillary wall orosomucoid may have a protective function and may
limit the possible damaging effect of high glucose concentrations of PD solutions
on the glycocalyx19,20. Increased production by mesothelial cells may also con-
tribute to the increased concentration in dialysate.
The upregulation of orosomucoid in chronic PD could be the effect of the pro-
longed inﬂammation of the peritoneal membrane due to long-term exposure to
bio-incompatible PD solutions inducing in addition a vasculopathy21. The up-
regulation of orosomucoid in the dialysate and peritoneal biopsies supports the
ﬁrst concept. Quantiﬁcation with Western blotting could only partially conﬁrm
the results found with proteomics. In one patient a decrease was found with
Western blotting instead of an increase. A possible explanation for the differ-
ence observed between proteomics and Western blotting could be the fact that
orosomucoid exists with multiple isoforms. Orosomucoid is a very heterogenous
protein, that presents both amino-acid chain polymorphisms as well as >30 dif-
ferent glycoforms22–25. It could be that not all isoforms are detected effectively
with the polyclonal antibody, while with proteomics the unique peptides of a pro-
tein are identiﬁed and these isoforms will be detected.
However, it has to be taken into account, that the relative quantiﬁcation with
proteomic techniques remains a challenge, with inevitable assumptions26. The
relative quantiﬁcation with spectral counts is now widely accepted as the most
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reliable, practical, label-free form of quantiﬁcation26,27, with proven linear rela-
tionship with speciﬁc measured protein quantities in complex protein mixtures9,
as is the case for dialysate. It is clear that with the application of proteomics
the inherent limitations of relative quantiﬁcation have to be considered. The dis-
concordance with the Western blot results in our study may thus for a part be
ascribed to the limitations of relative quantiﬁcation with proteomics as well.
Concluding, proteomics is an unbiased, high-throughput relative quantiﬁcation
technique that can elucidate interesting new proteins. It can pick up isoforms,
cleavage products, breakdown products and post-translational modiﬁcations that
cannot all be caught with quantitative techniques. This makes proteomics very
sensitive but the quantiﬁcations performed are still estimative values, which can
cause discrepancies compared to quantitative techniques. These controversies
are inherent to the current techniques of proteomics, and have to be taken into
account.
In this study orosomucoid was identiﬁed as a potentional biomarker, with up-
regulation in pediatric patients on longitudinal PD.
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Abstract
Background
Water transport in peritoneal dialysis occurs through small pores and aquapor-
ins. Free water transport (FWT) occurs through aquaporins only and gives a
reﬂection of peritoneal aquaporin function. In this study FWT in children was
calculated for the ﬁrst time in different settings.
Methods
A prospective cohort study was performed, 87 peritoneal equilibrium tests were
analyzed in 65 patients. Three subgroups were analyzed: patients with their 1st
peritoneal equilibrium test; patients in their 2nd year on dialysis; patients in their
3rd year on dialysis or thereafter. Patients using 3.86% glucose-solution with low
pH/high glucose degradation products (GDP) were compared to patients using
3.86% glucose-solution with neutral pH/low GDP. Sixteen patients using neutral
pH/low GDP solution were followed longitudinally. FWT was calculated using the
dialysate/plasma ratio of sodium.
Results
The proportional contribution of FWT was signiﬁcantly higher in patients using
dialysis-solution with neutral pH/low GDP solution compared to patients using
solutions with low pH/high GDP (50% versus 40%). Transcapillary ultraﬁltration
(TCUF) showed the same trend but was not statistically signiﬁcant. Total FWT
was higher as well. Higher FWT was observed with older age. In the longitudi-
nal group TCUF and water transport through small pores declined, while FWT
remained stable in the ﬁrst 1.5 years. The contribution of FWT increased in this
period (48% to 61%), then slowly declined again to baseline level during the third
year.
Conclusions
Total FWT and the relative contribution of FWT were signiﬁcantly higher with neu-
tral pH/low GDP-solution. This can reﬂect a better preservation of aquaporins.
The decline in the contribution of FWT in longterm dialysis could hypothetically
implicate aquaporin dysfunction or different trafﬁcking of aquaporins.
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Introduction
Fluid transport in peritoneal dialysis (PD) is dependent on the hydrostatic pres-
sure gradient, the colloid osmotic pressure gradient and the crystalloid osmotic
pressure gradient1. Solute coupled transport of water occurs by convection
through the small pores. Free water transport (FWT) induced by crystalloid os-
mosis occurs exclusively through the ultra small pores or aquaporin-1 channels,
being impermeable to solutes. The presence of water exclusive pathways means
that when an osmotic gradient is created across the membrane (by hypertonic
glucose) relatively more water than solute is transported, resulting in sieving.
The theoretical principles of FWT are based on the thee pore model of Rippe2,3,
whereby the heteroporous capillary wall is the main barrier. Despite reﬂection
coefﬁcients (sigma) of almost zero, sieving coefﬁcients of small solutes do not
approach 1 (1-sigma), because of FWT. The transendothelial water channels
have been identiﬁed as aquaporin-1 channels. Both aquaporin-1 and aquaporin-
3 were shown to be expressed in peritoneal mesothelial cells4,5. The function
of aquaporin-3 has not yet been established. Speciﬁc quaporin-1 expression
was demonstrated in endothelium lining peritoneal capillaries and venules in hu-
man peritoneum, in both apical as well as basolateral membranes, using im-
munostaining with aquaporin-1 antiserum6,7. Yang et al. and Ni et al. proved in
aquaporin-1 knock-out mice that FWT cannot occur without aquaporin-1 chan-
nels8,9. Several indirect methods have been applied to assess FWT, based
on the principle that highly osmotic active glucose 3.86% solutions will induce
FWT, while less osmotic active solutions like 1.36% glucose or 7.5% icodextrin
will induce little FWT. The difference in net ultraﬁltration between these differ-
ent osmotic active solutions gives an indication of FWT10–12. A direct way to
calculate FWT is by using the magnitude of the dip in the dialysate to plasma
ratio of sodium (D/Psodium). A dilution of dialysate sodium occurs because of
FWT, directed from the circulation to the peritoneal cavity in the initial phase of
a 3.86% glucose dwell2,13, causing a dip in D/Psodium. Direct quantiﬁcation of
FWT in adults has been performed in this way14,15. Direct quantiﬁcation of FWT
in children has never been performed. The aim of this study was to quantify
FWT in children in different settings, as a reﬂection of the function of the aqua-
porins in the peritoneal membrane. Different dialysis solutions were compared
as well as different age groups, and the time course of FWT was investigated.
Transcapillary ultraﬁltration (TCUF), the contribution of FWT to the TCUF, ﬂuid
transport through small pores (SPT), marker clearance (MC), glucose absorp-
77
4FREE WATER TRANSPORT
tion and mass transfer area coefﬁcients (MTACs) of small solutes were assessed
as well.
Patients and methods
Setting
A prospective cohort study was performed in 2 academic pediatric hospitals in
Utrecht and Nijmegen in the Netherlands. Patients were enrolled from 1993
until 2007. The total cohort consisted of 65 patients, with 87 peritoneal equilib-
rium tests (PETs) performed. In 37 patients 3.86% glucose solution with low
pH and high glucose degradation products (GDP) was used (Dianeal R©) and
in 28 patients a 3.86% glucose solution with neutral pH/low GDP was used
(Physioneal R©). For Dianeal R© the PD1 solution was used as a standard, con-
taining 35 mmol/l lactate. For Physional R©, the 35 solution was used as a stan-
dard, containing a concentration of 25 mmol/l bicarbonate and 10 mmol/l lactate.
Physioneal R© 40 (with 25 mmol/l bicarbonate, 15 mmol/l lactate and a lower cal-
cium content of 1.25 mmol/l) has been used in individual cases, to reduce the
calciumload. Cross-sectional groups and longitudinal groups were both ana-
lyzed.
Cross-sectional (Group 1): all 65 patients were analyzed as one group with a
PET performed after a median of 1 year on PD. Subsequently subgroups were
analyzed: group 1A (n=31) consisted of the ﬁrst PETs performed in patients,
group 1B (n=31) consisted of PETs performed in the 2nd year on dialysis and
the PETs in group 1C (n=25) were performed in the 3rd year on dialysis or there-
after. Patients could be analysed in more than one subgroup with a different
PET. Patients using low pH/high GDP solution were compared to patients using
neutral pH/low GDP solution.
Longitudinal (Group 2): 16 patients were prospectively followed for at least three
years, with 50 PETs performed with neutral pH/low GDP solution.
Subjects
Baseline characteristics of the total cohort and subgroups are shown in table
4.1 and 4.2. The total cohort consisted of 42 male patients and 23 female
patients. Underlying renal diseases were: urethral valves /reﬂux nephropathy
(25%), dysplastic kidneys (25%), nephrotic syndrome (11%), glomerulonephri-
tis (5%), hemolytic uremic syndrome (5%), focal segmental glomerulosclerosis
(5%), unknown (5%) and other diseases (19%; nephronophtisis, hereditary tubu-
lonephritis, Denys-Drash syndrome, ischeamic cortical necrosis, diffuse mesan-
gial sclerosis, hyperoxaluria, autosomal recessive polycystic kidney disease).
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The peritonitis rate in the total patient cohort was 0.9 episodes /patient year (=1
episode every 13.3 patient-months), no difference was found between the low
pH/high GDP and the neutral pH/low GDP group. The majority of the patients
used 1.36% glucose, 3 patients (5%) used a mixture of 1.36% and 2.27% glu-
cose solution, and 6 patients (9%) used 2.27% glucose solution. These patients
were equally divided amongst the low pH/high GDP group and the neutral pH/low
GDP group. Two patients in the neutral pH/low GDP group used icodextrine in
daytime.
Table 4.1: Baseline characteristics group 1: total patient cohort
Total patient cohort:
cross-sectional (n=65)
Low pH/high GDP Neutral pH/low GDP
PD solution (n) (n=37) (n=28)
Time on PD (months) 11 (1-68) 12.5 (4-58)
Age at start (months) 77 (0-201) 48 (0-171)
BSA (m2) 0.79 (0.24-1.79) 0.68 (0.35-1.68)
PD = peritoneal dialysis; BSA = body surface area;
GDP = glucose degradation products
Medians and ranges are given
Procedure and measurements
All PETs were performed during 4 hour dwells as described previously16,17. An
intraperitoneal volume of 1200 ml/m2 body surface area (BSA) was used in all
tests. Dialysate samples were taken before inﬂow (time-point 0), at 5, 30, 60,
120, 180 minutes and at the end of the dwell at 240 minutes with measurements
of sodium, urea, creatinine, glucose and dextran. Dextran 70 4g/L (Hyskon,
Medisan pharmaceuticals AB, Uppsala, Sweden or Macrodex NPBI; Emmercom-
pascuum, The Netherlands) was added as volume marker to calculate the time
course of TCUF and MC. Blood samples were taken halfway at time-point 120
minutes, with measurement of sodium, urea, creatinine and glucose. None of
the patients suffered from peritonitis at the moment of the PET or in the 4 weeks
preceding the PET. None of the patients had ultraﬁltration failure.
Calculations
All calculations were performed as described previously18,19. In brief, TCUF was
calculated from the dilution of the volume marker by subtraction of the initial in-
traperitoneal volume (IPV) from the theoretical IPV (when ﬂuid absorption and
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4
sampling are not taken into account) at any time-point. For the measurements
of effective lymphatic absorption rate, the MC from the peritoneal cavity was
used, calculated as the convective loss of dextran during the dwell20. The mass
transfer area coefﬁcient (MTAC), the maximal theoretical diffusive clearance of a
solute at time-point zero, was calculated for urea and creatinine according to the
Waniewski model21,22, with a correction of serum solute concentration for plasma
water. FWT at 60 minutes was calculated by subtracting total sodium transport
from the total ﬂuid transport, using the magnitude of the dip in D/Psodium , as
previously described by La Milia et al. and Smit et al.14,15. The maximum dip
in D/Psodium was calculated by subtracting the smallest D/P ratio at any of the
timepoints from the D/Psodium at timepoint zero. According to the three pore
model watertransport will occur through small pores and aquaporins. Transport
of water through the small pores is coupled to convective transport of sodium (no
sieving of sodium), while watertransport through the aquaporins (FWT) will occur
with complete sieving of sodium. This dissociation of watertransport from sodium
transport is used to calculate FWT. To correct for the diffusion of sodium from the
circulation to the dialysate a diffusion correction was performed using the MTAC
of creatinine as was validated by Zweers et al23. Glucose absorption at 60 min-
utes and at 240 minutes was assessed by calculating the ratio of the glucose
concentrations at these timepoints compared to timepoint zero (D60 /D0(glucose)
and (D240 /D0(glucose)) Transport studies of small solutes and ultraﬁltration in chil-
dren have been conducted using different methods. When comparing children to
adults, body surface area (BSA) has not always been taken into account. This
is important because the peritoneal surface area is smaller in children. When
corrected for BSA, the peritoneal surface is approximately 0.6m2 for children as
well as for adults24,25. All values of MTAC, FWT, UF, MC and SPT were corrected
for body surface area (BSA) according to the Mosteller formula26 and expressed
per 1.73m2.
Statistical Analysis
Results are expressed as median values and ranges for cross-sectional data.
For comparison of different dialysis ﬂuids (low pH/high GDP-solution versus neu-
tral pH/low GDP-solution) the Mann Whitney U test was used. For longitudinal
data the linear mixed model procedure was used to test whether a general model
for the time course exists for the transport parameters. The linear mixed model
examines the average changes in subjects, taking the association between vari-
ables into account in every individual subject, measured at different time-points.
Results of the longitudinal data are expressed as means and standard error of
the mean (SEM).
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Results
Baseline characteristics of the total group and the subgroups were not different
with respect to dialysis ﬂuid used, except for sex distribution in the total group,
with signiﬁcantly more male patients in the low pH/ high GDP group compared
to the normal pH/low GDP group. The patients who were the longest time on PD
and the longitudinal patients tended to be younger at start, but these differences
were not signiﬁcant.
Table 4.3: Transport characteristics of group 1: total patient cohort
Total patient cohort:
cross-sectional (N=65)
Low pH/high GDP Neutral pH/low GDP
PD solution (n) (n=37) (n=28)
FWT: 60 min (ml/1.73m2) 173 (34-300) 239 *** (38-536)
FWT% 40 (10-64) 50*** (20-75)
TCUF: 60 min (ml/1.73m2) 448 (238-639) 508 (173-802)
SPT 60 min (ml/1.73m2) 271 (150-469) 256 (90-416)
Max dip D/P Na+ 0.09 (0.02-0.16) 0.10 (0.02-0.18)
D/P Na+ 60 min 0.88 0.84***
MC 240 min (ml/1.73m2) 243 (-96-780) 351 (26-1337)
MTAC creatinine (ml/min/1.73m2) 11 (4.5-20) 8.8 (4.8-30)
MTAC urea (ml/min/1.73m2) 19 (12-36) 19 (13-38)
FWT = free water transport; TCUF = transcapillary ultraﬁltration;
SPT = ﬂuid transport through small pores; D/P = dialysate to plasma ratio;
MC = marker clearance; MTAC = mass transfer area coefﬁcient;
GDP = glucose degradation products
*** = p<0.01 for neutral pH/low GDP versus low pH/high GDP
Medians and ranges are given
Results of the cross-sectional study
A signiﬁcantly higher contribution of FWT (p=0.007) and a higher total FWT at
60 minutes (p=0.007) and 240 minutes (p=0.014) were found with the neutral
pH/low GDP solution compared to the low pH/high GDP solution in the whole
cross-sectional group (table 4.3). The same trend was seen in the subgroups
but signiﬁcance was not reached in each separate subgroup (table 4.4). The
trend was most pronounced in group 1A (1st PET) and group 1B (2nd year on
PD) with signiﬁcant higher FWT at 60 minutes and 240 minutes in the neutral
pH/low GDP group versus the low pH/high GDP group. In group 1B a signif-
icantly higher TCUF was seen in the neutral pH/low GDP group compared to
the low pH/high GDP group. In the other subgroups and the total group TCUF
tended to be higher in the neutral pH/low GDP groups in comparison with the low
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pH/high GDP groups as well, without statistical signiﬁcance being achieved. The
maximum dip in D/Psodium did not differ signiﬁcantly between the low pH/high
GDP group and the neutral pH/low GDP group. In the neutral pH/low GDP group
a smaller median D/P ratio was found at the individual timepoints in the whole
group (ﬁgure 4.1) as well as in subgroup 1A, giving a higher dip of D/Psodium
at each timepoint, including at baseline. The area under the curve (AUC) was
calculated for both the neutral pH/low GDP group and for the low pH/high GDP
group, with a higher AUC for the neutral pH/low GDP group, independently of
the D/Psodium at baseline (21.9 versus 17.9). This gives an indication that an
overall higher dip in D/Psodium is present in the neutral pH/low GDP group, al-
though the AUC can overestimate the true difference between the two groups.
The calculations of FWT were not inﬂuenced by the difference in the D/Psodium
at baseline. The (D60 /D0(glucose) and the (D240 /D0(glucose) in the total group were
0.61 and 0.29 respectively. There were no differences between the low pH/high
GDP group and the neutral pH/low GDP group.
Figure 4.1: Time course of median D/P sodium in the total cross-sectional patient group,
with a PET performed after a median of 1 year, comparing low pH/high GDP versus neu-
tral pH/low GDP*.
D/P = diaysate to plasma ratio, PET = peritoneal equilibrium test, GDP = glucose degra-
dation products
*p=<0.02 for all individual timepoints.
Age dependent effect
The whole patient cohort as well as the low pH/high GDP group and neutral
pH/low GDP group were divided into two different age groups: 0-5 years and
older than 5 years, to evaluate a possible effect of age. The results are shown in
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table 4.5. A signiﬁcant higher contribution of FWT was seen in all patients older
than 5 years, with the low pH/high GDP group and neutral pH/low GDP group
combined (p=0.045). Total FWT at 60 minutes tended to be higher in the neutral
pH/low GDP group as well, with a p-value of 0.07. This trend towards a higher
FWT was observed in the two groups separated on basis of dialysis solution as
well, but these results were not signiﬁcantly different.
Longitudinal results
The TCUF showed a steady decrease over the years, reﬂecting the changes in
FWT as well as SPT (Figure 2a-h). Total SPT decreased at a slightly larger rate
in concordance with TCUF in the ﬁrst 1.5 years, with a stabilization thereafter.
Total FWT remained stable in the ﬁrst 1.5 years, with a slow decline afterwards.
An increase in the contribution of FWT was seen during the ﬁrst 1.5 years, from
48% to 61%, followed by a decrease after the second year to baseline level (51%)
at the end of the 3rd year. The maximum D/Psodium showed an increase followed
by a decrease. MTACs of urea and creatinine remained fairly stable, showing a
shallow U-shaped curve. In the group using low pH/high GDP dialysis solution
the number of patients with longitudinal follow-up was too small to allow for a
valid linear mixed model.
Discussion
In this present study a higher FWT was observed in pediatric patients using
a more biocompatible neutral pH/low GDP dialysis solution compared to pe-
diatric patients using a conventional low pH/high GDP dialysis solution. This
could be because of better preservation of peritoneal membrane quality with
more biocompatible solutions. With the low pH/high GDP solutions acute and
chronic toxicity lead to progressive deterioration of the mesothelial cell layer
with increased compact zone thickness leading to ﬁbrosis, and vasculopathy
with progressive subendothelial hyalinization and higher density of blood ves-
sels27. GDP’s are involved in stimulation of vascular endothelial growth factor
and transforming growth factor-beta release, and induce advanced glycosylation
end product (AGE) formation and upregulation of the AGE-receptor with augmen-
tation of chronic inﬂammation, neoangiogenesis and endothelial cell dysfunction.
This all leads to progressive peritoneal damage28,29. More biocompatible ﬂuids
show less AGE formation and better preservation of peritoneal integrity30. Pe-
diatric patient studies performed with a low GDP, bicarbonate buffered solution
(Bicavera R©) support the hypothesis of better membrane preservation with less
AGE formation and an increase of mesothelial cell mass measured by higher
carcinogen-antigen 125 values31,32.
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Differences in overall solute transport were not observed in short-term studies,
comparing conventional versus more biocompatible solutions during two consec-
utive PETs in both children and adults33,34. An explanation lays in the fact that
only acute effects of different solutions can be seen in this way, instead of longer
term effects. Vasodilatation plays a more prominent role in low pH/high GDP so-
lutions35,36, resulting in transient increase of peritoneal surface area in the early
phase of a dwell, which affects the capillary pressure gradient and thus water
and solute transport as well.
FWT can be a sensitive parameter in the chronic effect of different dialysis so-
lutions on the peritoneal membrane. A speciﬁc role of aquaporin functioning
in chronic PD was shown in the comparison of transport characteristics in pa-
tients with peritonitis to patients with increased surface area on long-term PD37.
These ﬁndings lead to the suggestion that peritonitis patients have only vascular
changes, with a temporary increased number of perfused peritoneal capillaries,
without disturbed osmotic conductance, while in chronic PD, with an increased
number of peritoneal microvessels, impaired FWT was regarded as a contribut-
ing factor, because of a different shape of the curve and a smaller D/Psodium dip.
This supports the hypothesis that the differences found in FWT between
(a) Free water transport at 60 minutes (b) Proportional free water transport
(c) Transcapillary ultraﬁltration at 60 minutes (d) Small pore transport at 60 minutes
Figure 4.2: a-d. Longitudinal course of water and solute transport characteristics with
neutral pH/low GDP solution. (continued on next page)
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(e) Maximum dip in D/P sodium (f) D/P sodium at 60 minutes
(g) MTAC of urea (h) MTAC of creatinine
Figure 4.2: e-h. Longitudinal course of water and solute transport characteristics with
neutral pH/low GDP solution.
PET numbers: 0 = start PD; 1 = 6 months on PD (N=8); 2 = 12 months on PD (N=11); 3
= 18 months on PD (N=8); 4 = 24 months on PD (N=9); 5 = 30 months on PD (N=7) ; 6 =
36 months on PD (N = 7).
FWT = free water transport; min = minutes, mL = milliliter; PET = peritoneal equilibrium
test, time interval between PETs = 6 months; TCUF = transcapillary ultraﬁltration; SPT =
ﬂuid transport over small pores; D/P = dialysate to plasma ratio; MTAC = mass transfer
area coefﬁcient.
Means with standard error of the mean are given. The p-values indicate the signiﬁcance
of the ﬁrmness of the observed trend model 2a: p=0.09; 2b p=0.16; 2c p=0.13; 2d p=0.10;
2e p=0.04; 2f p=0.25; 2g p=0.84; 2h p=0.48)
conventional and more biocompatible solutions in our chronic population are
aquaporin-1 mediated. Lower UF because of hyperpermeability could also play
a role in our patients, with the trend of a higher TCUF in our patients on neutral
pH/low GDP solution compared to low pH/high GDP solution.
The calculation of FWT is made by subtracting the SPT from the TCUF. Both the
maximum D/Psodium and the TCUF showed a higher trend but were not signif-
icantly higher in this group. The time-course of D/Psodium indicated an overall
larger dip in D/P sodium in the neutral pH/low GDP group, but the calculated
AUCs can overestimate the true difference between the two groups. The fact that
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the D/Psodium was statistically signiﬁcant at baseline was an unexpected ﬁnding.
Hypothetically in the neutral pH/ low GDP group the total residual intraperitoneal
volume at start could be slightly different or the residual intraperitoneal ﬂuid could
be more diluted because of a slightly higher FWT during the preceding nightly
dialysis episode, but this baseline difference could on the other hand reﬂect sys-
tematical differences not attributable to FWT. To be sure that the FWT results
were not inﬂuenced by this ﬁnding, it was tested and conﬁrmed that after correc-
tion for this difference in baseline D/Psodium the statistically signiﬁcant difference
in FWT between the two groups remained uninﬂuenced.
Our results on FWT in low pH/ high GDP solution are in concordance with the re-
sults found in adults with conventional low pH/ high GDP solution (Dianeal R©)15.
FWT on the longer term has not been compared between conventional acidic so-
lutions and more biocompatible solutions before. The longitudinal results show
a decline in TCUF that reﬂects the trend of a better preservation of FWT com-
pared to TCUF as well as the larger decrease of SPT compared to TCUF that
is seen in the ﬁrst 1.5 years of the patients using neutral pH/low GDP dialysis
solution. The same trend of a decrease in long term TCUF due to the combi-
nation of an increase in the contribution of FWT together with a decrease in the
contribution of SPT was seen in adult patients that were followed longitudinally
by Parikova et al.35, although these patients used low pH/high GDP solutions as
well as neutral pH/low GDP solutions and the follow-up period was longer. In
another longitudinal adult study by Coester et al.37 patients with and without ul-
traﬁltration failure (UFF) on conventional dialysis solution were followed for over
4 years. The patients with UFF showed a much lower proportional FWT with
a higher proportional SPT than the patients without UFF, suggesting peritoneal
damage leading to impaired FWT combined with a fast loss of the osmotic gra-
dient.
The relationship between loss of UF and aquaporin-1 expression however re-
mains a difﬁcult one. A quantitative loss of aquaporins is unlikely to be respon-
sible for UFF, since no differences in aquaporin-1 expression were seen in nor-
mal subjects compared to subjects on PD6 and it was shown in a patient with
UFF that the aquaporins were still present38. Impairment of FWT may there-
fore be caused by dysfunctioning of aquaporin-1 due to structural or conforma-
tional changes rather than quantitative changes in aquaporin-1 expression. A
proposed mechanism of aquaporin-1 dysfunctioning is less effective trafﬁcking
of aquaporins to the endothelial cell membrane. Furthermore a loss of osmotic
conductance contributes to the decrease in FWT. Inﬂammation and vasculopathy
lead to hyperpermeability for small solutes, so the osmotic gradient disappears
fast, explaining a part of the impaired FWT as well6,39. This loss of osmotic
conductance with rise in MTAC of creatinine was observed in adult patients on
long term PD by Clerbaux et al.39. Another contributing factor in UFF, possibly
inﬂuencing FWT as well, is the alteration of the glycocalyx, that leads to subme-
sothelial thickening and vasculopathy of the peritoneal membrane, leading to an
impaired ultaﬁltration coefﬁcient38,40.
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When a subdivision in the cross-sectional group was made according to age,
the contribution of FWT was higher in the patients older than 5 years compared
to children under the age of ﬁve. In the separate low pH/high GDP and neutral
pH/low GDP groups the same trend was seen, without statistical signiﬁcance,
likely due to the relative small patient numbers. Time on PD in these groups
did not differ signiﬁcantly, so bias for time on PD is not an explanation. A hy-
pothesis for the higher FWT in children of older age is that maturation of the
peritoneal membrane plays a role, with more recruitment of aquaporins to an ef-
fective localization in older children. The other transport characteristics revealed
no differences with age. Warady et al.41 investigated the effect of age in chil-
dren concerning membrane transport function and found higher MTAC values for
creatinine and glucose in the youngest children, under 1 year of age, suggesting
a higher membrane permeability. The number of patients aged under one year in
the present study was too small to conﬁrm these ﬁndings. The values of MTACs
of creatinine and urea in Warady’s overall patient group were similar compared
to our patients. Comparing transport parameters to earlier performed pediatric
studies16,42 MTACs of creatinine and urea and marker clearances are similar as
in our patients and show no differences with adult data35. Values of TCUF in
our study are also similar to earlier pediatric PET data performed with 3.86%
glucose16.
A ﬂaw in our study is the fact that the neutral pH/low GDP solution that was used
in this study still contains more GDP’s than the newer solutions like Bicavera R©.
In future investigations it would be very useful to investigate FWT in these newer,
more biocompatible solutions. In this study we did not distinguish between the
different subtypes of the used neutral pH/low GDP solution, with 10 mmol/l ver-
sus 15 mmol/l lactate, as it was not expected that this small difference would
have an effect on FWT.
In conclusion, the contribution of FWT is signiﬁcantly higher when normal pH/low
GDP-solution is used compared to low pH/high GDP-solution, with a trend of a
higher TCUF as well. This can reﬂect a better preservation of aquaporin func-
tion, as well as less impairment of osmotic conductance. The longitudinal results
show a decline of TCUF over time that reﬂects the decrease in SPT as well as
the initial preservation of FWT, followed by a decline in FWT after two years., This
suggests aquaporin dysfunction or different trafﬁcking of aquaporins as well as
loss of osmotic conductance on the long term. With longer follow-up duration the
course of FWT in time can be investigated more profoundly. To further conﬁrm
the hypothesis of aquaporin dysfunction with low pH/high GDP solutions and in
time, peritoneal membrane biopsies in these patient groups might be useful to
explore aquaporin-1 expression and function in future studies.
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Abstract
Background
Acute renal failure can be treated with different dialysis modalities, depending
on patient characteristics and hospital resources. Peritoneal dialysis (PD) can
be the ﬁrst choice in situations like hypotension, disturbed coagulation or difﬁcult
venous access. The main disadvantage of PD is the relatively limited efﬁcacy.
The aim of this study was to investigate whether continuous ﬂow peritoneal dia-
lysis (CFPD) is a more effective treatment than conventional PD in acute renal
failure.
Patients and Methods
A pilot study was performed at The Red Cross University Hospital in Cape Town
in six patients. Patients were treated with both CFPD and conventional PD for
8-16 hours. CFPD was performed with two bedside placed catheters. After initial
ﬁlling, dialysate ﬂowrate (100 ml/1.73m2/min) was maintained with an adapted
continuous venovenous hemoﬁltration machine. Ultraﬁltration ﬂow rate was set
at 2.5 ml/1.73m2/min. Urea, creatinine, electrolytes and ultraﬁltration were mea-
sured.
Results
Mean ultraﬁltration was 0.20 ml/1.73m2/min with conventional PD versus 1.8
ml/1.73m2/min with CFPD. Mean clearances of urea and creatinine were 5.0 and
7.6 ml/1.73m2/min with conventional PD versus 15.0 and 28.8 ml/1.73m2/min
with CFPD respectively. No complications occurred. Five patients had recovery
of renal function.
Conclusions
In this ﬁrst report of CFPD in 6 pediatric patients with acute renal failure, CFPD
was on average 3 to 5 times more effective for urea and creatinine clearance and
ultraﬁltration than conventional PD, without complications observed. CFPD has
the potency to improve the therapy for acute renal failure.
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Introduction
The choice of renal replacement therapy in acute renal failure (ARF) is depen-
dent on the clinical status of the patient as well as on hospital resources. Mortal-
ity rates stratiﬁed by dialysis modality in children have remained fairly constant
in the past decades, with an overall mortality rate of around 45%, ranging from
27% to 62%1–4. The better survival rate for hemodialysis (HD) found in the study
by Bunchman et al1 was attributed to a pre-selection of more hemodynamically
stable patients for HD. Peritoneal dialysis (PD) is preferred in clinical situations
like hypotension/ hemodynamic instability, disturbed coagulation or difﬁcult ve-
nous access3,5–7. In pediatric patients these clinical problems are encountered
frequently, especially in infants and with sepsis. Practical advantages of PD are
the requirement for less specialized expertise, fewer equipment resources and
lower costs. For these reasons PD is the mostly used modality in countries with
limited clinical resources8–11. Technically, access in PD can be obtained rela-
tively quickly and safely. Percutaneously inserted PD-catheters can be placed
at the bed-side and are used in the majority of children with acute renal failure
who are treated with PD5. The main disadvantage of PD relative to HD and con-
tinuous venovenous hemoﬁltration/dialysis (CVVH/D) is the lower efﬁcacy. HD
and CVVH/D provide more rapid clearance of higher molecular weight solutes
and faster ﬂuid removal and are therefore more efﬁcient in toxin removal, inborn
errors of metabolism and massive ﬂuid overload. It has partly been due to these
limitations in clearances and ultraﬁltration (UF) that there has been a general
movement away from PD for the treatment of ARF in developed countries12.
Clearances and UF can theoretically be vastly improved in acute PD by using
the technique of continuous ﬂow peritoneal dialysis (CFPD). CFPD requires two
peritoneal catheters, or one double lumen catheter, instead of the usual one. Af-
ter initial ﬁlling of the abdomen continuous ﬂow of PD ﬂuid is maintained at a high
ﬂow rate. The transporting potential of the peritoneal membrane is maximized in
this way by: a) maintaining the highest possible plasma to dialysate concentra-
tion gradient and osmotic gradient, thus maximizing the diffusion rate of solutes
and the UF, b) increasing mixing of dialysis ﬂuid and c) maximizing dialysis time
by minimizing exchanges during the procedure. The very ﬁrst report of CFPD
dates from 195313. CFPD was initially reported for patients in chronic renal fail-
ure in the sixties and seventies,14–16 but due to limitations of catheter technology
and costs of ﬂuid it was never further developed. Recently because of better
technological possibilities there has been renewed interest in this technique, with
animal studies17,18 as well as a few case studies in adult patients with chronic
renal failure19–22. In these studies clearances and UF where higher compared
to conventional PD. In this study we performed CFPD on children with ARF, to
investigate whether CFPD is a more effective treatment than conventional PD in
ARF and to establish a practical bed-side technique.
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Patients and methods
Study design
A prospective case study was performed in 6 pediatric patients, each patient
serving as his or her own control, undergoing both CFPD and conventional PD.
Outcome parameters were: survival, UF, clearance of urea and clearance of
creatinine, mass transfer area coefﬁcients (MTACs) of urea and creatinine and
morbidity (minor and serious adverse effects).
Patients
Six patients were included, baseline characteristics are shown in table 5.1. In-
clusion criteria were:
• Pediatric patients 1 day to 5 years of age admitted to the pediatric intensive
care unit.
• Biochemical criteria of acute kidney injury (AKI): according to the RIFLE cri-
teria/ criteria of the international AKI workgroup23–25. In summary: creatinine
>150% above normal level for age and oliguria (0.5 ml/kg/hour for six
hours) and/or the occurrence of acidosis with pH <7.2, and/or urea, phos-
phate, potassium, ammonia outside the normal range for age.
• The decision to start acute dialysis was in every case made based on the
biochemical criteria in combination with the clinical opinion of the pediatric
nephrologists and pediatric intensivists.
Exclusion criteria were:
• Life threatening hyperkalemia.
• Clinical condition too critical for procedure of catheter placement.
• Peritonitis, other abdominal pathology.
Procedure and measurements
Catheter placement
Catheter placement was performed by a pediatric nephrologist according to stan-
dard practice. Local anaesthesia and general sedation were used during the pro-
cedure. Cooke catheters were used (8 french), placed at the bedside using the
Seldinger technique. First a venﬂon needle was inserted through the abdominal
cavity about 1 centimeter below the umbilicus in the midline. The abdominal cav-
ity was then ﬁlled with 20 ml/kg of sodium chloride 0.9% in order to create space.
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A guidewire was introduced through the needle into the abdominal cavity and the
needle was withdrawn. After dilation the dialysis catheter was then pushed into
the abdominal cavity in the direction of the pelvis and secured. This catheter was
used for conventional intermittent PD. For CFPD a second catheter was inserted
using the same technique, at a point midway between the superior iliac crest and
the umbilicus (right or left) (ﬁgure 5.1). The abdomen was then already ﬁlled. For
CFPD the ﬁrst catheter was dedicated to outﬂow and the second catheter was
dedicated to ﬁlling.
Figure 5.1: Catheter placement for CFPD. 1=Lateral catheter halfway superior iliac crest
and umbilicus, pointing laterally (dedicated to inﬂow), 2=Umbilicus, 3=Midline catheter
one cm below umbilicus, pointing downwards and contralaterally away from 1 (dedicated
to outﬂow)
Conventional PD
Conventional intermittent PD was performed as per standard practice, with man-
ual or automated technique. An initial ﬁlling volume of 20 ml/kg (865 ml/1.73
m2), 1.5% bicarbonate/lactate buffered glucose-solution (Physioneal R©, Baxter
Healthcare, South Africa), was used. Dwell time was 1 hour. An inﬂow time of 10
minutes was used, and an outﬂow time of 20 minutes, completing one full cycle
in 1.5 hours. The dwell time, dwell volume and glucose concentration could be
adjusted according to the individual needs of the patient. Blood samples were
taken before start, at 1.5 hours (after 1 cycle) and at 6 hours (after 4 cycles) and
sent for urea, creatinine, phosphate, sodium, potassium, albumin and blood gas
analysis. Dialysate samples were taken at the end of the ﬁrst cycle and the end
of the fourth cycle and sent for urea, creatinine, phosphate, sodium, potassium
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and albumin. The dialysate was pooled after measuring the UF and this pooled
dialysate was also sent for urea, creatinine, phosphate, sodium, potassium and
albumin.
CFPD
Set up of CFPD and circulation of ﬂuid: Initial ﬁlling was performed with 20 ml/kg
1.5% bicarbonate/lactate buffered glucose solution (Physioneal R©, Baxter Health-
care, South Africa). After initial ﬁlling a dialysate ﬂow rate of 100 ml/1.73m2/min
was maintained with single pass fresh dialysate using an adapted CVVH ma-
chine (BM 25, patented by Baxter Healthcare, Brussels, Belgium). UF ﬂow rate
was set at 2.5 ml/1.73m2/min faster than the inﬂow rate, extrapolated from adult
data19,20,26. Every four hours the abdomen was completely drained in order to
accurately measure the UF and the outﬂow rate could be adjusted if needed. The
ﬁll volume could be adjusted according to tolerance. The glucose concentration
could also be adjusted if low UF would occur. The BM 25 machine was adapted
to circulate the in- and outﬂow of dialysis ﬂuid, modiﬁed from Freida et al20, see
ﬁgure 5.2: The BM 25 monitor is composed of two monitors: The BM 11 (left side)
and the BM 14 (right side). The BM 11 is dedicated to blood circulation during
CVVH. When the BM 25 is set up to perform CFPD, the BM 11 (that is the blood
pump in CVVH) is not needed, but will be set up to simulate the usual function of
the BM 11 in order to enable the BM 14 monitor to function. The BM 14 monitor
(right side) is designed to pump PD ﬂuid through the peritoneal cavity (driven by
the substitution pump). It also has a further pump situated downstream from the
patient, which can be set to run slightly faster than the substitution pump. This
pump then regulates UF. During dialysis the abdomen was monitored for overdis-
tension or underﬁlling, which could happen if the true UF rate is much more or
less than the estimated UF rate. Monitoring consisted of:
• hourly clinical examination for the ﬁrst four hours and then four hourly, by
measuring abdominal circumference and possible leakage of catheter en-
trance sites.
• close monitoring of oxygenation and ventilation to detect interference with
respiratory function.
• detection of high in- and outﬂow pressures at the points of the transduc-
ers of the BM 25. The alarm limits were adjusted to as low as possible
(10 mmHg from baseline). If there is obstruction to outﬂow the machine
immediately stops and further ﬁlling of the abdomen ceases automatically.
Obstruction to inﬂow, which is less likely except if there is a kink in the line,
or if there is excessive intra-abdominal pressure also causes the machine
to cease working. If the abdomen is too empty to allow for proper drainage,
in the case of underﬁlling, then the alarm on the BM 25 gives an alert and
the machine stops automatically as well.
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Blood was taken before the start and halfway through the four-hour sessions, at
two and six hours after start and sent for urea, creatinine, phosphate, sodium,
potassium, albumin and blood gas analysis. Dialysate was collected from the
drainage bag after each 4 hour session (so after 4 and 8 hours). The volume
of ﬂuid was measured and samples were sent for urea, creatinine, phosphate,
sodium, potassium and albumin.
Figure 5.2: Set up of modiﬁed CVVH machine (BM 25) for CFPD. BM 11 = set up as a
dummy only to enable the BM 14 to function; BM 14 = true CFPD pump; Blue pump =
substitution pump, to pump the dialysate to the patient at a given rate (100 ml/1.73m2/min);
Yellow pump = ultraﬁltration pump, set at 2.5 ml/1.73m2/min faster than substitution pump
to regulate ultraﬁltration; Pressure transducer to BM 11 monitors intra-abdominal pressure
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Calculations
For conventional PD UF was measured manually and clearances and MTACs
were calculated as described previously27,28. For CFPD UF (ml) was calculated
by the volume recovered minus the volume infused:
UF at timepoint t :
UF = Vt(out)− Vt(in) (5.1)
Clearances at each timepoint t were calculated (ml/min):
Kt =
Dt/Pt × Vt(out)
t× 60 (5.2)
MTACs were calculated according to Gotch26 (ml/min):
MTAC =
Kt(Qp + Qf (1− 0.33S)− 0.67QfS(Qp + Qf )
(Qp −Kt + Qf ) (5.3)
Where:
Kt = clearance;
Qp = ﬂux into patient in ml/1,73m2/min (= set at 100 at start)
Qf = ﬂux by UF in ml/1,73m2/min (= UF/min) (=set at 2.5 at start)
S = sieving coefﬁcient, approximately 1 for small solutes
All values of clearance, MTACs and UF were corrected for body surface area
(BSA) according to the following formula:
√
(weight in kg× height in cm)/3600
and expressed as per 1.73 m2.
Calculation of ﬂuids needed for 12 hours of dialysis
(average patient 0.4 m2):
Conventional PD:
8 ﬁlls× 865 ml/1.73 m2 = 6920 ml/1.73m2
= 1.6 l/patient
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CFPD:
3 ﬁlls× 865 ml/1.73m2 + ﬂow at 100ml/1.73m2/min× 60× 12 = 74600ml/1.73m2
= 17.2 l/patient
Analysis of results
Results are given as means with standard deviations. One-sided paired t-tests
were used to give an indication of differences between patients on conventional
PD compared to CFPD. Proportional differences were given.
Ethics
The study was approved of by the hospital ethics committee and written informed
consent was obtained from all parents.
Results
Patients were treated with CFPD for 8 to 12 hours and treated with conven-
tional PD for 8 to 16 hours, either before CFPD (patient 1), after CFPD (pa-
tient 2), or before and after CFPD (patient 3-6). Five patients had recovery of
renal function, one patient died two days after the study. For all patients UF
and clearances of urea and creatinine were higher with CFPD compared to
conventional PD (table 5.2, ﬁgure 5.3 and 5.4). Since no statistical signiﬁcant
differences were found between the two periods of conventional PD in patient
3-6, means for conventional PD were given for these patients. Mean UF was
0.2 ml/1.73m2/min on conventional PD, versus 1.8 ml/1.73m2/min with CFPD
(p=0.002) Mean clearance of urea was 5.0 ml/1.73m2/min on conventional PD
versus 15.0 ml/1.73m2/min on CFPD (p=0.0005), mean clearance of creatinine
was 7.6 ml/1.73m2/min on conventional PD versus 28.8 ml/1.73m2/min on CFPD
(p=0.004). MTAC of urea did not differ signiﬁcantly between conventional PD
and CFPD. Mean MTAC of creatinine was 12.0 ml/1.73m2/min on conventional
PD, versus 27.9 ml/1.73m2/min with CFPD (p=0.026). No major complications of
peritoneal dialysis occurred during the study. As a minor complication the inﬂow
catheter was blocked in patient 2, 5 and 6 for a short period . This was solved
by switching the in- and outﬂow catheter and by adding heparin standard to the
dialysis solution, to prevent ﬁbrin clotting.
108
CONTINUOUS FLOW PERITONEAL DIALYSIS
5
Table 5.2: Conventional PD versus CFPD per patient
Patient Used %
of
glucose
UF Clearance
urea
Clearance
creatinine
MTAC
urea
MTAC
creatinine
solution (ml/1.73m2 (ml/1.73m2 (ml/1.73m2 (ml/1.73m2 (ml/1.73m2
/min) /min) /min) /min) /min)
Conventional
Patient 1
(conventional
before CFPD)
1.5% -0.41 2.1 3.5 2.4 4.9
Patient 2
(conventional
after CFPD)
1.5% 0.77 6.1 5.4 18.4 11.2
Patient 3
(mean before
and after)
1.5% 0.17 5.6 3.8 10.2 5.1
Patient 4
(mean before
and after)
2.5%/4.25% 1.4 4.6 4.1 4.5 5.6
Patient 5
(mean before
and after)
2.5% -1.1 4.0 21.5 9.4 9.9
Patient 6
(mean before
and after)
4.25% 0.37 7.5 7.5 20.2 35.5
CFPD
Patient 1 1.5% 1.28 12.3 18.0 8.8 14.2
Patient 2 1.5% 1.47 14.4 14.7 10.9 11.1
Patient 3 1.5% 2.07 13.1 15.7 8.5 10.8
Patient 4 2.5%/4.25% 4.3 18.2 43.1 11.2 43.7
Patient 5 2.5% 0.6 15.4 39.2 11.7 42.1
Patient 6 4.25% 1.3 16.9 41.9 12.6 45.7
Mean results
Conventional
PD
0.2 5.0 7.6 10.9 12.0
CFPD 1.8 15.0 28.8 10.6 27.9
%-difference
with CFPD
+344% +498% +157% +323%
UF = ultraﬁltration, MTAC = mass transfer area coefﬁcient;
CFPD = continuous ﬂow peritoneal dialysis; PD = peritoneal dialysis
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Figure 5.3: UF with conventional PD versus CFPD for all patients.
UF = ultraﬁltration; PD = peritoneal dialysis; CFPD = Continuous Flow Peritoneal Dialysis
Discussion
This ﬁrst report of CFPD for clinical use in ARF in pediatric patients shows that
with CFPD clearances and UF were signiﬁcantly higher than with conventional
PD. Values did however not reach levels predicted in theoretical studies26 and
levels achieved in previous case studies on CFPD in adult patients22,29 with UF
rates of 15 to even 45 ml/min. One explanation for the lower values of clear-
ances and UF compared to these studies could be our relatively low ﬂow rate
of 100 ml/1.73m2/min, while Kraus29 and Diaz-Buxo22 used rates up to 200
ml/1.73m2/min. A second explanation for the lower clearances and UF compared
to adult studies could be suboptimal distance between the two catheters, due to
the smaller patient size of our pediatric patients, which could lead to more recir-
culation. In general, CFPD done with two catheters has been shown to be more
effective in terms of clearances achieved than when one double lumen catheter
is used. This is thought to be because of streaming of dialysate directly from in-
ﬂow to outﬂow port of the double lumen catheter resulting in poor mixing as well
as recirculation of dialysate which in turn results in lower effective dialysate ﬂow
rate30,31. With two catheters average urea clearances of 44 to 58 ml/min have
been achieved14,22,29 versus 14 to 20 ml/min with double lumen catheters17,32.
Recently Ronco et al21,33 have developed a new type of double lumen catheter
with a diffuser to maximize mixing, whereby higher clearances can be achieved.
In the present study we used the CFPD technique with two separate catheters
instead of one double lumen catheter, because of the above mentioned better re-
sults as well as for the practical reason that the available double lumen catheters
have to be placed surgically and are not available in pediatric sizes.
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Figure 5.4: Paired t-tests for conventional PD versus CFPD.
UF = ultraﬁltration; MTAC = mass transfer area coefﬁcient; NS = not signiﬁcant
Clearances with CFPD are in the range, and even higher than the calculated
MTACs, as was predicted by Gotch’s calculations26 and explained by Ronco et
al31 as a result of different utilization of the available peritoneal surface area. The
MTACs of creatinine on CFPD are higher compared to conventional PD. This was
also shown in the study by Freida at al20; the impact of high dialysis ﬂow rate on
MTACs could play a role by constant renewing of the normally more static layer
of ﬂuid at the tissue surface. For MTACs of urea, no statistical signiﬁcant dif-
ference compared to conventional PD was found. A possible explanation are
the relatively low values of urea, with less impact compared to creatinine values.
Diaz-Buxo et al34 proposed the possibility of higher sodium sieving in CFPD be-
cause of the high contribution of free water transport with fresh dialysate with a
maintained high glucose gradient. This could theoretically lead to hypernatremia,
which was not observed in our patients during CFPD, but should be closely ob-
served in future studies. Lower sodium concentrations in dialysis solution could
be used to prevent hypernatremia.
Complications in CFPD in acute renal failure will mainly be caused by catheter
related problems or infection as in conventional PD, with catheter malfunctioning,
peritonitis and excessive intra-abdominal pressure as most frequently occurring
complications. Acute PD catheter placement is a well accepted procedure that al-
lows for rapid access with a major complication rate reported as less than 2%5,35.
The second catheter will provide a smaller risk because the abdomen is already
ﬁlled with ﬂuid. Peritonitis will theoretically be a smaller problem in CFPD than in
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conventional manually performed PD because of the closed system that is being
used. Because a separate inﬂow and outﬂow catheter are used in CFPD an extra
ﬁlter could be implemented on the inﬂow site to further minimize infection risks18.
Abdominal pressure was carefully monitored in our study, with frequent measure-
ments of inﬂow and outﬂow pressure at the transducers. Direct measurement of
intra-abdominal pressure however remains a technical challenge8,31.
A disadvantage in general are the costs of fresh ﬂuids, but these play a minor
role in acute PD with a limited period of time on CFPD and are further minimized
in pediatric patients because of smaller volumes used. For more long term use
in adults regeneration of ﬂuid could be preferred, as proposed by Diaz-Buxo et
al30, for cost reduction, as well as for reduction of protein losses and nutrients by
UF.
In our opinion CFPD is a technique that is especially useful for ARF in children.
The advantages of conventional PD over CVVH/D are maintained while provid-
ing importantly improved UF and clearances. It would be most useful in the
small hemodynamically unstable infant. Children with high ventilatory require-
ments could also be dialysed with lower ﬁll volumes while maintaining adequate
clearances and UF.
Recently it has been suggested by several authors that CFPD should be consid-
ered as a potential future therapy in acute renal failure36,37. In one case report
CFPD was successfully used in an adult patient with acute renal failure38. The
only data on children come from six children in a intensive care setting with acute
respiratory distress syndrome (not in renal failure), who were treated with CFPD
to manage severe anasarca39. These children (age 0-37 months) were treated
with CFPD at a relatively slow rate (10-30ml/kg/hr) and without a ﬁxed intraperi-
toneal volume because of ventilation problems. They attained adequate UF of up
to 4ml/kg/ hr. Clearances were not calculated but would probably have been low
due to lack of ﬁxed intraperitoneal volume and slow ﬂow rates. There were no
complications associated with percutaneous catheter placement or with CFPD
therapy.
CFPD is a potentially successful therapy which could importantly improve the
treatment for acute renal failure in developing as well as in developed countries.
Studies with larger patient numbers are needed in the near future to conﬁrm our
ﬁndings. Further optimization of CFPD therapy could be achieved by a higher
ﬂow volume, improvements in catheter technology and future use of regenera-
tion of ﬂuids, to minimize nutritional losses and maximize biocompatibility for the
peritoneal membrane.
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Abstract
Introduction
Fungal peritonitis is a rare but serious complication in children on peritoneal
dialysis (PD). The reported incidence is less than 3% of the total peritonitis
episodes. Morbidity and mortality are disproportionally high in fungal peritoni-
tis. In this study risk factors were evaluated and the therapeutic measures were
reviewed.
Patients and methods
A retrospective, multi-centre study was performed in Dutch pediatric PD patients.
Between 1980 and 2005, a total of 159 patients was treated with PD, for a total
treatment period of 3573 months. All patients were reviewed considering peri-
tonitis rate and causative organism. Fungal peritonitis episodes were evaluated
on possible risk factors and treatment strategy.
Results
Three hundred and twenty-one episodes of peritonitis occurred (0.09/ patient-
month). In 9 patients a yeast or mold was found in the dialysate (2.9%). The
majority of patients had a candida peritonitis (78%). Seven patients (78%) had
used antibiotics in the prior month. Patients with a fungal peritonitis had a higher
previous bacterial peritonitis rate compared to the bacterial peritonitis rate of the
total study population (0.09 versus 0.13 episodes/patient-month), with twice as
much gram-negative organisms in the fungal peritonitis group. Seven patients
were treated with ﬂuconazole, with or without ﬂucytosine, 2 patients with ampho-
tericin B. In all patients the PD catheter was removed and the patients were con-
verted to hemodialysis, in 3 patients immediately after the diagnosis was made.
In 4 patients restart on PD was possible after the fungal peritonitis. The mortality
rate was zero.
Conclusions
Fungal peritonitis is a rare complication of PD in children, but is associated with
high technique failure. Most important risk factors are a high bacterial peritonitis
rate, prior use of antibiotics, and previous bacterial peritonitis with gram-negative
organisms. The PD catheter should be removed early, but in children peritoneal
lavage with ﬂuconazole before removal might be useful to prevent technique fail-
ure.
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Introduction
The majority of children with end-stage renal disease are treated with peritoneal
dialysis (PD). Peritonitis is a frequent complication of PD in children as well in
adults. Fungal peritonitis (FP) accounts for 2.8-15% of all peritonitis episodes in
adults1–4. The reported incidences in pediatric populations are less than 3%5–7.
Morbidity and mortality are relatively high in FP. Loss of peritoneal function oc-
curs frequently, resulting in temporary or deﬁnite conversion to hemodialysis.
Risk factors for the development of FP are multifactorial, and only partly un-
derstood. The most important known risk factors are a previous bacterial peri-
tonitis treated with antibiotics and prior antibiotic treatment in general. Whether
the causative organisms in previous bacterial peritonitis play a role is not clear.
There are only a few studies focussing on FP in children. There is no complete
consensus regarding treatment for FP, neither about antimycotic use, nor about
the policy around catheter-removal. In this study we give a survey of FP in the
two largest Dutch pediatric medical centers for PD and we give an overview of
the literature. We evaluate the etiologic features, especially previous episodes of
peritonitis, and review the therapeutic and preventive strategies.
Patients and methods
Study design
A retrospective clinical study was carried out at the Radboud University Nijmegen
Medical Centre in Nijmegen, from 1980 until 2005, and the Wilhelmina Children’s
Hospital, University Medical Centre, in Utrecht from 1997 until 2005. These
two centers include the vast majority of the pediatric PD patients in the Nether-
lands.
Study population
All pediatric patients enrolled in the PD program between 1980 and 2005 were
analyzed. In this period, 159 patients with end stage renal disease were treated
with PD for a total of 3573 months. All patients on PD were reviewed consider-
ing clinical peritonitis rate and causative organisms cultured. Each patient with
a positive dialysate culture for yeasts or molds was evaluated on the following
characteristics: age, gender, time on PD, underlying disease, medical history (fo-
cussed on prior peritonitis and prior antibiotic use) and other possible risk-factors
(gastrostomy catheter and immunosuppression). More speciﬁc data concerning
the FP episode were noted: the causative organism, the clinical symptoms, cell
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count in dialysate, antimicrobial regimen, catheter policy and time of removal and
whether and when successful continuation on PD was possible.
Microbiologic methods
From all patients with clinical suspicion of peritonitis a culture was made of the
dialysate. The clinical diagnostic criteria for peritonitis included: cloudy dialysate,
abdominal pain, and fever. Elevated white cell count in the dialysate of >100/
mm3 is suggestive for peritonitis. For culture 50-ml aliquots of dialysate ﬂuid
were centrifuged and the pellet was cultured on speciﬁc media for both bacte-
ria and fungi (including blood, Sabouraud dextrose, brain-heart-infusion agar as
speciﬁc anaerobic media). Gram staining was performed directly on the pellet.
For bacterial cultures, plates were incubated for 4 days under aerobic and anaer-
obic conditions, liquid media were incubated for 5 days. For fungal cultures, the
plates were incubated for 7 days, the liquid media were cultured for a period of
21 days. If dimorphic fungi were expected, the culture period was extended to 8
weeks. Identiﬁcation of fungi and bacteria was performed by standard laboratory
methods. Susceptibility testing for the fungal isolates was performed by microdi-
lution method following the National Committee for Clinical Laboratory Standards
M27-A-2 (yeasts) and M38-A (ﬁlamentous fungi) protocols8,9.
Deﬁnitions
Peritonitis rate was deﬁned as the number of episodes of peritonitis divided by
the total patient-months on PD (for completeness the peritonitis rate was also
expressed as number of episodes/patient-year and as one peritonitis episode
every x patient-months). Recurrent infection was deﬁned as an infection with
the same causative organism within 2 weeks after completion of an antibiotic
treatment course and documentation of at least one negative dialysate culture2
and was not included as a new peritonitis in the peritonitis rate. Prior antibiotic
use was deﬁned as use of antibiotic treatment, whether orally, intravenously or
intraperitoneally, for peritonitis or for any other infection in the month prior to the
occurrence of FP.
Results
Three hundred and twenty one episodes of peritonitis occurred in 159 patients
(0.09 episodes/ patient-month or 1.08 episodes/ patient-year or one episode ev-
ery 11.1 patient-months). In 9 patients either a yeast or a mold was found in the
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dialysate (table 6.1). This accounted for 2.9% of all peritonitis episodes. The un-
derlying renal disease was multicystic dysplastic renal disease (3 patients), ure-
thral valves (3 patients), hemolytic uremic syndrome (1 patient), focal glomeru-
losclerosis (1 patient) and nephronophtisis (1 patient). In two patients the FP
was the ﬁrst peritonitis episode, in both patients within 1 month after start of PD
treatment. The other patients all had one or more episodes of bacterial peritonitis
prior to the fungal peritonitis. Seven (78%) patients were treated with antibiotics
in the month before the fungal peritonitis. None of the patients had had a gastros-
tomy catheter and none of the patients had been on immunosuppressive therapy.
In 7 patients (78%) Candida spp. were cultured, in one patient a Rhizopus sp.
and in one patient a Rhodotorula rubra. Six patients were treated according to
our protocol with ﬂuconazol orally (100 mg/1.73 m2 with a double dosis on the
ﬁrst day) and ﬂucytosine intraperitoneally (100 mg/l) for 3 weeks. In 2 of these 6
patients the antifungal therapy was switched after the results of the susceptibility
testing of the organism became available. The other 3 patients were treated with
a different antifungal regimen. Patient 2 was in a very bad general condition and
received amphotericin B intravenously because of suspicion of resistent fungal
organisms. Patient 3 had his PD catheter removed as soon as the diagnosis
of FP was made and he was treated with ﬂuconazole intravenously because of
suspicion of a septic shock. Patient 6 received amphotericin intraperitoneally be-
cause of suspected resistence of the causative organism for ﬂuconazole. The
PD catheter was removed in all patients, in 3 patients (33%) immediately after
the culture results became positive. In patient 1, removal of the PD catheter
was delayed for more than 2 months. It was attempted to maintain this patient
on PD because of a long-planned overseas family-visit at that time. However,
the patient developed a recurrent fungal infection after 2 months and this time
the catheter was removed directly after the culture became positive. In patient
2 the PD catheter had been removed before the fungus was cultured, because
of recurrent occlusion of the catheter with technique failure. Four patients could
restart with PD, 6 weeks to 10 weeks after the development of FP. None of the
patients died as a result of the FP.
Comparing the previous episodes of bacterial peritonitis between the patients
who developed a FP and the total group, the FP patients had a higher bacte-
rial peritonitis rate than the overall patient group (0.13 versus 0.09 episodes per
patient-month, table 6.2). The causative organisms in the bacterial peritonitis
episodes showed a different pattern as well, with twice as much gram-negative
organisms in the FP group (46% versus 23%). The FP patient group had as
much gram-positive organisms as the overall patient group, but with a larger part
of streptococci and enterococci involved.
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Table 6.1: Clinical and microbiological characteristics of 9 pediatric cases of fungal peri-
tonitis.
Patient
(Gender)
Age
(Years)
Time
on
PD
(Years)
AB within
one
month
before FP
Fungus
cultured from
PD-ﬂuid
Antimicrobial
treatment
Time of
catheter
removal
PD
after-
wards
1(M) 12.4 2.5 - Candida
albicans
Fluconazole po
Flucytosine ip
2
months
+
2(M) 3.5 1 + Rhizopus sp. Amphotericin B iv 0 days -
3(M) 5.8 1.7 + Candida
albicans
Fluconazole iv 5 days -
4(M) 3.2 2.8 + Candida
albicans
Fluconazole po
Flucytosine ip
Amphotericin B iv
13 days -
5(F) 2.8 1.4 - Candida
parapsilosis
Fluconazole po
Flucytosine ip
4 days +
6(M) 3.5 1.3 +* Candida
parapsilosis
Amphotericin B ip 5 days +
7(M) 1.0 0.08 + Candida
albicans
Fluconazole po
Flucytosine ip
22 days -
8(M) 11.9 0.08 + Candida sp. Fluconazole po
Flucytosine ip
11 days -
9(M) 3.3 0.23 + Rhodutorula
rubra
Fluconazole po
Flucytosine ip
Ketoconazole ip
9 days +
* prophylactic use of trimethoprim
F = Female, M = Male, PD = peritoneal dialysis, AB = antibiotics, FP = fungal peritonitis,
po = per os, ip = intraperitoneally, iv = intravenously
Discussion
Fungal peritonitis is a rare but serious complication of PD, with disproportionally
high clinical consequences. The incidence in the present study was in concor-
dance with the literature with fungal episodes of peritonitis accounting for 2.9%
of all peritonitis episodes.
Several predisposing factors for FP have been reported. Prior use of antibiotics,
for bacterial peritonitis in particular, has been most consistently reported. Goldie
et al.2 stated that 65% of FP patients had received broad-spectrum antibiotics
in the month prior to FP and 87% in the prior 6 months. Eighty-nine per cent of
antibiotics were prescribed for treatment of bacterial peritonitis. Prasad et al.10
and Wang et al.11 both reported 77% of patients to have had antibiotic treatment
within the preceding 3 months. The only larger pediatric study by Warady et al.5
found that 56% had received antibiotics in the preceding month, half of them for
bacterial peritonitis. In our study, 78% of the children received antibiotic treat-
ment in the prior month, 86% of them for bacterial peritonitis.
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Table 6.2: Incidence of bacterial peritonitis in pediatric patients on PD and causative
micro-organisms: comparison of patients with and without a subsequent fungal peritonitis
1980-
1994
% 1994-
1999
% 1999-
2004
% Total
pa-
tients
% Fungal
peri-
tonitis
patients
%
Pediatric patients on PD 70 40 53 150 9
Episodes of bacterial
peritonitis
195 53 60 308 13
Patient-months on PD 1921 633 916 3470 103
Episodes/patient-month 0.1 0.08 0.07 0.09 0.13
Cultures from PD-ﬂuid
S. epidermidis 47 24% 9 17% 7 12% 63 20% 1 8%
S. aureus 35 18% 12 23% 8 13% 55 18% 1 8%
Streptococci/enterococci 34 17% 7 13% 6 10% 47 15% 4 31%
Total gram + bacteria 120 62% 29 55% 24 40% 173 56% 6 46%
Total gram - bacteria 33 17% 13 25% 24 40% 70 23% 6 46%
Culture negative 46 24% 14 26% 13 22% 73 24% 2 15%
Cultures not available 0 0% 0 6 10% 6 2% 0 0%
Two possible mechanisms responsible for the development of FP after antibiotic
treatment are postulated12,13. First, inﬂammation itself renders the peritoneum
more susceptible for fungal infections and secondly, antibiotics interfere with nor-
mal intestinal and skin ﬂora and may cause overgrowth of fungi. In general chil-
dren are more likely to receive antibiotics for common pediatric infections, which
could further enhance their susceptibility for FP.
The overall rate of peritonitis episodes was higher in our patients with FP than in
the overall PD group. This higher peritonitis rate was also found by Warady et al.5
and in most adult studies2,14. Not only the peritonitis rate, but also the causative
organisms in previous peritonitis may play a role as predisposing factor for FP.
In the literature on FP this has not been evaluated before. In the present study
we found that the FP patient group had twice as much gram-negative peritoneal
infections. The antibiotics used for gram-negative infections could disturb nor-
mal intestinal ﬂora more severely and thus may cause more overgrowth of fungi.
FP as the primary episode of peritonitis occurred in 2 of our patients (22%). In
Warady’s study 49% of children had a FP as a ﬁrst episode of peritonitis, while
Prasad et al. found 18% of FP in adults to be the ﬁrst peritonitis episode.
Murugasu et al.15 suggested that a gastrostomy catheter could be a predispos-
ing factor for FP, based on 3 cases of malnourished children with a gastrostomy
catheter in situ who developed FP. Warady et al. could not conﬁrm a statis-
tical relationship between FP and gastrostomy catheter in a larger number of
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patients. None of our patients with FP had a gastrostomy catheter, but gastros-
tomy catheters were very rarely used in our overall PD population. Immunosup-
pressive medication can predispose to FP as well16. In our cohort none of the
patients were on immunosuppressive medication.
In general, the peritonitis rate in our population is declining over the years, as is
seen in most PD populations, with better dialysis techniques (double-chambered
bags with bicarbonate buffered solutions, automated PD) and better preventive
measures for exit-site infections that have become available over the years. This
also explains the relative increase in gram-negative bacterial infections in the
period 1999-2005, which does not reﬂect a real increase, but merely reﬂects
the decrease in gram-positive bacteria due to local antibiotic prophylaxis with
mupirocin for exit-site infections caused by gram positive bacteria. Regarding
the fungal infections, we do not observe a decline in frequency, with one third of
the cases presenting in the last 5 years.
In the present study Candida spp. contributed for 78% of fungal peritonitis
episodes. Candida albicans and non-albicans infections occurred in respectively
44% and 33% of all infections. Candida spp. are the most frequently encountered
causative organisms in FP, with 68 to 89% of adult cases2,4,10,11,17 and 79% to
100% of pediatric cases5,18. C. albicans still is the predominating organism but in
the more recent studies non-albicans Candida spp. form a slight majority, around
55% in both children and adults5,11,14,17. Warady’s pediatric study even found C.
parapsilosis to outnumber C. albicans. In our study the two most recent cases of
FP were both caused by C. parapsilosis, so this trend may develop in our popu-
lation as well.
Antimycotic treatment according to our protocol consists of ﬂuconazole orally
and ﬂucytosine intraperitoneally. As can be seen from our data on antimycotic
regimen, treatment was individualized in most cases. To our opinion treatment
should become more uniform, which might be achieved by the development of
national guidelines ﬁtting into the international guidelines. The most recent Inter-
national Society of Peritoneal Dialysis (ISPD, 2000) pediatric guidelines19 recom-
mend ﬂuconazole as ﬁrst choice antimycotic, for its excellent bioavailability and
peritoneal absorption and good spectrum against most Candida species, except
for C. krusei and some isolates of C. glabrata. The 2005 ISPD adult guidelines20
recommend amphotericin B combined with ﬂucytosine as ﬁrst choice therapy,
whereby ﬂuconazole, voriconazole or caspofungin may replace amphotericin B.
Amphotericin B is not our ﬁrst choice because of difﬁculties in route of administra-
tion and limited peritoneal absorption. When given intravenously, more than 90%
of amphotericin becomes protein-bound, which does not facilitate peritoneal pas-
sage21. Thereby, patients have to be hospital-admitted for treatment. Intraperi-
toneal amphotericin B is irritating to the peritoneum and may result in severe
abdominal pain5 and for this reason should be avoided. The question is if there
is still a role for ﬂucytosine in the treatment of FP, now we have the availabil-
ity of antifungals like ﬂuconazole, with good penetration in the peritoneum, that
are suitable for intraperitoneal use as well. Several studies have shown that ﬂu-
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conazole monotherapy is effective and reaches good plasma and dialysate con-
centrations, when given orally22–24 as well as intraperitoneally22,25,26. Chen et
al.27 recently compared oral ﬂuconazole monotherapy with either amphotericin
B intraperitoneally; or amphotericin B intraperitoneally combined with ﬂucona-
zole orally or intravenously. They did not ﬁnd any differences in effectiveness.
The occurrence of more resistant Candida spp. in the future could limit future
use of ﬂuconazole, although the evolution towards ﬂuconazole-resistant species
noted in bloodstream infections has not yet developed in FP28,29. The newer
azole derivates like voriconazole and posaconazole can be a good alternative in
case of future development of resistance.
There is consensus about the fact that the catheter should be removed in FP,
because fungi can colonize the PD catheter and cause a bioﬁlm at the surface,
which will prevent eradication of the infection. The time of removal has been the
subject of discussion. The most recent ISPD guidelines for adults state that the
catheter should be removed immediately after the diagnosis of FP is conﬁrmed20.
Wang et al.11 found a higher mortality rate if catheter removal was delayed until
24 hours, although the difference was not statistically signiﬁcant. Goldie et al.2
found that removal within one week gave a much smaller rate of technique failure
compared to patients who did not have their catheter removed, but in this study
no data on immediate removal were available. The most recent pediatric reports
question the need of immediate catheter removal5,19. The main reason to pro-
mote early but not immediate removal is to allow for a period of peritoneal lavage
that could help prevent formation of peritoneal adhesions and maintain viability
of the peritoneal membrane5,12. Especially for children, the goal is to achieve
long-term preservation of peritoneal membrane function. In children no relation-
ship has been established between the time of catheter removal and mortality
rate or technique failure5.
Generally the mortality rate for FP in children seems to be lower than in adults,
0-6%5,18 versus 13-53%2,4,10,11,17. Technique failure on the other hand is high in
both adults and children, around 50% as well in literature5,14,17,18 as in our study.
To our opinion this might justify early, but not immediate removal of the catheter
in children, after peritoneal lavage with antimycotics has been ensured, to mini-
mize peritoneal damage.
Prophylactic use of antimycotics with nystatin during bacterial peritonitis is not
generally used. The 2005 ISPD adult guidelines only recommend this practice
in centres with a very high fungal peritonitis rate20. Whether nystatin prophylaxis
could be useful for high risk patients, like patients with a high bacterial peritonitis
rate or patients with peritonitis caused by gram-negative bacteria, needs further
investigation. Presently, its use should be decided for each individual patient,
based on risk factors and epidemiology.
125
6FUNGAL PERITONITIS
Conclusions
1. Fungal peritonitis is a rare complication of PD in children, but is associated
with high technique failure.
2. Most important risk factors are a high bacterial peritonitis rate, prior use of
antibiotics, and previous bacterial peritonitis with gram-negative organisms.
3. The PD catheter should be removed early, but in children peritoneal lavage
before removal with ﬂuconazole until disappearance of clinical symptoms
might be useful to prevent technique failure.
4. Monotherapy with ﬂuconazole is the ﬁrst choice treatment for fungal peri-
tonitis. In children intraperitoneal ﬂuconazole prior to removal of the PD
catheter is preferable, followed by ﬂuconazole orally. The occurrence of
more resistent Candida spp. and more rare occurring fungi in the future
could limit the use of ﬂuconazole. The new azole derivates may be a good
alternative. Amphotericin B should be avoided, unless a fungus resistant
for the other available antifungals is cultured.
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Abstract
Introduction
Peritonitis is a frequent complication of peritoneal dialysis (PD) in children as
well in adults. Data on PD and peritonitis in pediatric patients are very scarce
in developing countries. The aim was to evaluate PD treatment and peritonitis
epidemiology in pediatric patients in South Africa and identify risk factors for
peritonitis
Patients and methods
A retrospective cohort study was performed between 2000 and 2008. Base-
line characteristics and potential risk factors of peritonitis were recorded, includ-
ing: housing, socio-economic circumstances, distance to PD centre, type of PD,
mode of catheter placement, race, presence of gastrostomy tube, weight and
height. Outcome indices for peritonitis were peritonitis rate, time to ﬁrst peritoni-
tis and peritonitis free patients.
Results
Sixty-seven patients were included, who were on PD for a total of 544 months.
The total number of peritonitis episodes was 129. Median peritonitis rate was
1 episode every 4.3 patient months (2.8 episodes/patient-year, range 0-21.2).
Median time to ﬁrst infection was 2.03 months (range 0.1-21.5 months), 28.4%
of patients remained free from peritonitis. Patients with good housing and good
socio-economic circumstances had a signiﬁcantly lower peritonitis rate and a
longer time to ﬁrst peritonitis episode.
Conclusions
Peritonitis rate is high in this cohort, compared to numbers in the developed
world, the characteristics of causative organisms are comparable. Most impor-
tant risk factors for development of peritonitis are poor housing and poor socio-
economic circumstances. More intensive counseling may be beneﬁcial, but im-
provement of general socio-economic circumstances will have the greatest inﬂu-
ence on PD success.
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Introduction
Frequently occurring diseases in developing countries, like acquired immuno-
deﬁciency syndrome (AIDS), tuberculosis, malaria, gastro-enteritis and hyper-
tension are often complicated by renal diseases1. No reliable statistics are avail-
able on causes of end stage renal disease (ESRD), the only data available are
those from dialysis and transplantation, but these databases represent a selec-
tion of patients based on eligibility for transplantation and patients with access
to renal replacement therapy (RRT). The reported prevalence of patients with
ESRD in Africa in 2004 was 70/million population and the prevalence of RRT was
65/million population. The global prevalence in 2004 for ESRD was 280/million
population, with a prevalence of RRT of 215/million population2.These numbers
clearly reﬂect the under-rapportage of ESRD in Africa together with the shortage
of RRT.
In recent years peritoneal dialysis (PD) has become increasingly available in de-
veloping countries. PD has been described as the dialysis technique of choice
in developing countries, where mass poverty and poor resources play an impor-
tant role in health care3. PD can be performed at a relatively low cost as it is
less reliant than other dialysis techniques on expensive infrastructure and health
care professionals. The fact that PD is a home based technique saves on travel
expenses as well.
In developing countries PD is growing as a renal replacement modality. In 2004
the worldwide growth was 11% in countries other than Europe, the United States
or Japan, where no growth was observed2. In developing countries dialysis pa-
tients tend to be of a younger age than in developed countries2. The ﬁrst reported
experiences with PD in South Africa originate from the eighties4,5. These early
attempts were successful but multiple problems were encountered restricting the
success rate. Most important problems were lack of transportation, poor housing
and sanitation, inadequate education and poor acceptance of therapy.
Peritonitis is a frequent complication of PD in children as well as in adults. Peri-
tonitis characteristics in children vary highly over the world, inﬂuenced by ge-
ographical and socio-economic differences among others6. Data on PD and
peritonitis in pediatric patients in developing countries are scarce.
In this study the epidemiology of peritonitis in children on PD in Cape Town,
South Africa is evaluated and potential risk factors for peritonitis are identiﬁed.
Patients and methods
Study design
A retrospective clinical cohort study was carried out at the Red Cross Children’s
Hospital in Cape Town, South Africa. The Red Cross Children’s Hospital is one
133
7PERITONITIS
of the two university hospitals in South Africa where pediatric PD is performed.
Only patients considered eligible for transplantation are accepted into the dialysis
program. All patients from 0 to 18 years enrolled in the PD program between
2000 and 2008 were analyzed.
Figure 7.1: Age distribution of all patients
Patients
Sixty seven patients were included, 35 males and 32 females, who were treated
with PD for a total of 544 months. Median age at start was 10.1 years (range 1.2-
17.4 years). Age distribution is shown in ﬁgure 7.1. Median time on PD was 7.0
months (range 0.4-36.8 months). All patients were on PD due to ESRD. Under-
lying diseases were glomerulonephritis (24%), dysplastic kidneys (16%), focal
segmental glomerulosclerosis (13%), reﬂux nephropathy (9%), nephrotic syn-
drome (5%), urethral valves (5%), HUS (3%), unknown (12%) and other diseases
(13%; nephronopthisis, primary hyperoxaluria, cystinosis, Alport syndrome, sys-
temic lupus erythematosus, infection). All patients in this cohort had single cuff,
upward pointing straight catheters for dialysis. This is preferred by the local sur-
geons, since single cuff catheters are easier to remove if necessary. The same
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type of catheter was used in all patients to achieve maximum routine and hence
a smaller risk of operation related complications. Omentectomy was performed
as a routine where possible. Catheters were not used for two weeks and were
secured to the abdomen and not redressed for this time period. Antibiotics were
not routinely given at time of placement. Training on exit-site care was provided
standard for all patients. Nurses teach patients and parents about exit site care,
including dressing and general hygiene. All peritonitis episodes were primarily
treated according to the local protocol with cefotaxim and vancomycin intraperi-
toneally. Treatment was individualized once culture results were available.
Methods
Demographic and biomedical data were obtained by evaluation of the patients
medical records. Socio-economic data were clinically evaluated by a clinical so-
cial worker and the pediatric nephrologist taking care of the patient. Patient base-
line characteristics, patient survival, technique survival and all episodes of peri-
tonitis were analyzed. Recorded for each peritonitis episode were the causative
organism, occurrence of a gram-negative or fungal infection (noted as severe
infection, because of the relative high risk of catheter removal, technique failure
and relapse7–9, occurrence of technique failure because of peritonitis and sur-
vival after peritonitis.
The following primary peritonitis outcome indices were assessed: (1) peritonitis
rate (expressed as one peritonitis episode every × patient months and as num-
ber of episodes/ patient year); (2) Peritonitis free period (time to ﬁrst peritonitis
episode); (3) Peritonitis free patients (patients not suffering from peritonitis ver-
sus all the patients that did suffer from one or more peritonitis episodes and
versus the 25% of the patients with the highest rate of peritonitis.
Occurrence of peritonitis was diagnosed by a pediatric nephrologist. Patients
were considered to have peritonitis with two of the following criteria present:
abdominal pain, cloudy dialysis ﬂuid, leukocyte count >100/mm3 and positive
culture of dialysate. An infection with the same causative organism as in the im-
mediately preceding episode according to culture results and antibiotic suscepti-
bilities within four weeks after completion of antibiotic treatment was considered
as a recurrent peritonitis and was not included as a new peritonitis episode.
In all patients possible risk factors were assessed: age of the patient (in months);
weight and height (both expressed as good = above the 10th percentile, fair = 3rd
to 10th percentile and poor = below the 3rd percentile); type of PD (continuous
ambulatory PD (CAPD) versus nightly intermittent PD (NIPD)); mode of catheter
placement (laparoscopic versus laparotomic); distance to PD centre (more or
less than 200 kilometers); presence of gastrostomy tube; race (black versus
black mixed with other races versus white); housing; socio-economic circum-
stances. Criteria for assessment of housing included availability of (1) electricity
(2) running water and (3) adequate sanitation with bathroom available. Housing
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was classiﬁed as good when electricity, running water and bathroom were all
available, housing was classiﬁed as fair when either one of these three criteria
was missing and classiﬁed as poor when two or more of the above three crite-
ria were missing. Institutional housing (in hospital or clinical care centre) was
classiﬁed as a separate category. Criteria for assessment of socio-economic cir-
cumstances were: (1) One or two parents/care-givers present, (2) employment
of care-givers and (3) availability of adequate social support around the family.
Socio-economic circumstances were classiﬁed as good when two parents/care-
givers were present, with one or both care-givers employed and an adequate
social network present. Socio-economic circumstances were classiﬁed as fair
when either one of the above three criteria was suboptimal (e.g only one care-
giver present or unemployment of care-givers or inadequate social network) and
was classiﬁed as poor when two or more of the above three criteria were subop-
timal.
Statistical analysis
Variables were not distributed normally, therefore results were expressed as me-
dians with ranges and percentages. Outcome indices were assessed with non-
parametric tests and with different types of tests to improve the robustness of the
statistical analysis. Spearman’s correlation coefﬁcient was calculated for the con-
tinuous risk factor age. Differences between categorical dichotomous risk factors
(type of PD, catheter placement and distance to PD centre) were tested with the
Mann Whitney U test. For categorical risk factors with more than 2 categories
(for the risk factors weight, height, housing and socio-economic circumstances)
both the Kruskal Wallis test as well as the Mann Whitney U test were performed,
whereby with the Mann Whitney U test the category ’good’ was tested against
the other categories. For the risk factor ’race’ black, mixed and white race were
tested separately with the Kruskal Wallis test as well as combined (black/mixed
versus white) with the Mann Whitney U test. For the outcome variable ’time to
ﬁrst peritonitis’, peritonitis episodes without exact time indication and peritonitis
free patients were excluded. The outcome variable peritonitis free patients was
tested dichotomously with Chi-square tests. For statistically signiﬁcant risk fac-
tors the degree of correlation was tested with linear backward regression with
multicollinearity diagnostics. Collinearity diagnostics give an estimation of the in-
dependent effect of speciﬁc risk factors. The degree of collinearity is a measure
for the correlation between risk factors. Kaplan Meier hazard regression anal-
ysis was used for the cumulative risk of developing a ﬁrst infection, according
to Vonesh et al10. With this analysis the relative probability of developing a ﬁrst
infection is compared between subgroups of the study population. Differences
were considered signiﬁcant if p-values were below 0.05.
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Table 7.1: Classiﬁcation of causative organisms
Causative agents Number of peritonitis episodes %
Gram-positive 39 30.2
Gram-negative 29(+1)* 23.3
Fungal 9(+1)* 7.7
M. Tuberculosis 1 0.8
Fungal and gram negative 1* 0.8
Culture negative 37 28.7
Unknown 13 10.1
Total 129 100
*A fungus and a gram-negative organism were both cultured in one culture
Figure 7.2: Peritonitis rate distribution of all patients
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Ethics
The study was approved by the hospital ethics committee.
Results
During the total treatment period of 544 months, 129 peritonitis episodes oc-
curred. The median peritonitis rate was 1 episode every 4.3 patient months,
or 2.8 episodes/ patient year (range 0-21.2). The distribution of the peritonitis
rate over the total patient group is shown in ﬁgure 7.2. Median time to ﬁrst peri-
tonitis was 2.03 months (range 0.1-21.5 months). Eleven patients had the ﬁrst
peritonitis within the ﬁrst month. Nineteen patients (28.4%) remained free from
peritonitis. Median time on dialysis was 7.0 months. Classiﬁcation of the peri-
tonitis episodes according to causative organism is shown in table 7.1. Ten per
cent of cultures is classiﬁed as unknown, the causative organism could not be re-
trieved from these patients. Eleven patients developed a fungal peritonitis (14.9%
of all patients, 7.7% of all peritonitis episodes). Of these patients, 91% had suf-
fered from one or more bacterial peritonitis episodes prior to the fungal peritonitis
episode. Further the fungal peritonitis patients had a signiﬁcantly higher number
of peritonitis episodes (p = 0.001, a signiﬁcantly higher peritonitis incidence (p =
0.006) and a higher rate of technique failure (p = 0.0001) compared to the other
patients. One patient developed a tuberculous peritonitis, with good clinical out-
come. Patient survival on peritoneal dialysis was 100%. Technique failure with
temporary switch to hemodialysis occurred in 11 patients (16.4%), being signif-
icantly higher in patients with a higher peritonitis rate (p = 0.001). Fifty-three
patients (79.1%) were transplanted.
All potential risk factors for the peritonitis indices were analyzed. No correlation
was found between age and peritonitis incidence (Spearman’s correlation coefﬁ-
cient -0.009, p = 0.94) or age and peritonitis free period (Spearman’s correlation
coefﬁcient 0.14, p = 0.42). The analysis of all dichotomous risk factors is shown
in tables 7.2 and 7.3. With good housing peritonitis incidence was signiﬁcantly
lower (p = 0.03) and peritonitis free period was longer, with near signiﬁcance (p
= 0.052), compared to fair and poor housing. When all types of housing were
tested separately with the Kruskal-Wallis test, small numbers of patients were
present in each subgroup and these results did not reach signiﬁcance (data not
shown). When good socio-economic circumstances were compared to fair and
poor socio-economic circumstances peritonitis rate was signiﬁcantly lower (p =
0.02) and time to ﬁrst peritonitis was longer (p = 0.01). These results remained
statistically signiﬁcant when all 3 socio-economic categories were tested sep-
arately with the Kruskal-Wallis test, despite of relatively small numbers in each
subgroup with p-values of 0.006 and 0.03 for peritonitis incidence and time to ﬁrst
peritonitis respectively (table 7.4). The statistically signiﬁcant risk factors hous-
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ing and socio-economic circumstances were positively correlated but collinearity
was sufﬁciently low (variance inﬂation factor 1.28, tolerance 0.78), so the degree
of correlation was not considered a bias factor in the analysis. Peritonitis free pa-
tients had signiﬁcantly better housing and social circumstances compared to the
patients with the highest rate of peritonitis. The cumulative hazard for developing
a ﬁrst peritonitis was evaluated for 53 patients (excluding the patients in whom
the exact time of the 1st peritonitis episode was unknown). Patients with good
socio-economic circumstances had a signiﬁcantly lower cumulative hazard com-
pared to patients with fair and poor socio-economic circumstances with a p-value
of 0.003 (ﬁgure 7.3). Patients with good housing also had a lower cumulative haz-
ard for developing a ﬁrst peritonitis compared to fair and poor housing (p = 0.001)
(ﬁgure 7.4). For the combined risk factors housing and socio-economic circum-
stances the same trend was seen, but even more pronounced, with a p-value of
<0.0001 (ﬁgure 7.5).
Table 7.2: Mann Whitney U test for potential risk factors
Potential risk factors Peritonitis rate: Peritonitis free period: time to
peritonitis/patient-year ﬁrst peritonitis episode (months)
Median Range p Median Range p
Distance to PD centre
>200 km
2.81 0-21.2 0.39 2.7 0.33-21.5 0.15
Distance to PD centre
<200 km
2.49 0-9.2 1.8 0-8.9
Type of PD: NIPD 2.83 0-17.6 0.75 2.2 0.07-21.5 0.18
Type of PD: CAPD 1.99 0-7.45 1.8 0-5.73
Catheter placement
laparoscopic
2.94 0-21.2 0.36 2.2 0-8.9 0.73
Catheter placement open 2.69 0-9.20 1.8 0.87-2.8
Weight good 2.02 0-17.6 0.47 1.8 0.43-2.83 0.21
Weight fair/poor 2.86 0-21.2 2.2 0-21.5
Height good 2.56 0-17.6 0.51 1.23 0.43-2.83 0.6
Height fair/poor 2.76 0-21.2 2.03 0-21.5
Housing good 2.21 0-7.56 0.03 2.52 0.37-21.5 0.05
Housing fair/poor/
institutional
3.86 0-21.2 1.37 0-8.87
Socio-economic
circumstances good
1.91 0-17.6 0.02 2.83 0.43-21.5 0.01
Socio-economic
circumstances fair/poor
3.88 0-21.2 1.35 0-8.87
Race black/mixed 2.81 0-21.2 0.27 1.8 0.1-8.87 0.09
Race white 1.13 0-5.71 6.97 2.83-21.47
Gastrostomy tube no 2.69 0-21.2 0.45 2.07 0-21.47 0.97
Gastrostomy tube yes 4.46 2-5.71 1.8 0.5-6.97
PD = peritoneal dialysis
NIPD = Nightly Intermittent Peritoneal Dialysis
CAPD = Continuous Ambulatory Peritoneal Dialysis
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Table 7.3: Chi square test for potential risk factors: peritonitis free patients versus all
patients with peritonitis and peritonitis free patients versus patients with the highest rate
of peritonitis
Risk factors Peritonitis Yes Peritonites High rate
vs. No peritonitis vs. No peritonitis
Yes No p High rate No p
Distance to PD centre
>200 km
28 9 0.42 12 9 0.10
Distance to PD centre
<200 km
20 10 4 10
Type of PD: NIPD 32 9 0.18 11 9 0.14
Type of PD: CAPD 13 8 3 8
Catheter placement
laparoscopic
18 6 0.57 7 6 0.67
Catheter placement open 10 5 4 5
Weight good 11 8 0.12 5 8 0.51
Weight fair/poor 37 11 11 11
Height good 9 7 0.12 4 7 0.45
Height fair/poor 39 12 12 12
Housing good 24 14 0.08 5 14 0.01
Housing
fair/poor/institutional
24 4 11 4
Socio-economic
circumstances good
21 13 0.07 5 13 0.03
Socio-economic
circumstances fair/poor
27 6 11 6
Race black/mixed 45 16 0.51 11 16 0.8
Race white 3 2 1 2
Gastrostomy no 43 18 0.67 14 18 0.45
Gastrostomy yes 5 1 2 1
PD = peritoneal dialysis
NIPD = Nightly Intermittent Peritoneal Dialysis
CAPD = Continuous Ambulatory Peritoneal Dialysis
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Table 7.4: Kruskal-Wallis test for socio-economic circumstances
Socio-economic Peritonitis rate: Peritonites-free period:
circumstances peritonitis/patient-year time to ﬁrst peritonitis episode
Median
(number
of
patients)
Range p Median
(number
of
patients)
Range p
Socio-economic
circumstances good
1.91 (34) 0-17.6 0.006 2.83 (14) 0.43-21.5 0.03
Socio-economic
circumstances fair
2.94 (22) 0-9.20 1.80 (11) 0.10-8.87
Socio-economic
circumstances poor
4.86 (11) 1.99-
21.2
0.87 (9) 0.10-2.77
Figure 7.3: Kaplan Meier hazard model for socio-economic circumstances
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Figure 7.4: Kaplan Meier hazard model for housing
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Figure 7.5: Kaplan Meier hazard model for socio-economic circumstances and housing
combined
Discussion
In this study an overview of PD and peritonitis in pediatric patients in Cape Town,
South Africa is given, the epidemiology of peritonitis is evaluated and risk factors
are identiﬁed.
Socio-economic circumstances and quality of housing signiﬁcantly inﬂuenced the
peritonitis rate and socio-economic circumstances also signiﬁcantly inﬂuenced
time to ﬁrst peritonitis in our patients. When both socio-economic circumstances
and housing were fair or poor the cumulative risk to develop a peritonitis was even
more elevated than for the separate categories alone. The higher risk group for
housing includes the subgroup ’institutional housing’. The poor results in this
group were most likely due suboptimal PD care due to nursing staff shortages,
especially in the clinical care centre. Children were not well supervised or su-
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pervised by unexperienced staff. Children only go to this clinical care centre
when the situation at home is considered too unfavourable to perform dialysis,
so this may reﬂect a pre-selection bias in this subgroup. Socio-economic risk fac-
tors have been investigated in only a few adult PD studies3,11. In a South-African
study by Zent et al.11 poor socio-economic status (SES) and inadequate housing
(high occupants-to-bedroom ratio, no electricity), alcohol abuse and psychiatric
disease were found to be associated with higher peritonitis rates. Black race
was also associated with higher peritonitis rates in the study by Zent, but this
reﬂected merely the poorer socio-economic conditions of this population group.
In our study the large majority of our patients were black or black mixed with
other races, and no inﬂuence of race on peritonitis rate was found. In another
South-African study by Katz et al.3 a relationship between socio-economic pa-
rameters and peritonitis rate was not conﬁrmed: education, employment status,
home conditions, and earnings did not inﬂuence peritonitis and technique failure
in this study. Two pediatric studies looked at socio-economic risk factors in PD.
The study by Grunberg et al.12, performed in Uruguay, showed no differences
in patient and technique survival for SES. Ariza et al.13 did report a higher peri-
tonitis rate for Venezuelan pediatric patients with lower SES. Socio-economic
circumstances can be assessed in many ways, and it is a challenge to obtain an
objective, adequate mode of measurement, without losing clarity because of too
many details, but neither losing important information by ﬁtting data into a sim-
pliﬁed model. The above mentioned studies all used an equivalent of the same
criteria that were used in the present study, with classiﬁcations based on edu-
cation/employment, housing, social support and family income. Grunberg et al.
and Ariza et al. used a modiﬁcation of an old scoring system, called the ’Graffar’
score14, which divides SES into categories, based on parents’ education, par-
ents’ educational level and family source of income. A possible ﬂaw in our study
is the absence of a criterion on family income, but inadequate data were avail-
able to include this in our classiﬁcation of socio-economic circumstances.
For the other potential risk factors that were analyzed in this study we did not ﬁnd
a statistical relationship with peritonitis outcome indices. Distance to PD centre
did not inﬂuence peritonitis rates in our study, neither did it in the study of Grun-
berg et al12. Younger age has been identiﬁed as a possible risk factor for adults
as well as children11,15–17, but this association was not found in the present study.
In our patients no relationship between catheter insertion technique or type of PD
was found with peritonitis outcome. In a large systematic review of randomized
controlled trials by Strippoli et al18 statistically signiﬁcant differences in peritonitis
rates with catheter type or catheter insertion technique were not found either.
A possible bias in the epidemiology of our PD population is the fact that only pa-
tients eligible for transplantation are included in the dialysis program, inﬂuencing
particularly the time on PD, that is relatively short in the present study, with a high
transplantation rate.
Peritonitis rates in general were high in our patient group compared to other pedi-
atric studies with 2.8 episodes/patient year. This is especially true if compared to
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studies from developed countries like Japan, with 0.29 episodes/patient year19,
the United States of America with 0.19 to 0.91 episodes/patient year16,20 and
Europe with 0.71 to 1.1 episodes/patient year7,15,17. Compared to studies from
South America with 1.3 to 2.1 episodes/patient year12,13 peritonitis rates are also
still relatively high in the present study. Worse socio-economic circumstances in
developing countries with poor hygiene form a clear explanation for these differ-
ences. Cultural factors also probably play a role when comparing one region to
another. The pattern of causative organisms in other studies comprised 44-64%
gram-positive infections, 14-25% of gram-negative infections, 2-7% fungal infec-
tions and 14-31% of cultures remaining negative7,16,19,21. These percentages are
rather comparable to those in the present study. The rather low percentage of
gram-positive infections however is probably an underestimation due to the rela-
tive high percentage of culture negative peritonitis episodes and the percentage
of unknown cultures (10%).
The percentage of peritonitis episodes due to unknown organisms in addition to
the culture negative peritonitis episodes is 39%. This means the percentage of
peritonitis episodes on which no speciﬁc information about a causative organism
was available is particularly high in this study. The fact that in all these cases
only empiric treatment was given may help to explain the high overall peritonitis
rate and the high incidence of fungal peritonitis. Another explanation for the high
percentage of fungal peritonitis is the overall high peritonitis rate and the relative
high rate of gram-negative infections, that are both considered to be a risk factor
for fungal peritonitis7,8.
One patient in this study was diagnosed with peritonitis caused by mycobac-
terium tuberculosis. Mycobacterium infections rates are increasing worldwide
and dialysis patients are at higher risk of acquiring mycobacterial infections, due
to impaired cellular immunity with chronic renal failure22. Only 2 cases of tuber-
culous peritonitis in children on PD have been reported before23. Since tubercu-
lous peritonitis is difﬁcult to diagnose the actual rates could very well be higher
than reported. More extensive evaluation of culture negative peritonitis and peri-
tonitis resistant to antibiotic treatment could reveal more cases.
In conclusion PD is an important modality for renal replacement therapy, es-
pecially in developing countries, with recent growing rates of PD. Poor socio-
economic circumstances play an important role in these societies and inﬂuence
the peritonitis rate and the success rate of PD. More intensive social counseling
and education can hopefully decrease infection rates and rates of PD failure in
this respect, but improvement of general socio-economic circumstances will be
the factor with the greatest inﬂuence on PD success.
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Abstract
Intestinal perforation is an unusual but serious complication of peritoneal dia-
lysis. Pediatric cases are incidentally described. The etiology in pediatric pa-
tients varies from adults. We present a total of 3 cases of intestinal perforation in
128 children since 1980. The ﬁrst patient suffered from a perforation most likely
due to (delayed) catheter perforation. Perforation was due to hypotension with
bowel infarction in the second patient. The third patient had a perforation most
likely due to necrotizing enterocolitis as a complication of the hemolytic uremic
syndrome. The difﬁculties in diagnosis in these cases are discussed. Often there
are no obvious radiological or clinical signs of perforation. Intestinal perforation
in peritoneal dialysis patients should be suspected in polymicrobial peritonitis
without improvement on antibiotics.
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Introduction
Intestinal perforation is an unusual but very severe complication of peritoneal
dialysis (PD). In adults on PD the incidence ranges from 1% to 10%, with most
reported incidences between 3-3.5%1–3. Mortality is high, up to 46%3. The most
important causes of intestinal perforation in adults are diverticulitis or perforation
by catheter insertion. Pediatric cases are incidentally described, with one or two
cases per study. Reported incidences are up to 3.2%4–6. We present a total of 3
cases of intestinal perforation in 128 children on PD in Nijmegen, the Netherlands
since 1980 (3.1%), the largest pediatric survey as far as we know. The speciﬁc
etiology of perforation in pediatric patients and the diagnostic challenges are
discussed.
Patients
A diagnostic and clinical summary of the patient cases is given in table 8.1.
Case 1 A 6 years old boy was on nightly intermittent peritoneal dialysis (NIPD)
for more than two years because of end-stage renal disease due to renal dys-
plasia. He had a laparotomic replacement of his PD catheter because of a
persistent purulent catheter tunnel infection with Staphylococcus aureus. Three
months later he presented with a fulminant peritonitis, characterized by fever, dif-
fuse abdominal pain, vomiting and cloudy dialysate with a yellow-green colour.
The chest X-ray showed a small amount of free air below the diaphragm. White
cell count in the dialysate was far above 100/mm3. Multiple gram-positive and
gram negative organisms were cultured from the dialysate: Enterobacter cloa-
cae, Pneumococci, Streptococci, Staphylococci, gram-negative rods and non-
fermenting bacteria. Intraperitoneal antimicrobial treatment did not lead to clini-
cal improvement and eight days after presentation a laparotomy was performed.
This revealed multiple adhesions and a large perforation in the small intestine,
where the PD catheter penetrated the intestine. The patient died shortly after
operation. Perforation was most likely due to delayed catheter perforation.
Case 2 A 6 days old boy presented with renal failure due to bilateral renal dys-
plasia with prune belly syndrome. At the age of two months he started continu-
ous cycling peritoneal dialysis (CCPD) because of end-stage renal failure. Two
weeks after starting with CCPD the patient developed unexplained severe hy-
potension with bradycardia, requiring repeated intravenous volume supplemen-
tation. Two weeks later he developed peritonitis with septic shock. Antibiotic
therapy was started, ﬁrst intraperitoneally, later intravenously. White cell count
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was 700/mm3. Enterobacter cloaca and Enterococcus faecium were isolated
from the dialysate. PD had to be discontinued due to ultraﬁltration failure, based
on poor clearance and ﬂuid retention, without signs of catheter malfunction. The
patient had to be switched to hemodialysis. Ten days after the development of
the peritonitis a pneumoperitoneum developed. Laparotomy was performed, re-
vealing multiple perforations of colon, ileum and duodenum. The patient died
shortly after the operation due to severe diffuse intestinal bleeding. Hypotension
with bowel infarction probably led to fatal multiple intestinal perforations in this
patient. This patient has been reported brieﬂy by our group previously7.
Case 3 An almost 3 years old girl presented with severe bloody diarrhea, vomit-
ing and abdominal pain. Laboratory analysis revealed acute renal failure, trom-
bocytopenia and hemolytic anemia. She was diagnosed with the typical form
of hemolytic uremic syndrome (HUS) complicated by necrotizing enterocolitis
and started with CCPD. She had two revisions of her catheter due to malfunc-
tion. Two weeks later Streptococcus faecalis and anaerobic micro-organisms
were cultured from the dialysate. White cell count in the dialysate was more
than 100/mm3. She was treated with ceftazidime and vancomycin intraperi-
toneally. Four days later she underwent a replacement of her PD catheter. Fecal
intra-abdominal contamination was found, with a covered perforation of the sig-
moid and 3 necrotic spots in the wall of the colon. The patient was switched
to hemodialysis and gradually recovered with antimicrobial therapy. The most
plausible cause of perforation was necrotizing enterocolitis in HUS.
Discussion
Intestinal perforation is a rare but very dangerous complication of PD. In adults
more than 50% of perforations are caused by diverticulitis3. The causes of per-
foration in the previously described pediatric cases were catheter insertion and
catheter-decubitus4–6. In the present study the causes varied. The ﬁrst patient
most likely had a delayed catheter perforation. In this boy the catheter could have
perforated by decubitus, or at the time of insertion, with delayed symptoms. The
second patient had a bowel infarction due to unexplained hypotension. In the
third patient the perforation was caused by the underlying cause of renal failure,
HUS. The incidence of colonic perforation in HUS patients is 1-2%, with most
perforations occurring 2 weeks after clinical presentation of HUS8. Diagnosis
of bowel perforation may be difﬁcult, because clinical signs are often not clear.
PD itself can mask clinical symptoms of perforation. Further, radiological signs of
free air are more difﬁcult to interpret because of the occurrence in uncomplicated
PD as well9. The meaning of the amount of free air remains controversial. De-
layed appearance of free air has also been described9. In neither of our patients
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large amounts of free air were present initially, but in one patient it developed
later in the course of disease.
The cultured organisms give important information about a possible intestinal
perforation as a cause for the peritonitis. Multiple organisms, anaerobic orga-
nisms and enteric organisms should all raise suspicion of perforation, although
multiple organisms occur in less than 10% of non-perforated peritonitis as well2.
In our total population 13 polymicrobial peritonitis episodes out of a total of 241
peritonitis episodes were identiﬁed (5.4%). In 10 of these patients gram-negative
organisms were found, in one patient an enteric organism and in one patient an
anaerobic organism. None of these patients had clinical symptoms of perfora-
tion or sepsis and all patients had an immediate adequate response to antibiotic
treatment. Our patients with intestinal perforation all had multiple organisms, all
patients had enteric organisms, in 2 out of 3 patients gram-negative organisms
were found and anaerobic organisms were present in 1 patient. Thus polymi-
crobial peritonitis is a risk factor, especially with enteric organisms in patients
without clinical improvement on antibiotic treatment. Because of the difﬁculties
in diagnosis, surgery is often delayed, as was the case in patient 1 and patient
3. Retrospectively, earlier surgery should have been performed, as soon as the
culture results were known. Bowel perforation in our patients on PD resulted in
a high mortality and failure of PD in the surviving patient. To prevent this high
morbidity and mortality, early surgery should be considered in any case of peri-
tonitis with suspicious culture in children on PD without clinical improvement on
antibiotics.
Bowel perforation in pediatric PD patients is rare, but associated with a high mor-
tality. Diagnosis is often difﬁcult, without obvious radiological or clinical signs of
perforation. It should be suspected in polymicrobial peritonitis without improve-
ment on antibiotics.
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Abstract
Introduction
Hyperphosphatemia leads to metastatic calciﬁcations and an increased risk of
cardiovascular complications. Sevelamer is an effective phosphate-binder. For
children important practical disadvantages exist: sevelamer clogs all enteral feed-
ing tubes and can cause gastro-intestinal complaints. Pre-treatment of dairy
products to reduce their phosphate content could solve these problems.
Methods
Sevelamer hydrochloride and sevelamer carbonate were suspended in differ-
ent dairy products. Cow’s milk, breastmilk, baby formula and tube feeding for-
mula were tested with different concentrations of sevelamer. After suspension
the samples were stored for 10 minutes to allow for sevelamer to precipitate.
The supernatant was collected and analyzed. Phosphate, calcium, magnesium,
potassium, sodium, chloride and pH were determined.
Results
A signiﬁcant decrease in phosphate content in all dairy products was observed.
With sevelamer hydrochloride phosphate reduction was 48% to 91% for differ-
ent products. With sevelamer carbonate phosphate reduction was 22% to 87%.
The highest effectiveness was found in breastmilk. A pH increase was found
in all products. With sevelamer hydrochloride a signiﬁcant increase in chloride
occurred. Calcium decreased especially in breastmilk.
Conclusions
Sevelamer hydrochloride and sevelamer carbonate can be added to different
dairy products to effectively lower the phosphate content, to avoid troublesome
ingestion of sevelamer in children. The change in pH for sevelamer hydrochloride
is remarkable, reﬂecting buffering mechanisms. The calcium decrease found with
breastmilk has to be taken into consideration.
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Introduction
Patients with renal failure have a disturbed bone metabolism. Phosphate reten-
tion, decreased synthesis of calcitriol and loss of calcium occur with declining
renal function. Fibroblast growth factor-23 and later parathyroid hormone (PTH)
levels increase as an initial adaptive response to maintain adequate calcium and
phosphate levels, but after the glomerular ﬁltration rate declines to stage 3-4 (60-
30 ml/minute/1.73m2), hyperphosphatemia starts to occur1,2. With hyperphos-
phatemia further progression of hyperPTH occurs and often with treatment of
hyperphosphatemia hypercalcemia develops as well. Hyperphosphatemia and
an elevated calcium × phosphate product both predispose to metastatic cal-
ciﬁcations and directly correlate with mortality risk in adults3. In children with
chronic kidney disease increased phosphate and an increased calcium × phos-
phate product correlate with arterial stiffness and increased intima-media thick-
ness of the carotid artery respectively4. To treat hyperphosphatemia oral phos-
phate binders are practically always necessary, next to a dietary phosphate re-
striction and eventually dialysis.
A number of different phosphate binders have been used so far. The early used
aluminium containing phosphate binders have been abandoned because of as-
sociations with toxic accumulation in the body5,6. With lanthanum containing
phosphate binders deposition leading to toxicity has been shown in animal stud-
ies as well7,8. Although the intestinal absorption of lanthanum is very low in
healthy volunteers9, safety in pediatric patients remains unclear and further stud-
ies are warranted. The frequently used calcium salts have the disadvantage of
causing hypercalcemia as well, associated with vascular alterations and calciﬁ-
cation10,11. A novel, promising iron-based phosphate binder has been introduced
recently, called SBR759, but studies are still in the preliminary phase12.
Sevelamer is a polymeric ion-exchange phosphate binder, available as seve-
lamer hydrochloride and recently has become available as sevelamer ’carbonate’
as well. Wrong and Harland correctly pointed out that sevelamer ’carbonate’ is
not the correct name, for the resin will only exist as a mix of the free amine and
bicarbonate forms, as the carbonate form is too unstable, except in very alkaline
conditions13. For uniformity the name ’sevelamer carbonate’ will still be used in
this study. Sevelamer carbonate showed an equivalent phosphate control and
lowering of calcium × phosphate product compared to sevelamer hydrochloride.
With sevelamer carbonate a signiﬁcant rise in bicarbonate levels was seen as
well, while with sevelamer hydrochloride equal or decreased bicarbonate levels
were found14–18.
In pediatric patients, in majority treated with peritoneal dialysis, important disad-
vantages of sevelamer use exist: both sevelamer hydrochloride and sevelamer
carbonate cause clogging of feeding tubes due to the hydrogel that is formed
with ﬂuids. Gastro-intestinal complaints have been described after oral adminis-
tration as well19. If sevelamer would be added to phosphate rich soluble foods
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like tube-feeding formula, baby-formula or milk, and then decanted, these prob-
lems would be solved. One study has been published before, in which sevelamer
hydrochloride was successfully added to breastmilk20.
We conducted this study to evaluate the effect of both sevelamer hydrochloride
and sevelamer carbonate on different formulas and breastmilk. To be able to
use this technique in patients it is necessary to know what the magnitude of the
effect on the phosphate level is and to understand what occurs in the chemical
interaction with sevelamer and what the effect on other minerals is.
Methods
Sevelamer hydrochloride and sevelamer carbonate were suspended with sev-
eral dairy products: semi-skimmed cow’s milk, standard baby formula (Nutrilon R©,
Nutricia, The Netherlands), standard tube feeding formula (Frebini R©, Fresenius,
United Kingdom) (for speciﬁcations of the formulae see table 9.1 ) and breast-
milk.
Table 9.1: Average values of baseline constituents in baby formula and tube feeding
formula
Nutrilon 1 R©* Frebini R©*
Phosphate (mmol/l) 7.7 16.1
Calcium (mmol/l) 11.2 15.0
Chloride (mmol/l) 12.1 28.0
pH Not described Not described
*Values are averages given by the manufacturer and may vary with the source
of protein
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(a) Semi-skimmed cows milk (50 ml) with 800 mg sevelamer hydrochloride versus
800 mg sevelamer carbonate: mean % change in phosphate, calcium, chloride and
pH (n=3)
(b) Breastmilk (50 ml) with 800 mg sevelamer hydrochloride versus 800 mg seve-
lamer carbonate: mean % change in phosphate, calcium, chloride and pH (n=3)
Figure 9.1: a-b. Proportional mean results of treatment with sevelamer hydrochloride
(Renagel R©) versus sevelamer carbonate (Renvela R©)
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Sevelamer
For sevelamer hydrochloride (Renagel R©, Genzyme Europe) 800 mg tablets were
used. These are oval, ﬁlm coated, compressed tablets containing 800 mg of
sevelamer hydrochloride on an anhydrous basis. Sevelamer hydrochloride is a
poly-allylamine hydrochloride, a polymeric phosphate binder, developed for oral
administration. The poly-allylamine hydrochloride is crosslinked with epichloro-
hydrine. De chemical structure is poly(allylamine-co-N,N’-diallyl-1,3-diamino-2-
hydroxypropane) hydrochloride. Sevelamer hydrochloride is hydrophilic but not
soluble in water. It binds phosphate by a combination of anionic and hydrogen
binding18.
For sevelamer bicarbonate (Renvela R©, Genzyme Europe) either 800 mg tablets
were used, or Renvela R© powder. Tablets are oval, ﬁlm coated tablets contain-
ing 800 mg of sevelamer carbonate on an anhydrous basis. Sevelamer car-
bonate, poly(allylamine-co-N,N’-diallyl-1,3-diamino-2-hydroxypropane)2 carbon-
ate has the same polymeric structure as sevelamer hydrochloride in which car-
bonate replaces chloride as the counter-ion. The powder form contains 2400 mg
sevelamer carbonate per sachet on an anhydrous basis21.
General procedure
Tablets or powder were added to samples of the dairy products and stirred or
shaken until they were visibly suspended. (In our experiments it took 5-10 min-
utes for whole tablets to dissolve completely. When tablets were cut into halves
or suspended in 10 ml of hot water they dissolved within 1-3 minutes). After that
suspensions were stored for 10 minutes to allow for sevelamer to precipitate with
phosphate (ﬁgure 9.1). Previous time experiments of sevelamer hydrochloride
with breastmilk by Ferrara et al.20 showed that within 5 to 10 minutes maximum
phosphate decrease occurred and the sevelamer hydrogel was settled maximally
to the bottom of the cup. The supernatant was collected and analyzed. Phos-
phate, total calcium, magnesium, potassium, sodium, chloride and pH in dairy
products were determined before and after treatment with sevelamer. Exper-
iments were performed in every dosage for all different formulae and for both
types of sevelamer. All experiments were repeated at least 3 times for all 50 ml
dosages and at least 2 times for the other dosages (only for sevelamer carbonate
the highest dose of 400 ml was not tested).
Measurement methods
All samples were centrifuged for 10 minutes at 14.000 rpm before measure-
ments because of technical reasons (Mikro 24-48R, Hettich R©, Tuttlingen, Ger-
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many). (For home use samples can just be decanted). Phosphate, total cal-
cium and magnesium were measured by spectrophotometric method with the
Aeroset R© chemical analyzer (Abbott R© Laboratories, USA). Sodium, potassium
and chloride were measured by potentiometric method with the Aeroset R© chem-
ical analyzer (Abbott R© Laboratories, USA). pH was measured by a glass elec-
trode containing a constant buffer (PHM220, Radiometer R©, Copenhagen, Den-
mark).
Speciﬁc experiments
1.) First, experiments with sevelamer hydrochloride were performed using in-
creasing dosage in all dairy products mentioned above, to obtain a dose re-
sponse curve and to compare the different dairy products. Subsequently these
measurements were performed with sevelamer carbonate and compared with
sevelamer hydrochloride.
2.) Secondly, measurements with sevelamer hydrochloride were performed by
different temperatures: after refrigerating (4◦C) , at room temperature (20◦C)
and at near boiling point (80-90◦C). Because no effect on temperature was seen,
these experiments were not repeated with sevelamer carbonate.
3.) Because of an observed time-dependent effect on pH of treated samples,
pH was measured in time from 0 to 120 minutes after treatment with sevelamer
hydrochloride and sevelamer carbonate.
Data analysis
Results were given as mean proportional values, to be able to compare differ-
ent dairy products. For each dairy product absolute values of one represen-
tative sample were given as well. Independent t-tests were used to compare
different dairy products and to compare sevelamer hydrochloride with sevelamer
carbonate. Paired t-tests were used to compare samples before and after treat-
ment.
Results
Overview results for all different dairy products
Absolute concentrations and proportional mean changes of phosphate, calcium,
chloride and pH before and after treatment with sevelamer hydrochloride and
sevelamer carbonate are given in table 9.2 and table 9.3 respectively. An overview
of the proportional mean results are shown for breastmilk and semi-skimmed
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cow’s milk in ﬁgure 9.1a-b. For all these experiments 800 mg of sevelamer was
suspended in 50 ml of dairy product. A signiﬁcant phosphate reduction was seen
with both sevelamer hydrochloride as well as sevelamer carbonate for all differ-
ent products, together with a signiﬁcant pH rise. For sevelamer hydrochloride a
signiﬁcant rise in chloride was seen for all dairy products. For breastmilk a high
signiﬁcant reduction in calcium was seen with both sevelamer hydrochloride and
sevelamer carbonate, that was smaller or absent in the other dairy products. No
differences were found in potassium and sodium before and after treatment. For
magnesium a small decrease was observed after treatment, varying from 5% to
25%. No differences were found with different temperatures. All samples were
tasted before and after treatment with sevelamer hydrochloride and sevelemer
carbonate by the same observer. No difference in taste was observed.
Dose-response results
Evident dose-dependency was seen for phosphate, as is shown for cow’s milk
in ﬁgure 9.2a. Comparable curves were seen with baby formula and tube feed-
ing formula (results not shown). Efﬁcacy of sevelamer hydrochloride compared
to sevelamer carbonate was somewhat higher for all concentrations. This was
most pronounced in cow’s milk. With breastmilk initial phosphate concentration
was signiﬁcantly lower than with other products. Both sevelamer hydrochloride
and sevelamer carbonate showed more efﬁcacy with the lower doses in breast
milk compared to the other dairy products, probably because of the lower ini-
tial phosphate concentrations with more abundancy of sevelamer (ﬁgure 9.3a).
The dose response effect for calcium, chloride and pH is shown in ﬁgures 9.2b-d
(cow’s milk) and 9.3b-d (breastmilk).
Differences between sevelamer hydrochloride and sevelamer carbonate
The largest difference is the evident rise in chloride for all dairy products with
sevelamer hydrochloride, while no change in chloride occurred with sevelamer
carbonate. The decrease in phosphate was signiﬁcantly less with sevelamer
carbonate for cow’s milk and tube feeding formula. For breastmilk and baby
formula the same trend was seen, but these differences were not statistically
signiﬁcant.
Differences between dairy products
Breastmilk and baby formula had a signiﬁcantly better result on phosphate de-
crease than cow’s milk and tube feeding formula. With breastmilk also a much
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larger decrease in calcium was observed compared to the other dairy products.
Another difference between breastmilk and the other dairy products was the rise
in pH, that was signiﬁcantly less with breastmilk, especially with sevelamer hy-
drochloride. A remarkable observation with the rise in pH was that with time the
pH of breastmilk decreased again, for sevelamer hydrochloride even almost to
the value of pre-treatment. Such time-dependency was not shown for any of the
other dairy products, their pH remained stable in time after treatment with either
sevelamer hydrochloride and sevelamer carbonate (results not shown).
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(a) Phosphate decrease (mmol/l) in semi-skimmed cow’s milk after treatment with seve-
lamer hydrochloride and sevelamer carbonate, dose-response course of two representa-
tive samples
(b) Calcium decrease (mmol/l) in semi-skimmed cow’s milk after treatment with seve-
lamer hydrochloride and sevelamer carbonate, dose-response course of two represen-
tative samples
Figure 9.2: a-b (continued on next page)
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(c) Chloride change (mmol/l) in semi-skimmed cow’s milk after treatment with sevelamer
hydrochloride and sevelamer carbonate, dose response course of two representative sam-
ples
(d) pH increase in semi-skimmed cow’s milk after treatment with sevelamer hydrochloride
and sevelamer carbonate, dose-response course of two representative samples
Figure 9.2: c-d. Dose-response course of phosphate, calcium, chloride and pH in semi-
skimmed cow’s milk after treatment with sevelamer hydrochloride (Renagel R©) and seve-
lamer carbonate (Renvela R©) ).
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(e) Phosphate decrease (mmol/l) in breastmilk after treatment with sevelamer hydrochlo-
ride and sevelamer carbonate, dose-response course of two representative samples
(f) Calcium decrease (mmol/l) in breastmilk after treatment with sevelamer hydrochloride
and sevelamer carbonate, dose-response course of two representative samples
Figure 9.3: a-b. (continued on next page)
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(g) Chloride change (mmol/l) in breastmilk after treatment with sevelamer hydrochloride
and sevelamer carbonate, dose response course of two representative samples
(h) pH increase in breastmilk after treatment with sevelamer hydrochloride and sevelamer
carbonate, dose-response course of two representative samples
Figure 9.3: c-d. Dose-response course of phosphate, calcium, chloride and pH in breast-
milk after treatment with sevelamer hydrochloride (Renagel R©) and sevelamer carbonate
(Renvela R©).
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Discussion
In this study we treated semi-skimmed cow’s milk, breastmilk, baby formula and
tube feeding formula with sevelamer hydrochloride and sevelamer carbonate to
investigate if phosphate would be reduced effectively, and to investigate the pos-
sible effect on other minerals and pH. With the highest dose of sevelamer hy-
drochloride we found a mean reduction in phosphate of 48% to 91% for the dif-
ferent dairy products, and with the highest dose of sevelamer carbonate we found
a mean reduction in phosphate of 22% to 87% for the different dairy products.
The most important other effects were a distinct rise in chloride with sevelamer
hydrochloride and a rise in pH with both sevelamer hydrochloride and sevelamer
carbonate. The calcium content declined in all samples, with the largest decline
found in breastmilk.
For sevelamer carbonate the pH rise was expected and can be explained by
the bicarbonate ions being exchanged. For sevelamer hydrochloride however
we surprisingly found a signiﬁcant increase in pH as well, together with a rise
in chloride. From previous studies in patients an acidosis could be expected
with sevelamer hydrochloride17,18,22. Sevelamer hydrochloride is a quaternary
amine anion exchange resin with a non-absorbed polymer chain with covalently
linked aminogroups. Approximately 40% of these groups consist of amine hy-
drochloride. Hydrochloride molecules from sevelamer are exchanged in the hu-
man gastro-intestinal tract with monovalent phosphate, bicarbonate and bilesalts
according to Brezina et al.23. According to Wrong et al.24 acidosis could also
develop because of the exchange of chloride with short chain fatty acid anions
present in the gastro-intestinal tract. These proposed mechanisms would mean
an increase in chloride and development of metabolic acidosis. In our study we
can explain the increase in chloride ions with the above mentioned mechanisms;
we assume that the exchange occurs with mostly divalent phosphate anions in
the pH range of milk25. Further, chloride could also exchange with other anions,
explaining the observed rise in chloride.
The in vitro pH increase of the decanted milk must be caused by a release of
base or binding/loss of acid in the reaction of dairy products with sevelamer hy-
drochloride during the precipitation. A suspension of sevelamer hydrochloride in
distilled water did not change the pH of the distilled water, so the pH rise has to
be explained by the interaction of sevalamer with substances in milk. An alkaline
load was likely to be released due to the molecular interaction of the proteins
in milk, especially caseins. The casein content of cow’s milk represents 80% of
the milk proteins. Most of the casein proteins exist in a colloidal particle known
as the casein micelle. Calcium and phosphate are present as Ca3[PO4]2. The
exchange of chloride with phosphate occurs mainly with the divalent phosphate
anion H2PO−4 as described above. This means that during the precipitation of
sevelamer with phosphate in skimmed cow’s milk at pH 6.7 about 20 mEq H+
ions will be bound by the interaction of sevelamer hydrochloride. In addition the
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interaction with proteins can alter their spatial structure and consequently affect
proton exchange. In the decanted milk base release has to occur resulting in the
formation of bicarbonate and the slow formation of CO2.
Pretreatment of formulae or breastmilk has been performed before, to reduce
dietary intake of phosphate or potassium, to avoid the practical disadvantages or
potential side-effects of taking the medication. For potassium Bunchman et al.26
found that sodium polystyrene sulfonate effectively reduced potassium content
in several formulae. However, sodium increased disproportionally, while calcium
and magnesium decreased. Schrder et al.27 pre-treated four different fomulae
with calcium polystyrene sulphonate to reduce the potassium content. They ef-
fectively reduced the potassium content with 50%, without an important increase
of sodium, as was reported by Bunchman et al. with sodium polystyrene sul-
fonate. For phosphate reduction calcium acetate has been used to pre-treat milk
for reduction of phosphate content28 but no effect on phosphate was seen, while
the calcium content in the formula increased up to threefold. The formula also
developed an unpleasant sour taste with the addition of increasing amounts of
calcium acetate. It is likely that the phosphate contained in the casein micelles
in milk cannot be reached by calcium acetate, but only by the interaction with
sevelamer.
The only study with sevelamer to reduce the phosphate content has been per-
formed by Ferrara et al.20, who used breastmilk and added sevelamer hydrochlo-
ride. In this study an effectively reduced phosphate content of 80% was found
when 806 mg of sevelamer was added to 180 ml of breastmilk, which is com-
parable with the results in the present study. Ferrara et al. found no change in
pH, unlike the pH rise in the present study. The explanation lies in the fact that
in breastmilk the pH declines again in time to almost the original value. Ferrara
measured the pH after one hour, and used a rather low dose of sevelamer hy-
drochloride, so the initial pH rise was less high to start with. The reason that the
pH declines again in time after the initial pH rise with breastmilk could be due to
the relative small buffering capacity of breastmilk, with a lower casein content. If
bicarbonate continues to escape in small amounts, via CO2, this will affect the
pH of the breastmilk in time because of the small buffering capacity. In the study
by Ferrara et al. chloride was not measured. The reduction in calcium that we
found was observed by Ferrara as well. We showed that this reduction in calcium
is dose-dependent, with a reduction of calcium as high as 75% when 800 mg of
sevelamer hydrochloride or sevelamer carbonate was added to 50 ml of breast-
milk.
A few differences were observed between the different dairy products. The
highest effectivity of sevelamer was seen with breastmilk, with a relative large
decrease in calcium as well and a less pronounced pH rise. This might be
due to the lower total phosphate and calcium content with relative excess of
sevelamer compared to the other dairy products, especially compared to semi-
skimmed cow’s milk and tube feeding formula. Another observed difference was
a somewhat lower effectiveness of sevelamer carbonate compared to sevelamer
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hydrochloride with the dairy products with the highest total phosphate content
(semi-skimmed cow’s milk and tube feeding formula). A difference in effective-
ness between sevelamer carbonate and sevelamer hydrochloride has not been
reported in clinical use in patients. Differences in afﬁnity of sevelamer carbonate
ions in dairy products with less exchange of bicarbonate ions with divalent phos-
phate could play a role.
An important limitation of the study for practical use is the individual variance
in dairy products, which makes it impossible to give exact values of changes in
minerals and pH for every product. Taken this into consideration only the mean
results can be extrapolated to other countries and settings. It could be that pre-
treated dairy products and breastmilk vary in their phosphate content due to dif-
ferent feeding patterns, but these variances are inevitable, and the proportional
decrease in phosphate is expected to be comparable.
In conclusion an effective phosphate reduction was achieved by using both seve-
lamer hydrochloride and sevelamer carbonate as a pretreatment of different dairy
products, with the highest effectivity in breastmilk. A dosage of 800 mg seve-
lamer hydrochloride as well as carbonate is effective for up to 400 ml of breast-
milk (phosphate decrease in all dosages of >85%). Sevelamer hydrochloride is
effective for 100 ml of semi-skimmed cow’s milk / tube feeding formula/ baby for-
mula (phosphate decrease in 100 ml of 42% / 48% / 68%). Sevelamer carbonate
is less effective for semi-skimmed cow’s milk and tube feeding formula (phos-
phate decrease in all dosages of <30%). The observed pH rise is not expected
to be clinically important. The decrease of calcium has to be taken into account
and calcium values should be monitored closely especially in patients receiving
pretreated breastmilk.
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Abstract
Introduction
Darbepoetin is a new, synthetic, erythropoiesis stimulating protein. The aim
of this study was to determine the effectiveness and safety of intraperitoneal
administration of darbepoetin in children with renal anemia on peritoneal dia-
lysis.
Methods
A single-arm, retrospective, two centre study was performed in which children
were treated with intraperitoneal darbepoetin at the end of nightly intermittent
peritoneal dialysis. Controls were children treated with intraperitoneal erythro-
poietin six months before conversion to darbepoetin. Patients were converted
with the conversion factor 200 Units erythropoietin = 1 μg darbepoetin. Patients
who started with darbepoetin, started with 0.45 μg/kg/week.
Results
19 children entered the study. The mean age was 6.8 years. Eight children were
converted from 201 U/kg/week intraperitoneal erythropoietin to 1.0 μg/kg/week
intraperitoneal darbepoetin. They were treated for a median period of 31.5 months.
Median darbepoetin dose over this period was 0.79 μg/kg/week. Mean hemoglobin
concentration in this period was 7.2 mmol/l (115 g/l). All 19 children were treated
with darbepoetin for a median period of 13.4 months. The median dose over this
period was 0.63 μg/kg/week. The mean hemoglobin concentration in this period
was 7.1 mmol/l (114 g/l). The peritonitis incidence during this study was once ev-
ery 25.1 months. Three patients developed hypertension, one patient developed
headache. These complications developed after a rapid increase of hemoglobin
concentration.
Conclusion
Intraperitoneal administration of darbepoetin is effective and safe for children on
peritoneal dialysis.
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Introduction
The treatment of renal anemia with erythropoietin is general clinical practice.
Darbepoetin is a new, synthetic, erythropoiesis stimulating protein. Darbepoetin
contains ﬁve amino acids different from human erythropoietin and is glycosy-
lated to a larger extent. Hereby, darbepoetin has a longer serum half life than
human erythropoietin1,2. This has been conﬁrmed in pediatric patients as well3.
In a number of clinical studies it was proven that darbepoetin is an effective and
safe treatment for anemia in adults4,5. Darbepoetin is generally administered
once weekly. There are reports however, that a monthly gift is adequate for
some patients6. There are few publications on the administration of darbepoetin
in children7,8. In these studies with small patient numbers, an adequate treat-
ment of anemia was accomplished with intravenous darbepoetin once weekly,
for a maximum period of six months. In our units erythropoietin is administered
intraperitoneally in children on nightly intermittent peritoneal dialysis (NIPD). Ery-
thropoietin is administered during the daytime in a small amount of dialysis solu-
tion, which is effective and safe9–11. Administration of darbepoetin once weekly
is easier, less time-consuming, and theoretically safer because disconnections
of the system are less frequent. The present study was performed in order to de-
termine the efﬁciency and safety of intraperitoneal administration of darbepoetin
in children on peritoneal dialysis.
Patients and methods
Eligible were all patients <18 years on stable NIPD, already treated with ery-
thropoietin or starting darbepoetin because of renal anemia. All patients and
their parents gave their informed consent prior to their inclusion. The ethical
committees of both hospitals approved of this study. Children with unstable hy-
pertension, severe liver disease or hyperparathyroidism, treatment for severe,
generalized epilepsy, inﬂammatory/infectious or hematological diseases in the
six months before the start of darbepoetin were excluded. From the children
already treated with erythropoietin, the hemoglobin concentration, dose of ery-
thropoietin, and weight were registered monthly during the preceding six months
before conversion. Patients on erythropoietin were converted using a conver-
sion factor for darbepoetin of 200 Units erythropoietin = 1 μg darbepoetin, which
is based on the administration of an equivalent protein mass. Children start-
ing on darbepoetin started with a dose of 0.45 μg/kg/week. Darbepoetin was
administered once a week at the start of the study. The children treated with
erythropoietin once a week started with a frequency of once every two weeks.
Darbepoetin was administered by the parents at the end of a nightly intermittent
dialysis period. The hemoglobin target range was 6.8 - 8.0 mmol/l (109 - 128
g/L). To reach this hemoglobin concentration either the dose or the frequency
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of administration was adjusted once a month, if necessary. During the study
hemoglobin concentration, darbepoetin dose and weight were collected monthly.
Iron stores were measured at the beginning and every following third month. A
serum ferritin >100 μmol/l and a transferrin saturation of >20% were considered
adequate, in accordance with the K/DOQI guidelines12. In case of iron deﬁ-
ciency, iron supplements were prescribed. Side effects and complications like
hypertension, headache and peritonitis were recorded.
Table 10.1: Demographic characteristics of the study group
Erythropoietin ip→
Darbepoetin ip
Start darbepoetin ip Total
n=8 n=11 N=19
Gender
Male 6 (75%) 6 (55%) 12 (63%)
Female 2 (25%) 5 (45%) 7 (37%)
Age (years)
Mean 5.9 7.7 6.8
Range 1-15.3 0-17.0 0-17.0
Time on PD before conversion (months)
Mean 21.7 0 9.4
Range 6-55 0 0-55
ip = intraperitoneal, PD = peritoneal dialysis
Results
Nineteen patients enrolled in the study. Eight patients were treated with intraperi-
toneal erythropoietin for at least six months, before conversion to darbepoetin
and 11 patients started directly with darbepoetin. The demographic character-
istics are presented in table 10.1. The mean age was 6.8 years (range 0-17).
Patients were treated with peritoneal dialysis for a median of 9.4 months (range
0-55). Of the eight patients that were converted, seven were treated three times
each week with erythropoietin and one once a week. Patients were converted
from 201 U/kg/week erythropoietin (range 101-345 U/kg/week) to 1.0 μg/kg/week
darbepoetin (range 0.51 - 1.72 μg/kg/week). The median baseline hemoglobin
concentration was 6.9 mmol/l (110 g/L). The course of hemoglobin concentra-
tion is shown in ﬁgure 10.1. In the six months before conversion, when children
were treated with erythropoietin, the mean hemoglobin concentration was 6.8 ±
0.9 mmol/l (109 ± 14 g/L) (SD)). There were no transfusions needed in this pe-
riod. All patients were treated with oral iron preparations. Patients were treated
with intraperitoneal darbepoetin for a median period of 31.5 months. The mean
hemoglobin concentration over this period was 7.2 ± 0.76 mmol/l (115 ± 12
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g/L) The darbepoetin doses are shown in ﬁgure 10.2. Darbepoetin was admin-
istered once a week. After the start of the study the mean dose decreased to
0.59 μg/kg/week after 28 months. The median darbepoetin dose over the whole
period was 0.79 μg/kg/week. The darbepoetin doses of all children treated with
intraperitoneal darbepoetin (converted and directly started) are shown in ﬁgure
10.3. The median dose of 0.63 μg/kg/week was stable during the study. This
dose was adequate for erythropoiesis with a mean hemoglobin concentration
over the study period of 7.1 mmol/l (114 g/L). The median treatment period for
all patients with intraperitoneal darbepoetin was 13.4 months (range 2-40). At
the end of the study 11 patients were still treated with darbepoetin. Six patients
had been transplanted. One patient was converted to hemodialysis during a
peritonitis episode. One patient recovered from renal failure and dialysis was
discontinued. During the study period 15 peritonitis episodes were observed.
The causative micro-organisms were Escherichia Coli, Enterobacter, Staphy-
ococcus Aureus, Corynebacterium2, Streptococcus species5, Candida2, multi-
ple microorganisms, and unknown2. Peritonitis incidence was one episode every
25.1 patient-months (peritonitis rate = 0.04 episodes per patient-month or 0.48
episodes per patient-year). Side effects were rare: one patient complained of
headache one month after start with darbepoetin, when the hemoglobin concen-
tration rose from 5.8 to 7.4 mmol/l (93 to 118 g/L). In the subsequent month the
complaints disappeared after stabilization of the hemoglobin level. Three pa-
tients developed hypertension not related to overhydration or the patients own
kidneys. In two cases hypertension developed one month after starting darbepo-
etin, and in one case after 14 months. In all cases there was a profound rise in
hemoglobin concentration during that period. All cases were easily treated with
antihypertensives.
Discussion
Longstanding experience exists with the treatment of renal anemia with erythro-
poietin. Erythropoietin has a relatively short serum half life. In most studies twice
to thrice weekly dosing is necessary for adequate treatment. A new erythro-
poiesis stimulating protein, darbepoetin, with a longer serum half life, is available
since a few years. In adults, an effective and safe treatment is achieved with
darbepoetin intravenously or subcutaneously once a week or less frequent dos-
ing4–6. In children only two studies with darbepoetin have been published. For
a short period, small groups of children have been successfully treated before
with darbepoetin for renal anemia7,8. In this study in children on NIPD darbe-
poetin was given intraperitoneally. This prevents frequent painful subcutaneous
injections. Eight patients were converted from intraperitoneal erythropoietin to
intraperitoneal darbepoetin. In the six months control period the patients needed
173 U/kg/week erythropoietin. In this study patients were treated with a median
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Figure 10.1: Hemoglobin concentration in the patients who were converted from erythro-
poietin to darbepoetin in the 6 months before and 3 years after conversion (month 0 =
month of conversion, N = number of patients)
darbepoetin dose of 0.79 μg/kg/week for a median of 31.5 months. Hemoglobin
concentrations remained stable. A total of 19 children were treated with intraperi-
toneal darbepoetin. They were treated for a median period of 13.4 months. With
a median dose of 0.63 μg/kg/week adequate treatment of renal anemia was
achieved.
The darbepoetin doses in the present study is somewhat higher compared to
the doses used in other pediatric studies. In studies by De Palo et al. a mean
dose of 0.45 μg/kg/week darbepoetin intravenously was needed after six months
of treatment in 7 patients7. The 26 patients in a study by Geary et al. also
needed a mean dose of 0.45 μg/kg/week darbepoetin intravenously or subcuta-
neously after 20-28 weeks8. Geary’s patient population had considerable resid-
ual renal function as they included children with a glomerular ﬁltration rate of <30
ml/kg/min/1.73m2. In both studies the patients were older than the patients in our
population. It is well-known from the literature that younger children need higher
erythropoietin dosages than older ones13,14. This may explain the differences
observed with respect to darbepoetin doses. Since the bio-availability of sub-
cutaneous and intraperitoneal erythropoietin is comparable10, a similar behavior
pattern of darbepoetin can be expected. A possible complication of intraperi-
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Figure 10.2: Mean dose of darbepoetin for the patients who were converted from ery-
thropoietin to darbepoetin, up to three years after conversion (N = number of patients)
toneal treatment is peritonitis. Weekly dosing darbepoetin could decrease the
peritonitis incidence compared to the two to three times a week dosage sched-
ule of erythropoietin. In the present study we observed a peritonitis incidence
of once every 25.1 months, which is better than the ﬁgures in our earlier reports
(once every 11-18 months)9–11. This improvement must also be seen in the light
of the generalized decreasing peritonitis incidence reported worldwide15. Side
effects like headache and hypertension were observed in 1-10% of adult patients
treated with darbepoetin5. De Palo et al. recorded an incidence of hypertension
in 43% of their patients7. It is not known if erythropoiesis stimulating protein itself
or the rise in hemoglobin concentration following its administration is responsible
for these side effects16. In the present study three patients (7.5%) developed
transient hypertension and one patient (2.5%) transient headache. In all cases
complaints were preceded by a rapid rise in hemoglobin. Therefore, it is our
recommendation to start with darbepoetin carefully thereby preventing too rapid
increase of hemoglobin concentration.
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Figure 10.3: Mean dose of darbepoetin for all patients, up to three years after conversion
(N = number of patients)
Conclusion
Darbepoetin is effective and safe for the treatment of renal anemia with chil-
dren. Next to intravenous and subcutaneous administration, darbepoetin can
be administered intraperitoneally. Darbepoetin makes administration less time-
consuming. The intraperitoneal route of administration prevents distress in both
child and parents because of pain related to subcutaneous administration. Peri-
tonitis incidence does not increase using this route, since, in the present study,
peritonitis incidence even decreased further compared to earlier studies. Mild
side effects, like hypertension and headache, may develop after a rapid rise in
hemoglobin concentration. A careful start of darbepoetin is therefore recom-
mended.
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Summary and discussion
Children on peritoneal dialysis (PD) are dependent on the preservation of their
peritoneal membrane for their future life. This thesis focused on gaining more
insight in peritoneal functionality and on providing improvements in clinical PD for
children. In this ﬁnal chapter the results of the thesis are summarized, discussed
and future perspectives are formulated.
Chapter 1 started with a general introduction and the aims and outline of this
thesis.
In Part I pathophysiological studies were performed.
Chapter 2 gave the ﬁrst overview of the proteins present in peritoneal dialysate,
as a reﬂection of transported plasma proteins as well as local peritoneal pro-
cesses. Proteomic technologies offer a high-throughput analysis of the expres-
sion of proteins in biological samples. In this study protein identiﬁcation and
proﬁling of peritoneal dialysate from 9 patients was performed, collected from
peritoneal equilibrium tests (PETs). Analysis was performed with the combined
techniques of 1-dimensional gel-electrophoresis, followed by liquid chromatog-
raphy and subsequent mass spectrometry cycles, in a well characterized setup,
giving a representative overview of peritoneal dialysate. A total number of 189
proteins were identiﬁed in the peritoneal dialysate of these 9 patients. Potentially
interesting proteins were revealed, like gelsolin, intelectin and paraoxonase. This
chapter formed the basis for further research at long term protein changes in
peritoneal dialysate, which was the focus of chapter 3.
In Chapter 3 a longitudinal follow-up was performed to examine whether speciﬁc
proteins vary in the course of the dialysis period, possibly reﬂecting changes in
the functioning of the peritoneal membrane. We collected the PD ﬂuid of 7 pa-
tients in the ﬁrst year of dialysis (t0) and again two years later (t1). Samples were
analyzed according to the same methods as in chapter 2, with the addition of
relative quantiﬁcation with spectral counts (unique peptide-ions per protein) and
normalized on the total counts in a sample. The protein orosomucoid was found
to be present in a higher concentration in all samples at t1, compared to t0. With
peritoneal biopsies the deposition of orosomucoid in time was conﬁrmed. Oro-
somucoid is an acute phase protein, that is upregulated in states of inﬂammation
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and tissue damage. The endothelial cell produces orosomucoid and other com-
ponents of its glycocalyx. Orosomucoid contributes to the functional properties
of the glycocalyx and impaired orosomucoid production could cause endothelial
dysfunction1,2. Increased production of orosomucoid by endothelial cells may
have a protective effect on vascular permeability. Quantitative Western blot stud-
ies could not completely conﬁrm the results found with proteomics. A possible
explanation for this could be the fact that with proteomics the multiple isoforms
of orosomucoid will be measured, while with a different peptide composition of
these isoforms a different interaction with the polyclonal antibody is possible.
This implies that the proteomic techniques used are probably more sensitive
but on the other hand less suitable for comparison with quantitative techniques.
However, the disconcordance with Western blot could for a part be ascribed to
the inherent limitations of relative quantiﬁcation with proteomics as well. Larger
quantitative studies will be necessary to further evaluate if orosomucoid could be
a valuable longitudinal marker for chronic inﬂammation and endothelial dysfunc-
tion in peritoneal dialysis.
Resuming, the proteome of peritoneal ﬂuid has interesting potential for high-
throughput qualitative protein analysis, revealing potentially interesting proteins,
but quantiﬁcation with proteomic techniques remains a challenge. Another point
to take into account with proteomics is the labour intensive technique and the
huge amount of data generated, that do not facilitate the analysis of large amounts
of samples. Furthermore, small proteins with a molecular weight below 10 kDa
will not be detected. Proteomic techniques will continue to have a place in re-
search of peritoneal dialysate to elucidate the presence of speciﬁc proteins in
dialysate and the up-or downregulation of proteins in the course of PD treat-
ment and in different conditions. Recently the effects of glucose concentration
on the proteomic proﬁle were studied, showing a different expression of proteins
involved in inﬂammation in the highest glucose concentration3. Furthermore, the
proteomic proﬁles of glucose-based versus icodextrine dialysate in pediatric pa-
tients were compared, indicating a better efﬁciency of icodextrine in removing
small proteins4. Quantitative techniques will be necessary for the evaluation of
the function of speciﬁc proteins, and for the development of biomarkers for com-
plications of PD. At this moment we are still just at the beginning of the era of
proteomic research of dialysate.
In Chapter 4 the results of the analysis of free water transport (FWT) in both
cross-sectional and longitudinal patient groups were presented, using different
PD ﬂuids. FWT occurs through aquaporins only and therefore gives a reﬂection
of peritoneal aquaporin function. The proportional contribution of FWT was sig-
niﬁcantly higher in patients using dialysis solution with neutral pH/low glucose
degradation products (GDP) compared to patients using dialysis solution with
low pH/high GDPs (50% versus 40%). Total FWT was higher as well. This can
reﬂect a better preservation of aquaporins, as well as less impairment of osmotic
conductance. Inﬂammation and vasculopathy lead to hyperpermeability for small
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solutes, so the osmotic gradient disappears fast, explaining part of the impaired
FWT as well. Higher FWT was observed in patients older than ﬁve years, which
may be caused by maturational changes of the peritoneal membrane. In the lon-
gitudinal group the contribution of FWT increased in the ﬁrst 1.5 years (48% to
61%) of PD treatment, then slowly decreased again to baseline level by the end
of the third year. This long-term decline of the contribution of FWT could be ex-
plained by aquaporin dysfunction, due to structural or conformational changes.
A proposed mechanism of aquaporin-1 dysfunctioning is less effective trafﬁcking
of aquaporins to the endothelial cell membrane. With longer follow-up duration
the course of FWT in time can be investigated more profoundly.
It has been suggested that pharmacological modulation of aquaporin-1 could
be used in the future to inﬂuence ultraﬁltration and response to inﬂammation in
peritoneal dialysis5. Compounds have been identiﬁed that could serve as antag-
onist of aquaporin-1 channels, like the tetra-ethyl-ammonium ion6. Compounds
that could serve as an agonist, to facilitate transport by binding at a speciﬁc site
of the aquaporin, are still hypothetical, like aryl sulfonamide-related derivates5.
In future investigations it would also be very useful to investigate FWT in the
newer, more biocompatible solutions like Bicavera R©, that contain considerably
less GDP’s than the neutral pH/low GDP solution in our study.
Part II focused on clinical studies.
In Chapter 5 we investigated whether continuous ﬂow PD (CFPD) is a more
effective treatment than conventional PD for the treatment of acute renal failure.
PD can be the therapy of ﬁrst choice in situations like hypotension, disturbed
coagulation or difﬁcult venous access, but the main disadvantage of PD is the
relatively limited efﬁcacy compared to hemodialysis and continuous venovenous
hemoﬁltration/dialysis. This study was performed as a prospective case-control
study at The Red Cross University Hospital in Cape Town in six patients, who
were treated with both CFPD and conventional PD for 8-16 hours, so each pa-
tient functioned as his or her own control. It was shown that CFPD was on
average 3 to 5 times more effective for urea and creatinine clearance and ultra-
ﬁltration than conventional PD, without complications observed. CFPD proved to
be a successful therapy for acute renal failure in children, offering the possibil-
ity to improve the treatment for acute renal failure for speciﬁc patient groups. It
would be an interesting option to study more long-term effects of CFPD as well.
Taking into account the high contribution of FWT with CFPD, long-term CFPD
could provide the interesting possibility to investigate the functioning and preser-
vation of the aquaporin-1 channels with the use of this technique as well. For
long-term use the higher costs of CFPD have to be taken into account. Regen-
eration of ﬂuids could be an option to overcome this problem.
Chapter 6 described the experience with a serious complication of PD, fungal
peritonitis, with a review of the literature. Fungal peritonitis is a rare but seri-
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ous complication in children on PD, with a disproportionally high morbidity and
mortality. A retrospective, multi-centre study was performed in Dutch pediatric
PD patients between 1980 and 2005. In 159 patients a total of 321 episodes of
peritonitis occurred (peritonitis rate of 0.09 episodes per patient-month or 1.08
episodes per patient-year). A yeast or mould was found in the dialysate in 2.9%.
The majority of these patients had a candida peritonitis. The most important
risk factors that were distracted from this cohort were a high bacterial peritoni-
tis rate, prior use of antibiotics in the preceding month and previous bacterial
peritonitis with gram-negative organisms. The PD catheter should be removed
early. The 2010 peritonitis guidelines for adults7 advise to remove the catheter
immediately, but in children we promote early but not immediate removal, to allow
for a period of vigourous peritoneal lavage with antimycotics that could possibly
prevent formation of peritoneal adhesions and maintain viability of the peritoneal
membrane8,9. Monotherapy with ﬂuconazole is a good ﬁrst choice treatment for
fungal peritonitis10, with intraperitoneal ﬂuconazole as preferred prior to removal
of the PD catheter in children, followed by oral administration of ﬂuconazole. The
occurrence of more resistent Candida species and more rarely occurring fungi
in the future could limit the use of ﬂuconazole. The new azole derivates may be
a good alternative. Voriconazole offers activity against Candida and Aspergillus
species and many other ﬁlamentous fungi, except for Zygomycetes, but in these
cases posaconazole has proven to be effective. Experience with the newer azole
derivates is still limited10. Another option are the echinocandins, like caspofun-
gin, micafungin and anidulafungin, that form a new class of antifungals. They
offer broad-spectrum activity against Candida species and several moulds, but
again experience in PD patients is still very limited10. Prophylactic use of an-
timycotic drugs during antibiotic treatment for bacterial peritonitis is not generally
used, but could prevent secondary fungal peritonitis. Few studies with nystatin or
ﬂuconazole prophylaxis have been carried out, with conﬂicting results. Only two
prospective, randomized controlled trials have been performed so far. In the ﬁrst
study by Lo et al.11 nystatin was used as prophylaxis and a reduction was found
in the incidence of all fungal peritonitis episodes. Another more recent study
from Colombia with ﬂuconazole prophylaxis also showed a prevention of sec-
ondary fungal peritonitis12. The fact that ﬂuconazole was used as prophylactic
treatment in this study may however be less favourable in the light of emerg-
ing resistant Candida species. Currently the ISPD guidelines only recommend
antifungal prophylaxis in settings with high fungal peritonitis rates, awaiting the
results of further clinical trials.
Peritonitis treatment in developing countries forms a speciﬁc challenge. This
was described in Chapter 7. PD is rising as a treatment modality in develop-
ing countries, with a distinct problematic nature of peritonitis. In this study PD
treatment and peritonitis epidemiology in pediatric patients in South Africa were
investigated and risk factors for peritonitis were identiﬁed. A retrospective cohort
study was performed between 2000 and 2008. In 67 patients a total number of
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129 peritonitis episodes were observed. This gave a high peritonitis rate of 0.23
episodes per patient-month or 2.8 episodes per patient-year, which is signiﬁ-
cantly higher than peritonitis rates observed in the developed world. Compared
to numbers in the developed world, the characteristics of the causative orga-
nisms were rather comparable. Remarkable was the high incidence of fungal
peritonitis in this cohort. An explanation can be found in the overall high peri-
tonitis rate and the relative high rate of gram-negative infections, that are both
considered to be a risk factor for fungal peritonitis (see also chapter 6). The
most important risk factors for development of peritonitis proved to be poor hous-
ing and poor socio-economic circumstances. More intensive counseling may be
beneﬁcial, but improvement of general socio-economic circumstances will have
the greatest inﬂuence on PD success.
In Chapter 8 the experience with intestinal perforation as a rare but high-risk
complication of PD was described. Pediatric cases are rare in literature and the
etiology in pediatric patients is distinct from the etiology in adults. In this study
three cases of intestinal perforation were presented that occurred in a cohort of
128 children. The difﬁculties in diagnosis were discussed. This is a challenging
aspect in these kind of cases. Often there are no obvious radiological or clinical
signs of perforation. Intestinal perforation in PD patients should be suspected in
poly-microbial peritonitis without improvement on antibiotics.
Part III focused on pharmacological studies, aimed to improve compliance and
patient satisfaction with treatment.
In Chapter 9 breastmilk and dairy products were pre-treated with sevelamer, to
avoid troublesome ingestion by children and to be able to safely prescribe seve-
lamer in this alternative manner. Sevelamer is known as an effective phosphate-
binder, but for children important practical disadvantages exist: sevelamer clogs
nasopharyngeal tubes and can cause gastro-intestinal complaints. Both seve-
lamer hydrochloride and sevelamer carbonate were suspended in different dairy
products. Cow’s milk, breastmilk, baby formula and tube feeding formula were
tested in different concentrations. A signiﬁcant decrease in phosphate content
in all dairy products was observed, with the highest effectivity found in breast-
milk. It was shown that sevelamer hydrochloride and sevelamer carbonate can
be added to different dairy products to effectively lower the phosphate content.
A remarkable pH increase was found in all products, reﬂecting buffering mech-
anisms. With breastmilk a considerable calcium decrease occurred, that has to
be taken into consideration with clinical use. Another point that has to be taken
into account with the use of sevelamer in general is the possible contribution to
folic acid deﬁciency in patients with insufﬁcient dietary intake13,14.
Chapter 10 evaluated the possibilities of more patient friendly intraperitoneal
prescription of darbepoetin. The safety and effectiveness of intraperitoneal ad-
ministration of darbepoetin in 19 children with renal anemia on peritoneal dia-
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lysis were evaluated. Children were either converted from erythropoietin (n=8)
or started directly with darbepoetin (n=11). The median darbepoetin dose for
an adequate erythropoiesis was 0.63 μg/kg/week. Four children developed tran-
sient minor adverse effects (headache or hypertension), all after rapid increase of
hemoglobin concentration. It could be concluded that intraperitoneal administra-
tion of darbepoetin is an effective, safe and patient-friendly treatment for children
on peritoneal dialysis, with minimal interference of peritoneal dialysis care.
Future perspectives
In this thesis a broad spectrum of pathophysiological and clinical insights con-
cerning PD in children were discussed, with the aim to improve PD treatment.
In future research it will be important to continue to focus on the development
of more biocompatible ﬂuids, as detrimental effects of bio-incompatible PD ﬂuids
with the formation of GDP’s are considered a major contributing factor to long
term membrane alterations, leading to progressive peritoneal damage. New
GDP’s are still being discovered, e.g. with proteomic techniques15,16. So far
a number of adaptations have been made to improve the biocompatibility of
PD ﬂuids. Lactate has been lowered or eliminated; glucose has been sepa-
rated from the acidic pH in double chambered-bags to prevent the formation of
GDP’s by heat sterilization of glucose at a lower pH; replacement of glucose
by icodextrine or amino-acids has been tested, and combinations of biocom-
patible ﬂuid in multi-chambered bags have been made, like NEPP (combining
solutions with amino-acids, icodextrin and glucose solution with neutral pH/low
GDPs (Nutrineal R©/Extraneal R©/Physioneal R©/Physioneal R©) and GLAD (glycerol/
amino-acids/dextrose). Several clinical studies suggest better long-term patient
outcomes with more biocompatible ﬂuids17–19, although the clinical evidence is
still rather limited and further studies are needed20. Based on the available evi-
dence so far, the European Pediatric Dialysis Working Group recommendations
of 2011 are to replace conventional single-chamber PD solutions by more bio-
compatible ﬂuids with reduced GDP content21. Despite the fact that it has been
generally accepted that more biocompatible solutions should be preferred over
conventional PD solutions, reality is different. In 2010 it was noted by the Inter-
national Pediatric PD Network Registry ∗ that only 60% of the children in Europe,
25% of the children in Asia and 10% of the children in North America were treated
with more biocompatible PD solutions. Improvements in this respect have to be
made in the upcoming years. The aim for new solutions will include a further
decrease of GDP’s. Another interesting option is to counter the effects of GDP’s,
as was investigated by Lee et al.22, with the aid of N-acetylcysteine (NAC). NAC
forms a neutralizing conjugate with 3,4-DGE (3,4-dideoxyglucosone-3-ene), the
∗www.pedpd.org
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most toxic GDP found in PD solutions, which would make it an attractive adju-
vant for PD solutions. Another suggested protective substance for the peritoneal
membrane is a peroxisome proliferator-activated receptor-gamma (PPAR-y) ag-
onist, named rosiglitazone. From the results in a mouse PD model it was sug-
gested that rosiglitazone has a protective effect as it reduces the accumulation
of AGEs and inﬂammation and it helps to preserve the mesothelial cell mono-
layer23. These studies are all still in the experimental phase.
Prevention of peritonitis is another key-factor for better preservation of the peri-
toneal membrane. To minimize the risk of infections it will be important to deﬁne
risk-factors in individual patients and to act pro-active in patients with a perceived
higher risk of peritonitis with gram-negative bacteria or fungi. The potential bene-
ﬁt of antifungal prophylaxis for broader patient groups has to be further evaluated.
Improvement of hygiene and catheter care plays a continuous role in preventing
contamination. Prophylactic mupirocin is widely used for the reduction of both
exit-site infections and peritonitis caused by Staphylococcus Aureus colonization,
and has shown to be effective in several studies, including meta-analyses24–26,
although mupirocin resistance can occur after long-term use27. Gentamycin has
been used as an effective alternative, which offers the extra advantage of gram-
negative coverage28. Another possible new option, without the risk of developing
resistance, is the application of antibacterial honey at the exit-site, with promising
results in the ﬁrst published study29, but this has to be conﬁrmed in other studies.
New techniques of PD will be another option to improve future treatment of PD
patients, for example with the broader use of CFPD. So far the clinical experience
with CFPD is still very limited, but as was shown in chapter 5 it can be a valuable
option for the treatment of acute renal failure in children. Its further potential for
the treatment of acute renal failure lies in the clinical application in developing
countries with limited resources, but also in developed countries, especially in
the hemodynamically instable child. In addition, interest is growing for CFPD
in chronic renal failure, with the continuing developments in catheter technology
and the possibility of regeneration of ﬂuids. CFPD could be applied to minimize
nutritional losses and to maximize biocompatibility for the peritoneal membrane.
The implementation in clinical practice could be further explored in larger patient
groups with both acute and chronic renal failure.
In developing countries the situation regarding dialysis is complex. The etiology
of renal failure in children in developing countries differs from that in developed
countries. Acute renal failure is more likely to occur due to fulminant sepsis or
malaria with intravascular hemolysis30 or due to severe dehydration with gastro-
enteritis, leading to acute tubular necrosis. Also toxins, poisons, endemic dis-
eases and natural disasters play a role31. Lack of adequate water supply and
medication and delayed referral will more frequently lead to irreversible damage
in acute and subacute renal diseases, although representative registries of in-
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cidence and prevalence of both acute and chronic renal failure are lacking31,32.
General life health indicators in developing countries are unfavorable. In Africa
life expectancy is only 47 years, with the highest mortality in children under the
age of 5 worldwide (16.3%) and the highest prevalence of HIV (5.8%)33. Access
to medical care is poor: well over 90% of end stage renal disease (ESRD) pa-
tients do not have access to medical care34. In Sub-Saharan Africa 0.2 nephrol-
ogists per million population are available, in contrast to 20 nephrologists per
million population in Western Europe35. ESRD is a growing entity in develop-
ing countries. The prevalence of PD varies highly between different developing
countries, but overall the use of PD is growing and it seems likely that in the fu-
ture the majority of PD patients will be living in developing countries36. In the light
of the limited economic resources in developing countries the questions whether
to provide ESRD care and to what extent are not easy to answer. But if PD is
offered, it was demonstrated in several developing countries that PD can be im-
plemented as a successful program.
A difﬁcult point is the selection of patients for dialysis. In South-Africa, only pa-
tients eligible for kidney transplantation are offered dialysis at no/low costs by the
state37, in order to offer their patients long-term perspective. Less than 50% of
patients with ESRD are selected for dialysis, depending on the perceived chance
of successful therapy. The problem is that the main reasons to deny patients dia-
lysis are based on poverty related factors, like unsuitable living circumstances for
PD, inability to travel to a dialysis centre, lack of insight in illness and illiteracy38.
Although rationing of a scarce therapy seems justiﬁed, it inevitably induces in-
equity of treatment. The most important conditions to establish a successful
peritoneal dialysis program are the development of an education and identiﬁca-
tion program for chronic kidney disease, the development of a viable ﬁnancial
model, appropriate training of medical staff and nurses, monitoring of outcomes,
implementation of adjustments, and maintaining contact with experts outside the
country for support34.
When locally a basis for the treatment of children with renal diseases exists, sev-
eral programs can offer help from outside. For example, the European Society
of Pediatric Nephrology and the International Nephrology Global Outreach pro-
vide training grants and fellowships for improvement of theoretical and practical
skills for doctors in developing countries. The European Renal Association offers
the opportunity to invite an established expert for a short term period for hands-
on teaching and help to establish new programs that would beneﬁt patient care.
The Sister Renal Centres Program stimulates collaboration between centres in
the developed and developing world. These programs offer hope-giving possibil-
ities to improve treatment for renal patients in developing countries.
The establishment of successful, affordable, and equally available care in devel-
oping countries will be one of the main challenges for future PD treatment.
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Samenvatting
Kinderen behandeld met peritoneale dialyse (PD) zijn mede afhankelijk van hun
peritoneale membraan voor hun toekomstige leven. Het onderzoek in dit proef-
schrift was erop gericht om meer inzicht te krijgen in het functioneren van het
peritoneale membraan en om verbeteringen te bewerkstelligen in de klinische
behandeling van kinderen aan PD.
Hoofdstuk 1 vormde de algemene inleiding en verwoordde de belangrijkste doe-
len van het onderzoek.
Deel 1 bestond uit pathofysiologische studies.
In Hoofdstuk 2 werd met behulp van proteomicstechnieken het eerste overzicht
gegeven van de eiwitten die aanwezig zijn in peritoneaal dialysaat, hetgeen
een representatieve weergave vormt van zowel geﬁltreerde plasma-eiwitten als
van lokale peritoneale processen. De proteomics-technologie biedt een analyse
met hoge verwerkingscapaciteit voor de expressie van eiwitten in biologische
monsters. In deze eerste studie werd het eiwitproﬁel van het dialysaat van 9
kinderen onderzocht, verzameld met behulp van peritoneale equilibriumtesten
(PETs). De analyse werd verricht met de gecombineerde technieken van 1-
dimensionale gel-elektroforese, gevolgd door chromatograﬁe en opeenvolgende
cycli met massaspectrometrie (MS). Er werd een totaal aantal van 189 eiwitten
geı¨dentiﬁceerd in het dialysaat van de 9 patie¨nten. Potentieel interessante eiwit-
ten werden gevonden, die nog onbekend waren in dialysaat, zoals gelsoline, int-
electine en paraoxonase. Dit hoofdstuk vormde de basis voor verder onderzoek
naar langetermijn-veranderingen in peritoneaal dialysaat, hetgeen het focus was
van hoofdstuk 3.
In Hoofdstuk 3 werd een longitudinale follow-upstudie verricht om te onder-
zoeken of de expressie van speciﬁeke eiwitten verandert gedurende het be-
loop van chronische dialyse. Dit kan een indicatie zijn voor veranderingen in
het functioneren van het peritoneale membraan. We verzamelden het dialysaat
van 7 patie¨nten gedurende het eerste jaar aan dialyse (t0) en nogmaals 2 jaar
daarna (t1). Alle monsters werden geanalyseerd volgens de genoemde metho-
den uit hoofdstuk 2. Hier werd nog een relatieve kwantiﬁcering aan toegevoegd
met behulp van ’spectral counts’. Hiermee wordt de frequentie van voorkomen
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van het aantal unieke peptide-ionen per eiwit bepaald (het spectrum) en afgezet
tegen het totaal aantal peptide-ionen in het monster. We vonden dat het ei-
wit orosomucoid op t1 bij alle patie¨nten in hogere concentratie aanwezig was
dan op tijdstip t0. Deze toename van orosomucoid in de tijd werd bevestigd
met peritoneale biopten. Orosomucoid is een acutefase-eiwit, dat verhoogd is
bij inﬂammatie en weefselschade. Orosomucoid wordt geproduceerd door en-
dotheelcellen en draagt bij aan de functionele eigenschappen van de glycocalyx
van de endotheelcel. Verstoorde orosomucoid-productie kan endotheliale dys-
functie veroorzaken1,2. Een toename van de productie van orosomucoid door
endotheliale cellen zou een beschermend effect kunnen hebben op de vaat-
permeabiliteit. Met kwantitatieve Western blot-studies konden de resultaten die
waren gevonden met proteomics niet geheel bevestigd worden. Een mogelijke
verklaring hiervoor is het feit dat met proteomics de multipele isovormen van
orosomucoid gemeten worden, terwijl niet iedere isovorm eenzelfde reactie met
het polyclonale antilichaam, dat gebruikt wordt met Western blot, zal hebben.
Hiermee is de gebruikte proteomicstechniek waarschijnlijk sensitiever, maar het
maakt de vergelijking met kwantitatieve technieken wel gecompliceerder. Boven-
dien zou een deel van de discrepantie in resultaten ook toegeschreven kunnen
worden aan de inherente beperkingen van de relatieve kwantiﬁceringstechnieken
van proteomics. Grotere kwantitatieve studies zijn dan ook nodig om verder
te kunnen onderzoeken of orosomucoid een waardevolle longitudinale marker
zou kunnen zijn voor chronische inﬂammatie en endotheliale dysfunctie bij peri-
toneale dialyse.
Resumerend heeft het proteoom van het peritoneale dialysaat zeer interessante
potenties om eiwit-analyse met hoge verwerkingscapaciteit te verrichten, waar-
bij interessante nieuwe eiwitten ontdekt kunnen worden, maar de kwantiﬁcatie
met proteomics blijft een belangrijke uitdaging vormen. Een ander punt dat in
overweging genomen moet worden is het feit dat de proteomicstechnieken erg
arbeidsintensief zijn en er een enorme hoeveelheid data gegenereerd wordt, het-
geen de analyse van grotere aantallen monsters gecompliceerd maakt. Ook
kunnen kleine eiwitten met een molecuulgewicht onder de 10.000 Dalton niet
gedetecteerd worden. Proteomicstechnieken zullen naar verwachting een nut-
tige aanvulling blijven in toekomstig PD-onderzoek om speciﬁeke nieuwe eiwit-
ten te ontdekken en de expressie van eiwitten in de loop van de PD-behandeling
en in verschillende omstandigheden verder te bestuderen. Kwantitatieve tech-
nieken zullen nodig blijven om de functie van speciﬁeke eiwitten in detail te
onderzoeken en voor de ontwikkeling van individuele biomarkers. Recent zijn
met proteomicstechnieken de effecten van de glucose-concentratie van dialy-
sevloeistoffen bestudeerd, waarbij een verschil in expressie van inﬂammatoire ei-
witten werd gezien in vloeistoffen met de hoogste glucose-concentratie3. Tevens
zijn met proteomicstechnieken de eiwitproﬁelen vergeleken van dialysevloeistof-
fen op glucosebasis ten opzichte van dialysevloeistoffen met icodextrine. In deze
studie was icodextrine efﬁcie¨nter om kleine eiwitten te verwijderen4. Op dit mo-
ment lijken we nog slechts aan het begin te staan van het proteomicstijdperk in
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het onderzoek van peritoneale dialyse.
InHoofdstuk 4werden de resultaten van de analyse van vrijwatertransport (Free
Water Transport = FWT) tijdens PD gepresenteerd, waarbij verschillende dialyse-
vloeistoffen vergeleken werden, zowel transversaal als longitudinaal. FWT ge-
beurt alleen via aquaporines (de kleinste porie¨n in het peritoneale membraan)
en vormt een weergave van de functie van peritoneale aquaporines. Zowel
het totale FWT als de procentuele bijdrage van FWT was signiﬁcant hoger in
patie¨nten die een meer biocompatibele dialysevloeistof gebruikten met een neu-
trale pH en lage glucosedegradatieproducten, in vergelijking met patie¨nten die
een conventionele dialysevloeistof gebruikten met een lage pH en hoge glu-
cosedegradatieproducten (50% versus 40%). Dat kan een reﬂectie zijn van een
beter behoud van aquaporines bij meer biocompatibele dialysevloeistoffen. Het
kan echter ook voor een deel verklaard worden door minder verslechtering van
de osmotische gradie¨nt bij gebruik van deze meer biocompatibele vloeistoffen.
Door inﬂammatie en vasculopathie wordt de peritoneale membraan hyperper-
meabel voor kleine deeltjes, waardoor de osmotische gradie¨nt snel verdwijnt,
wat ook voor een verslechtering van FWT kan zorgen.
Bij verdeling van de patie¨nten in 2 leeftijdsgroepen (jonger en ouder dan 5 jaar),
werd een hoger FWT gevonden bij de patie¨nten ouder dan 5 jaar. Dit zou kunnen
passen bij veranderingen in het peritoneale membraan door rijpingsprocessen.
In de longitudinale groep nam de procentuele bijdrage van FWT toe in de eerste
1.5 jaar (48% tot 61%) en liet vervolgens weer een langzame afname zien tot het
basale niveau gedurende het 3e jaar. Deze langetermijnafname van de bijdrage
van FWT zou verklaard kunnen worden door disfunctie van aquaporines, door
structurele of conformationele veranderingen. Een mogelijk mechanisme van
aquaporine-disfunctie is minder effectief gereguleerd transport van aquaporines
naar het endotheliale membraan. Met een langere follow-upduur zou het beloop
in de tijd van FWT in de toekomst nog beter onderzocht kunnen worden.
Farmacologische modulatie van aquaporine-1 zou in de toekomst een rol kunnen
spelen om de ultraﬁltratie, FWT en de respons op inﬂammatie te beı¨nvloeden5.
Er zijn inmiddels stoffen geı¨dentiﬁceerd die een rol kunnen spelen als antago-
nist van de aquaporine-1-kanalen, zoals het tetra-ethyl-ammonium-ion6. Stoffen
die zouden kunnen dienen als aquaporine-1-agonist, door te binden aan een
speciﬁeke bindingsplaats van het aquaporine, waarmee transport gefaciliteerd
wordt, zijn nog in de hypothetische onderzoeksfase, zoals de aryl-sulfonamide-
gerelateerde derivaten5. In toekomstig onderzoek zou het ook erg nuttig zijn
om FWT te onderzoeken in de nieuwere, nog meer biocompatibele dialyse-
vloeistoffen, zoals Bicavera R©, die nog minder glucose degradatieproducten be-
vatten dan de biocompatibele vloeistoffen die zijn gebruikt in de huidige studie.
Het focus van Deel II lag bij klinische studies.
In Hoofdstuk 5 werd onderzocht of PD met continue ﬂow (continuous ﬂow PD
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= CFPD) een effectievere manier van dialyse is dan conventionele PD voor de
behandeling van acuut nierfalen. PD kan de eerste keuze van dialysebehandel-
ing zijn in klinische situaties zoals bij een lage bloeddruk, gestoorde stolling, of
een moeilijke veneuze toegang, maar de nadelen van conventionele PD zijn de
lagere effectiviteit ten opzichte van bijvoorbeeld hemodialyse of continue veno-
veneuze hemoﬁltratie/dialyse. Deze studie werd uitgevoerd als een prospec-
tieve case-controlstudie, in het Red Cross University Hospital in Kaapstad, Zuid-
Afrika. Zes patie¨nten werden behandeld met zowel conventionele PD als met
CFPD gedurende 8-16 uur, waarbij iedere patie¨nt zijn eigen controle vormde.
CFPD bleek gemiddeld 3 tot 5 keer zo effectief te zijn voor de klaring van ureum
en kreatinine dan conventionele PD, zonder dat er complicaties van de behan-
deling optraden. Met deze studie werd aangetoond dat CFPD een succesvolle
techniek is voor de behandeling van acuut nierfalen bij kinderen, die de mogelijk-
heid biedt om de behandeling voor acuut nierfalen te verbeteren voor speciﬁeke
patie¨ntengroepen. Een interessante optie voor de toekomst zou zijn om de
langetermijneffecten van CFPD te bestuderen. De hoge bijdrage van FWT bij
CFPD biedt ook de mogelijkheid om het functioneren en de preservatie van
aquaporine-1-kanalen te onderzoeken met behulp van de CFPD-techniek.
Hoofdstuk 6 beschreef de ervaringen met een ernstige complicatie van PD,
schimmelperitonitis (fungale peritonitis), met een overzicht van de literatuur.
Schimmelperitonitis is een zeldzame maar ernstige complicatie bij kinderen aan
PD, met een disproportioneel hoge morbiditeit en mortaliteit. Wij voerden een
retrospectieve studie uit bij kinderen die behandeld werden met PD tussen 1980
en 2005 in 2 Nederlandse academische centra. Bij een totaal van 159 patie¨nten
werden 321 episodes van peritonitis vastgesteld (peritonitis ratio van 0.09 episo-
den per patie¨ntenmaand of 1.08 episoden per patie¨ntenjaar). In 2.9% van de
peritonitis-episoden werd een gist of een schimmel gevonden. De meerder-
heid van deze patie¨nten had een candida peritonitis. De belangrijkste risico-
factoren die uit dit cohort gee¨xtraheerd werden waren een hoog aantal bac-
terie¨le peritonitiden, eerdere peritonitiden met een gram-negatieve bacterie en
het gebruik van antibiotica in de voorafgaande maand. De PD-catheter dient
snel verwijderd te worden bij schimmelperitonitis. In de meest recente PD-
richtlijnen voor volwassenen7 wordt het advies gegeven de catheter direct te
verwijderen, maar wij raden bij kinderen aan om de catheter wel vroeg in de
behandeling te verwijderen maar pas nadat peritoneale antimycotische lavage
is toegepast, die de vorming van peritoneale adhesies mogelijk kan voorkomen
en kan zorgen dat het peritoneale membraan beter intact blijft 8,9. Als eerste
keus behandeling is monotherapie met ﬂuconazol een goede optie10, met zoals
genoemd intraperitoneale lavage met ﬂuconazol voorafgaand aan de verwijder-
ing van de PD-catheter, gevolgd door een orale behandeling met ﬂuconazol.
Het in toenemende mate voorkomen van meer resistente Candida-species en
het voorkomen van meer zeldzame schimmels, zou het toekomstige gebruik
van ﬂuconazol kunnen beperken. De nieuwere azol-derivaten kunnen hiervoor
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een goed alternatief vormen. Voriconazol is effectief tegen Candida en As-
pergillus species en vele andere ﬁlamenteuze fungi, uitgezonderd zygomyceten,
maar in deze gevallen biedt posaconazol een alternatief. De ervaring met de
nieuwere azol-derivaten is nog beperkt10. Een andere optie vormen een nieuwe
klasse van antifungale middelen, de echinocandines, zoals caspofungin, mica-
fungin and anidulafungin. Deze middelen bieden breed-spectrumactiviteit tegen
Candida-species en verschillende andere schimmels, maar ook met deze mid-
delen is de ervaring bij PD-patie¨nten nog zeer beperkt10. Het profylactische
gebruik van antimycotische middelen tijdens de antibiotische behandeling tegen
bacterie¨le peritonitis wordt nog niet breed toegepast, maar zou secundaire fun-
gale peritonitis kunnen voorkomen. Er zijn enkele studies verricht met profy-
lactische nystatine- of ﬂuconazol-behandeling, met tegenstrijdige resultaten. Er
zijn tot nu toe slechts twee prospectieve, gerandomiseerde studies gedaan. In
de eerste studie, door Lo et al.11, werd nystatine gebruikt en werd een reductie
gezien in de incidentie van alle schimmelperitonitis-episodes. Een tweede, meer
recente studie uit Colombia met ﬂuconazol als profylaxe liet ook een bescher-
mend effect zien tegen secundaire schimmelperitonitis12. Het feit dat ﬂuconazol
werd gebruikt kan als ongunstig bijeffect hebben dat resistente Candida-species
zich sneller kunnen ontwikkelen. Op dit moment wordt in de richtlijnen van de
International Society voor PD (ISPD) alleen antifungale profylaxe geadviseerd in
settings met een hoge schimmelperitonitis-ratio, in afwachting van de uitkomsten
van uitgebreider onderzoek in klinische trials.
De behandeling van peritonitis in ontwikkelingslanden vormt een speciﬁeke uit-
daging. Dit werd beschreven in Hoofdstuk 7. PD neemt toe als behande-
lingsoptie in ontwikkelingslanden, met een zich onderscheidende peritonitispro-
blematiek. In deze studie werden de PD-behandeling en peritonitis-epidemiologie
bij pediatrische patie¨nten in Zuid-Afrika onderzocht en werden risicofactoren voor
peritonitis geı¨dentiﬁceerd. Wij voerden een retrospectieve cohortstudie uit over
de periode 2000-2008. Bij een totaal van 67 patie¨nten werden 129 episoden
van peritonitis vastgesteld. Dit geeft een peritonitisratio van 0.23 episoden per
patie¨ntenmaand (2.8 episoden per patie¨ntenjaar), wat signiﬁcant hoger is dan de
peritonitis ratio’s die gezien worden in ontwikkelde landen. De kenmerken van
de peritonitis-veroorzakende organismen waren redelijk vergelijkbaar. Opvallend
was de hoge incidentie van schimmelperitonitis in dit cohort. Dit kan verklaard
worden door de absolute hoge peritonitisratio en het relatief hoge voorkomen
van gram-negatieve organismen, beiden vormen een risicofactor voor schim-
melperitonitis (zie ook hoofdstuk 6). De belangrijkste risicofactoren voor het ont-
wikkelen van peritonitis bleken echter slechte woonomstandigheden en slechte
socio-economische omstandigheden te zijn. Intensievere begeleiding bij de PD-
behandeling kan hierin helpen, maar verbetering van de algemene levensom-
standigheden zal de grootste positieve invloed hebben op het welslagen van de
PD-behandeling en het terugdringen van de peritonitis-cijfers.
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In Hoofdstuk 8 werd de ervaring met darmperforaties als een zeldzame, maar
risicovolle complicatie van PD beschreven. Casuı¨stiek bij kinderen is schaars
in de literatuur en de etiologie bij kinderen onderscheidt zich van die bij vol-
wassenen. In deze studie werden 3 gevallen van darmperforatie bij kinderen
aan PD beschreven, uit een cohort van 128 kinderen. De problemen inzake de
diagnose werden bediscussieerd. Het stellen van de juiste diagnose vormt in
deze gevallen een uitdaging. Vaak is het radiologische of klinische beeld niet
conclusief voor tekenen van perforatie. Darmperforatie bij PD-patie¨nten moet
overwogen worden bij poly-microbie¨le peritonitis zonder evidente verbetering op
adequate antibiotische behandeling.
In Deel III werd gefocust op farmacologische studies, met als doel de medicatie-
trouw en patie¨nt-tevredenheid te verbeteren.
In Hoofdstuk 9 werden moedermelk en zuivelproducten voorbehandeld met
sevelamer, om de vaak moeizame orale inname van dit medicament bij kinderen
te vermijden en om sevelamer op een veilige manier te kunnen voorschrijven via
deze alternatieve route. Sevelamer is bekend als een effectieve fosfaatbinder,
maar voor kinderen zijn er belangrijke praktische nadelen: sevelamer obstrueert
nasofaryngeale sondes en kan maag- en darmklachten geven. In deze studie
werden zowel sevelamer-hydrochloride als sevelamer-carbonaat gesuspendeerd
in verschillende zuivelproducten. Moedermelk, koemelk, zuigelingenvoeding en
sondevoeding werden getest met sevelamer in verschillende concentraties. Er
werd een signiﬁcante afname in het fosfaatgehalte gezien bij alle producten,
met de hoogste effectiviteit bij moedermelk. Deze studie toonde aan dat zowel
sevelamer-hydrochloride als sevelamer-carbonaat toegevoegd kunnen worden
aan verschillende zuivelproducten, om het fosfaatgehalte effectief te verlagen.
Er werd een opmerkelijke pH-stijging gezien in alle producten, die verklaard kan
worden door buffer-mechanismen in melk. Bij moedermelk werd een duidelijke
calciumafname gezien, waar rekening mee gehouden moet worden in de kli-
nische praktijk. Een ander meer algemeen punt waar op gelet moet worden bij
het gebruik van sevelamer is de mogelijke bijdrage aan foliumzuur-deﬁcie¨ntie bij
patie¨nten met een suboptimale dieetinname13,14.
In Hoofdstuk 10 werden de mogelijkheden gee¨valueerd om een meer patie¨nt-
vriendelijke manier van toediening van intraperitoneale erythropoietine te bewerk-
stelligen. De veiligheid en het effect van intraperitoneale toediening van dar-
bepoietine werden bekeken bij 19 kinderen met renale anemie die behandeld
werden met PD. De patie¨nten werden ofwel overgezet van erythropoietine naar
darbepoietine (n=8) ofwel begonnen direct met de behandeling met darbepoi-
etine (n=11). De mediane dosis darbepoietine om een adequate erythropoiese
te realiseren was 0.63 μg/kg/week. Vier kinderen ontwikkelden voorbijgaande
bijwerkingen (hoofdpijn of hypertensie), allen na een snelle toename van hun
hemoglobine-concentratie. Uit deze studie kon geconcludeerd worden dat de
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intraperitoneale toediening van darbepoietine een effectieve, veilige en patie¨nt-
vriendelijke behandeling is voor kinderen aan PD, met minimale interferentie van
de praktische zorg rondom de PD-behandeling.
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Dankwoord
Zonder mensen om te bedanken, geen proefschrift! Dat geldt zeker ook in mijn
geval. En nu ik eindelijk eens geen woorden hoef te tellen: bij deze een ﬁjn lang-
van-stof dankwoord!
Als eerste bedank ik alle PD patie¨nten, die de belangrijke gezichten achter de
studies waren en door en voor wie het vooral gedaan is.
Als promovendus verkeerde ik in de luxepositie om 3 promotoren, 1 co-promotor
en 1 ’ere-promotor’ te krijgen, wat beslist een weelde te noemen is, en heel af
en toe ook een organisatorische en diplomatieke uitdaging bleek te zijn..
Als eerste promotor: prof. dr. J.L. Willems, beste Hans, bedankt voor de bijdrage
vanaf de start, uw grote kennis van laboratoriumtechnieken (waarmee u mijn hi-
aten in kennis wat op kon vullen) en uw kritische en relativerende vragen tijdens
onze onderzoeksbesprekingen.
Prof. dr. L.A.A. Kollee, beste Louis, ik heb het erg gewaardeerd dat u het team
wilde komen versterken toen dat nodig was, bedankt voor uw samensmedende
bijdrage aan de af en toe roerige onderzoeksgroep.
Prof. dr. L.P.W.J. van den Heuvel, beste Bert, wat bewonderenswaardig dat je
naast je overvolle agenda ook nog promotor wilde en kon zijn. Het was zo nu en
dan laveren tussen de out-of-ofﬁce-replies door, maar ik wil je vooral bedanken
voor alles wat je gefaciliteerd hebt in de wondere wereld die de proteomics voor
me was (en deels nog steeds is..)
Mijn co-promotor: prof. dr. C.H. Schro¨der, beste Cock, ik had me geen betere
begeleider kunnen wensen. Ik had de eer het laatste kuiken in jouw met zorg
gebouwde PD-nest te zijn, waarin voor mij al een hele rits promovendi hun proef-
schrift uitgebroed had. Ook mij, als absolute beginner, heb je leren vliegen op
jouw relaxte manier, met zowel vakinhoudelijke als sociale ondersteuning: je
stond vaak letterlijk en ﬁguurlijk aan mijn zijde voor vliegles en bemoedigende
begeleiding tijdens de vele congressen. En extra dank voor het veelvuldig en
trouw transporteren van mijn posters-in-zuurstokkleuren!
Prof. dr. L.A.H. Monnens: iedereen die ooit de eer gehad heeft u als promotor te
mogen hebben, weet dat het lastig is u te bedanken, omdat er gewoon te veel is,
en omdat u het zelf allemaal zo vanzelfsprekend vindt. U bent met recht mijn ’ere-
promotor’, zonder enige twijfel de drijvende en onuitputtelijke kracht achter dit
onderzoek, tijdens de soms lange adem die nodig was. En de meest eervolle en
oprechte persoon in de wetenschappelijke wereld die ik heb mogen ontmoeten.
Met veel haast (heel soms had ik dat..) moet je bij u niet binnenkomen. Een
wetenschappelijke bespreking was nooit compleet zonder een bespiegeling van
het huidige politieke klimaat op macro- en microgebied, het bespreken van de
219
onrechtvaardigheid die er in de wereld nog op veel te veel plekken bestaat, of
wat diepergaande nefrologische casuistiek. En het liefst allemaal achter elkaar..
Al heb ik wel eens gezucht (sorry..) als er weer een wetenschappelijke knoop tot
op de draad ontward moest worden: het werd er altijd beter van. Ik zeg het graag
nog een keer: wat een eer om u als begeleider en mentor te mogen hebben.
Leden van de manuscriptcommissie: prof. dr. F.G.M. Russel, prof. dr. R.T.
Krediet en dr. H.W. van Hamersvelt, hartelijk dank dat u in de manuscriptcom-
missie wilde plaatsnemen en dank voor de beoordeling van mijn proefschrift.
Prof. Krediet, u speciaal bedankt voor het meedenken met de studie over het
watertransport bij kinderen en voor het delen van uw unieke kennis over de fysi-
ologie van PD.
De kindernefrologie-groep: dr. Marlies Cornelissen: bedankt voor je bijdrage
die je al die tijd aan de onderzoeksgroep hebt geleverd, en de waardevolle link
naar de kliniek die je voor mij altijd was. Erg leuk en bijzonder dat ik mijn ’eigen’
PD poli’s mocht meedraaien.
Ook alle andere collega’s van de kindernefrologie en de verpleging van de dia-
lyse wil ik graag bedanken voor het faciliteren van het onderzoek bij de PD
patie¨nten en de inwijding in de PD-kliniek. Met name dr. Nicole van de Kar,
veel dank voor de gezamenlijke PD poli en je laagdrempeligheid en gezelligheid
in de kliniek. En natuurlijk Marga: speciale dank dat ik je voor de voeten mocht
lopen tijdens de poli en bij alle PETs, ik heb ontzettend veel van je geleerd op
PD gebied en heb genoten van je nuchterheid, kordaatheid en droge humor, en
het feit dat je er altijd was.
Het echte labwerk bleek niet helemaal op mijn lijf geschreven. Ik wil met name
Thea en Wendy bedanken voor hun oneindige geduld met mijn geklooi; vooral
dankzij jullie zijn er gelukkig toch veel waardevolle onderzoeksresultaten ontstaan!
En iedereen van P & Q: bedankt voor de tijdelijke adoptie binnen het lab tijdens
kofﬁepauzes, lab-uitjes en sinter-kerstvieringen. Alle (oud)-collega’s uit onze in-
spirerende kantoortuin: bedankt voor de gezelligheid, de broodnodige kofﬁe-
en theepauzes, en de gezamenlijke cursussen.
En mijn allereerste onderzoeksbuurvrouw Maartje: in het pre-kantoortuin tijdperk
mochten we heel even echte bureau-buren zijn, daarna zat je een deur verder,
maar dat belemmerde niet een ﬁjn burencontact! Erg bedankt voor al je gezel-
ligheid, lunches, dinertjes en theepauzes. Die houden we er hopelijk in!
Alle co-auteurs van de artikelen, erg bedankt voor jullie bijdrage! Dr. Adilia
Warris, speciale dank voor je ﬁjne begeleiding bij de peritonitis & perforatie-
artikelen. Jolein, bedankt voor je kritische bijdrage. Berry, erg bedankt voor
je aanhoudende enthousiasme voor die rare melk-proeven die ik steeds weer bij
je kwam doen en voor de gastvrijheid in jullie lab.
Zina, Inge en Marloes, bedankt voor jullie concrete bijdrage aan hoofdstuk 9!
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De nefrologie collega’s in het AMC: Annemieke, Denise, Watske, Deirisa, Anniek
en Wieneke, dank voor alle hulp bij de watertransport-studies & berekeningen,
en voor de gezelligheid bij de gezamenlijke congressen!
Kindergeneeskunde collega’s: als soort van eeuwige onderzoeks-aios heb ik
de afgelopen jaren rond mogen lopen binnen het cluster Nijmegen. We hadden
altijd al een supercluster, maar sinds de komst van de ﬂex&relax-kamer en de
bijbehorende koelkastcommissie kan het echt niet meer stuk, ik zou er bijna altijd
aios voor willen blijven.
En dan mag in dit kader natuurlijk dr. Jos Draaisma niet ontbreken, die het hele
opleidingsklimaat vanaf GOED naar beter tot best heeft weten op te krikken: Jos,
wat ﬁjn dat ik mijn aios-tijd onder jouw hoede heb mogen beleven.
Sandra, jij heel erg bedankt voor het thuis-gevoel dat je iedereen weet te geven
en al het regelwerk dat je voor ons aios doet (wie is er nou weer zwanger..? )
Prof. Michel! Wat heerlijk dat jij mijn mentor wilde zijn binnen de kinderge-
neeskunde, bedankt voor alle inspirerende peptalks tussen je eigen bergen werk
door, en voor je supersteun tijdens de grootste onderzoeksdalen.
Bestuur van de junior-afdeling NVK: bedankt voor de gezellige en motiverende
bestuurstijd!
Pete, thanks a lot for giving me the chance to collaborate with you in the CFPD-
project and for inviting me to South Africa, I enjoyed your hospitality (and of
course from Sabine and Leffe too) and your relaxed personality. I’m very happy
we have met and we have managed to succesfully set up the CFPD-technique.
Baie dankie! Mandy and Gina, thanks a lot for your help with the CFPD study
and Prija for your help with the peritonitis study. Christel, thanks a lot for being
the most enjoyable landlady I’ve ever had (actually it’s not so boring at all!), and
thanks for introducing me to the surﬁng waves of Muizenberg! I hope we will
climb Lion’s Head and Table Mountain together once more, and I also hope you
will not tap George on the head too much anymore..
Alle lieve vrienden & vriendinnen, ik wil jullie allemaal heel erg bedanken voor
jullie steun en aﬂeiding tijdens het voor mijn (en jullie) gevoel eeuwigdurende
promotie-traject.
De ONSjes in het bijzonder, omdat we al zoveel hebben meegemaakt samen
en jullie er altijd zijn, en hopelijk altijd blijven! Bedankt voor alle relativerende
opmerkingen en de oprecht verbaasde vragen waarom ik toch in hemelsnaam
wilde promoveren (ik was het zelf halverwege ook even vergeten..).
Het Huis, omdat jullie nog steeds als thuis voelen, ook al zijn we al heel lang
geen huisgenoten meer, maar die 60.000 liter thee en honderden kilo’s chocola
(en de peperkoek met pindakaas natuurlijk, Lot!) scheppen gelukkig een onver-
brekelijke band zoals we hebben bewezen. En wie weet binnenkort weer ’s een
reu¨nie in de Pyreneee¨n..? ..En we gaan natuurlijk nog steeds voor een exclusief
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Sint Annastraat Bejaarden-resort in 2061.. B-MMP rules
Ing en Ellie, bedankt voor alle gezelligheid bij het hockeyen in dames 11 & 14,
jullie zijn mijn hockey-dames 1! Hoop dat we nog heel veel etentjes en feestjes
met bijbehorende goede gesprekken samen hebben.
Dear Carlo, Gabriella and Riccardo, grazie mille for your friendship, espero hasta
muy pronto!
Paranimfen: degenen die mijn hele studie- en promotietijd eigenlijk altijd al in
de buurt waren, ik ben zo blij dat jullie nu weer naast mij willen staan.
Lieve Go: je bent vanaf het allereerste begin in Leuven niet meer weg te denken.
Samenwonen met jou, Pluk en Fluf was onvergetelijk; ik hoor nog steeds ”there’s
only one way of life, and that’s your own” uit je boxen komen, terwijl we in de zon
in de dakgoot op de 3e verdieping een broodje chocomeli aten (en Fluf at mee
uiteraard), we gaan al zo lang mee samen, van Ecuador (even naar huis bellen
om te vertellen dat we 3 maanden Zuid-Amerika geboekt hadden..), tot Ghana,
tot de bergen van de Pyreneee¨n of de Alpen, waar we ook terecht komen, we
blijven er voor elkaar en we gaan ooit samen proosten op de bruiloft van Merel
& Kees! (”Seker Weten!” zou Kees zeggen)
Lieve Judith, wie had dat gedacht toen ik in 1998 op kijkavond binnenstapte in de
Sint Annastraat. Wat ben ik blij dat we huisgenoten en vriendinnen zijn gewor-
den, we hebben samen veel stormen meegemaakt, ik kon altijd uithuilen met
chocola op jouw gestreepte bank, we hebben samen kunnen genieten in Spanje
en ik mocht de meest chaotische ceremoniemeester ever zijn op jullie bruiloft..
Gelukkig ben jij mijn paranimf zodat je me een beetje extra kan organiseren!
Lieve papa en mama, het is echt een zegen om zulke ﬁjne ouders te hebben,
dank jullie wel voor alles. Marieke, Jasper en ik hebben heel veel geluk met
jullie, dat besef ik me steeds meer. En ook al hebben jullie ons geen optimaal
punctualiteitsbesef weten bij te brengen (ik hoop echt dat iedereen op tijd is
op 18 april), we hebben verder zo ongeveer alle waardevolle dingen van jullie
meegekregen, jullie zijn er altijd voor ons, en ik hoop nog heel lang!
Lieve Marieke, liefste Moustache, we waren vroeger al een soort van bijna-
siamese tweeling, ik ben zo blij dat jij er bent, ik zou niet zonder je kunnen.
Wat ﬁjn dat er mobiele telefoons zijn en dat we daarmee gemakkelijk 3x per dag
ultrasoon kunnen communiceren! Lieve Willem en Fien, wat een feest dat jullie
er zijn, wat zijn jullie een lieve familie samen met Marieke en we gaan zeker de
oprijlaan plat lopen in Nimmerdor.
Lieve Jasper, El Muenstro, je bent een superbroer, en ik kan altijd op je rekenen.
Inmiddels wonen we helaas niet meer bijna bij elkaar om de hoek in Nijmegen,
maar in Breda is er tenminste carnaval, zo is het ook! En bedankt voor het door-
ploegen van het manuscript.. Lieve Agnes, wat ﬁjn dat jullie elkaar gevonden
hebben, jij en Jasper zijn zo dol op elkaar. Hopelijk gaan we ieder jaar toch ten-
minste nog 1 keer naar de Stapmolen!
222
Ans en Carel, gelukkig zijn jullie het bewijs dat schoonouders ook echt ontzettend
lief kunnen zijn! Bedankt voor alles wat jullie voor ons doen, en ook voor Kees
en Cato.
Mariska en Wilfred en Gijs en Bart, bedankt voor jullie belangstelling en je bent
de meest attente persoon die ik ken Maris, echt super.
Liefste Tijs, Kees en Cato
Lieve Kees & Catootje, wat zijn jullie een groot geluk en wat gaan we nog veel
spelen samen!
Lieve lieve Tijs, samenwonen met een promoverende vriendin is zo ongeveer de
ultieme relatietest, bedankt dat je het zo goed hebt doorstaan, zonder jou was
er zeker geen proefschrift geweest. Bedankt voor alle tijd die je me hebt laten
nagelbijten op dit proefschrift en voor al je computerhulp: alle noodzakelijke data
waren ergens in de krochten van mijn computer blijven hangen zonder jou, en
deze hele waanzinnige lay-out is ook jouw monnikenwerk (paar daagjesK), ik
ben je daar echt zooo dankbaar voor.
Maar het allermooiste is dat we samen Kees en Cato hebben, wat een (ietwat
vermoeiende) heerlijkheid!
Je maakt me zo blij, ik hoop dat we samen nog heel veel moois gaan maken,
met jou naast me kan alles en is alles goed..
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Come live in my heart, please never move out
Voor Tijs, Kees en Cato

